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Dissertation Abstract 
Introduction 
Perinatal depression (PND) is a significant public health problem affecting up to 13% of mothers and 
often remains undiagnosed.  PND screening is usually conducted by medical practitioners or 
nurses/midwives in primary-care settings however there is scope to consider the role of a wider range 
of allied health providers in PND detection. Pharmacists in particular are one of the most accessible 
members of the primary healthcare team and are potentially in an ideal position to screen women for 
PND. Theoretically, equipping pharmacists with the tools and training to undertake such screening 
would increase the possibility of detecting women with PND and referring them to practitioners who 
could diagnose and treat them appropriately. However, questions about whether this is feasible 
remain unanswered. 
 
Objectives 
The first objective of this dissertation was to determine whether previous research attempts have 
investigated the possibility of allied health professionals conducting postpartum depression screening 
in the context of primary care. The second objective of this study was to explore the perspectives of 
Australian pharmacists about their current experiences with women in the perinatal period and their 
views on integrating perinatal depression screening into their professional practice. The third and final 
objective of this dissertation was to develop & deliver a pilot PND training program to community 
pharmacists and collect participant feedback to inform the development of a future feasibility study on 
PND screening in community pharmacy.  
 
Methods 
A literature review was conducted to explore previous attempts to integrate allied health professionals 
into the postpartum depression screening process. In Phase 1 of this study, semi-structured phone 
interviews were conducted with 20 Australian pharmacists to explore their experiences with pregnant 
and postpartum mothers and their views on delivering PND-screening services in community 
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pharmacies. These responses were combined with best practices for adult education to develop and 
deliver the "Perinatal Mental Health in the Pharmacy" (PMHP) educational program with 15 practising 
community pharmacists in Sydney, Australia. The development, implementation and evaluation of the 
PMHP program constituted Phase 2 of this study. 
 
Results 
The results of the literature review indicated that much of the previous research on primary-based 
postpartum depression (PPD) screening programs focused almost entirely on nurse practitioners, 
midwives and medical practitioners. There did not appear to be any studies in the literature which 
suggested that the role of pharmacists or indeed any allied health professional (apart from nurses and 
midwives) in PPD screening in primary care had been explored. The results of Phase 1 indicated that 
participants believed that pharmacists were easily accessible and thus ideally placed to screen for 
PND but that diagnosis was beyond their scope of practice. The prevailing view amongst participants 
was that although pharmacists were capable of screening for PND, they required further training to do 
so and proceeded to provide their views on the ideal format of such a program. Participants in Phase 
2 of the study reported that their tertiary training did not adequately prepare them for conducting PND 
screening and that the PMHP educational intervention which they completed improved their 
confidence in assessing and referring suspected cases of PND.   
 
Conclusion 
Casual interactions between a childbearing woman and her allied health provider represent possible 
opportunities for the detection of perinatal depression. Pharmacy represents just one of multiple 
avenues within the community where allied health providers may have the opportunity to detect and 
refer suspected cases of PND. The reported improvement in pharmacist confidence with PND 
detection and referral upon completion of the educational intervention suggests that pharmacists 
require further training before pharmacy-based screening programs can be implemented. There is 
also a need to consider redesigning tertiary pharmacy curricula to ensure that perinatal mental health 
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is adequately covered. Pharmacists are willing and pending appropriate training, able to conduct PND 
screening to detect hitherto unrecognised depression. Further research into the long-term outcomes 
of pharmacist-led PND screening is recommended. 
1 
 
 
Chapter 1: 
Introduction 
1.1 Research background 
The perinatal period is usually depicted as a time of intense happiness and well-being for families and 
mothers in particular. However, the reality of pregnancy and early motherhood can often be quite 
challenging, with dramatic physical changes and emotional turbulence sometimes resulting in 
psychological distress. Depression is considered one of the leading causes of disease-related 
disability among women and childbearing women in particular are at risk (Burke, Burke, Rae, & 
Regier, 1991). There is ample evidence linking depression in the perinatal period with various long-
term consequences on both the mother and infant involved. With perinatal depression (PND) affecting 
a significant number of childbearing women, there is a distinct need for health professionals to 
understand the features, predictors, consequences and screening instruments used to detect PND.  
 
1.1.1 Definition of PND 
The term perinatal in the context of mental health is used broadly to describe the period during 
pregnancy and up to 12 months after childbirth (Gaynes et al., 2005). However, the criterion used to 
define the onset of depression in the postpartum period is not well-defined. The Diagnostic and 
Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (American Psychiatric Association, 2013) 
stipulates that the criterion for postpartum onset is that the depressive episode occurs within 4 weeks 
after childbirth. This definition is problematic, however, given that up to 85% of postpartum women 
(Pearlstein, 2008) will suffer from ―postpartum blues‖ - a mild and transient dysphoria that can last up 
to two weeks postpartum (O‘Hara & Wisner, 2014). This occurrence is distinct from postpartum 
depression (PPD), and in most cases is a time-limited condition which will resolve on its own. This 
DSM-5 definition also stands in contrast to evidence suggesting that vulnerability to PND continues for 
at least the first 6 months after childbirth (Cooper & Murray, 1998) and potentially up to four years 
postpartum (Woolhouse, Gartland, Mensah, & Brown, 2015). Debate about the period of postpartum 
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depression (PPD) onset aside, the symptoms of PND are similar to a major depressive episode as 
defined by DSM-5. The DSM-5 also states that women in the perinatal period experiencing major 
depression must exhibit five of the following nine symptoms and that the symptoms cause significant 
distress or impairment to be diagnosed with PND: depressed mood, loss of interest or pleasure, 
change in weight or appetite, sleep changes, psychomotor retardation or agitation, fatigue, feelings of 
worthlessness, impaired concentration or recurrent thoughts of death or suicide. It is also important to 
note, however, that the DSM-5 does not classify perinatal depression as a separate disease but rather 
the onset of major depression within a specified perinatal period. There is some controversy in the 
literature about whether depression rates during the perinatal period are larger than that of non-
childbearing women and whether PND is a distinct phenomenon. Some researchers have suggested 
that the risk of depression in postpartum women is not any higher than in other young women 
(O‘Hara, Zekoski, Philipps, & Wright, 1990) whilst others have reported that there is a higher risk of 
depression in the postpartum period (Cox, Murray, & Chapman, 1993; M. Eberhard-Gran, Eskild, 
Tambs, Samuelsen, & Opjordsmoen, 2002). The clinical presentation of PND does mimic that of other 
major depressive disorders with the key difference being timing; the perinatal period is a critical time 
for fetal and infant development and depression has been shown to have detrimental effects on this 
development. It is worthwhile noting that the period after birth is often referred to in the literature as 
either the ―postpartum‖ or ―postnatal‖ period, and these terms are used interchangeably. Similarly, the 
period during pregnancy is referred to as either ―antepartum‖ or ―antenatal‖, and the terms are also 
used interchangeably.  
 
1.1.2 Prevalence, risk factors and consequences of PND 
Prevalence estimates for PND differ markedly between sources suggesting that there are inherent 
difficulties in attempting to arrive at a universal figure. The oft-reported figure of 13% for postpartum 
depression was derived from a meta-analysis conducted two decades ago (O‘Hara & Swain, 1996) 
though a more recent review placed the postpartum depression estimates between 6.5 and 12.9% 
(Gaynes et al., 2005). Globally, prevalence rates for depression across the perinatal period have been 
reported between 4.4% and 73.7% (Gaynes et al., 2005; Halbreich & Karkun, 2006; Leahy-Warren, 
McCarthy, & Corcoran, 2011; O‘Hara & Swain, 1996); these wide variances highlight the difficulty in 
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ensuring consistent prevalence estimation. The factors affecting prevalence estimates include the 
assessment method and outcome measures used, the length of postpartum period being studied and 
type of screening or diagnostic instrument utilised (Gorman et al., 2004; Halbreich & Karkun, 2006; 
Leahy-Warren et al., 2011). Generally, higher prevalence rates tend to be associated with the use of 
self-report instruments whilst lower prevalence rates are associated with the use of interview-based 
instruments (O‘Hara & Swain, 1996).  
 
A concerted effort within the research community to understand the predictors of PND has led to the 
identification of risk factors that appear to increase the likelihood of a woman developing PND 
(McCoy, Beal, Shipman, Payton, & Watson, 2006; O‘Hara & McCabe, 2013; O‘Hara & Wisner, 2014). 
Studies have identified several biological and psychosocial risk factors for PND including family 
history of depression, poor partner support or domestic violence, marital status, low socioeconomic 
status, young age and limited social support (Bloch, Rotenberg, Koren, & Klein, 2005; E. R. Myers, 
Aubuchon-Endsley, & Bastian, 2013; Stewart, Robertson, Dennis, Grace, & Wallington, 2003a). Prior 
personal history of depression has consistently been found to be a strong risk factor for PND, 
emphasising the need to focus PND assessment efforts on childbearing women with a past history of 
depression to prevent or ameliorate the effects of perinatal depression (Bloch et al., 2005). 
Conversely, protective factors have also been identified which potentially guard against the 
development of PND; namely, the existence of support structures within the mother‘s social sphere 
(Leahy-Warren et al., 2011). Evidence points to the protective benefits of adequate social support to 
new mothers in the postpartum period as it is seen to aid the woman better adapt and transition to 
motherhood (Kiehl & White, 2003; Plews, Bryar, & Closs, 2005). Women identified as having a high 
risk for postpartum depression (PPD), in particular, benefit from the support provided by healthcare 
providers (Shaw, Levitt, Wong, Kaczorowski, & McMaster University Postpartum Research Group, 
2006). However, informal social and infant care support from a new mother‘s family and friends have 
also been found to be beneficial (Häggman-Laitila, 2003; Leahy-Warren, McCarthy, & Corcoran, 
2012; Negron, Martin, Almog, Balbierz, & Howell, 2013).  
 
The effort to understand the factors that contribute to the development of PND is driven by the acute 
recognition of the detrimental (and sometimes catastrophic) effects of PND on mother and infant 
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(Verreault et al., 2014). PND is associated with significant morbidity for both the mother and her family 
and in extreme cases, PND can be fatal with suicide being reported as the leading cause of maternal 
death in the UK (Oates, 2003). Antenatal depression has been associated with unsafe practices 
during pregnancy such as illicit drug use, smoking and alcohol consumption (Dunkel Schetter & 
Tanner, 2012) and pregnant women with depression are less likely to comply with recommended 
pregnancy practices such as good nutrition and regular clinic visits (Grigoriadis et al., 2013). Maternal 
depression in pregnancy may also exert a biochemical effect with antenatal depression being 
associated with an alteration in the mother‘s neuroendocrine system (Field, Diego, & Hernandez-Reif, 
2006), potentially contributing to poor pregnancy and birth outcomes such as preeclampsia (Kurki, 
Hiilesmaa, Raitasalo, Mattila, & Ylikorkala, 2000; Qiu, Sanchez, Lam, Garcia, & Williams, 2007), low 
birth weight, intrauterine growth restriction and an increased risk of premature delivery (Alder, Fink, 
Bitzer, Hösli, & Holzgreve, 2007; Grote et al., 2010). Infants born to mothers who suffered from 
antenatal depression are also more likely to have poor temperament (E. P. Davis et al., 2007) and 
exhibit poor sleep patterns (Field et al., 2007). The effects of antenatal depression can last for a 
significantly long period after birth with studies reporting increased cortisol levels in adolescents 
whose mothers suffered from depression during their pregnancy (Halligan, Herbert, Goodyer, & 
Murray, 2004). Postpartum depression has similarly been shown to impart long-term detrimental 
effects. Affected mothers are less likely to breastfeed for the recommended period of time (Dennis & 
McQueen, 2007), to adhere to the recommended vaccination schedule (Minkovitz et al., 2005) and 
are at a significantly greater risk of expressing thoughts of harming their infant compared to non-
affected mothers (Jennings, Ross, Popper, & Elmore, 1999). Poor maternal-infant attachment 
(Zauderer, 2008) in the period after birth is a common outcome of postpartum depression which can 
sometimes persist and impair long-term bonding between mother and infant (Moehler, Brunner, 
Wiebel, Reck, & Resch, 2006). A mother with PPD is much less likely to engage in positive mother-
infant interactions essential to the infant‘s emotional development (Field et al., 2006) with potential 
long-term outcomes on the infant including delayed cognitive and emotional development (Grace, 
Evindar, & Stewart, 2003; Murray, Fearon, & Cooper, 2015), mental health disorders and social 
adjustment disorders (Bauer et al., 2015). The negative impacts of postpartum depression on the 
infant appear to remain even when the depression is treated (Forman et al., 2007). Given the 
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detrimental effects of perinatal depression on mother and infant, there is thus a need to detect and 
treat it early. 
 
1.1.3 Perinatal depression screening 
With an increasing recognition of the importance of early detection, the case for universal perinatal 
depression screening has often been made by researchers, clinicians and health agencies globally.  
The World Health Organisation (WHO) have published ten criteria (Wilson et al., 1968) for evaluating 
screening programs which have since underpinned many discussions around the value of screening. 
Wilson and Jungner (Wilson et al., 1968) stipulated that to proceed with universal screening, the 
condition must be an important health problem that is well-understood, be detectable at an early 
stage, that treatment be available, that the criteria for ideal candidates for treatment be established 
and that the cost of screening be balanced against the benefits of doing so. Given the low rates of 
help-seeking amongst women with PND (Dennis & Chung-Lee, 2006; McGarry, Kim, Sheng, Egger, & 
Baksh, 2009) and the likelihood that a case of PND will be missed by a woman‘s health provider 
(Georgiopoulos, Bryan, Wollan, & Yawn, 2001; Goodman & Tyer-Viola, 2010; Nishizono-Maher et al., 
2004), there is a need to consider the evidence supporting the benefits of universal PND screening. 
Indeed, the latest US Preventive Services Task Force Recommendation Statement (Siu et al., 2016) 
has endorsed the utility of universal screening, recommending that such programs should form the 
backbone of perinatal mental health care policies. Studies (Buist et al., 2006; Milgrom & Gemmill, 
2014; Milgrom, Mendelsohn, & Gemmill, 2011) have demonstrated that routine screening for PND 
results in more cases of PND being detected that may otherwise have remained unnoticed. Though 
the long-term clinical and cost-effectiveness of universal PND screening programs have been called 
into question (L. Harris, 2016; Thombs, Ziegelstein, Roseman, Kloda, & Ioannidis, 2014), there is 
nonetheless a broadly acknowledged need to consider ways of detecting PND as early as possible. 
The utilisation of a validated screening tool is a fundamental aspect of any screening program (UK 
National Screening Committee, 1998) and can aid in the detection of PND regardless of whether it is 
utilised in the context of a universal screening program or at the discretion of the health provider 
administering it. In fact, evidence suggests that in the absence of a screening tool, the ability of health 
providers to detect PND is significantly diminished (Goodman & Tyer-Viola, 2010; Heneghan, Silver, 
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Bauman, & Stein, 2000; Holden, 1994; Milgrom et al., 2011; Nishizono-Maher et al., 2004). 
Interestingly, routine screening by healthcare professionals throughout the perinatal period has been 
associated with increased help-seeking behaviour by women who are screened, suggesting that 
simply asking about a woman‘s mental health in this period can itself spur women with PND to seek 
help (Reilly et al., 2014). 
 
Several screening instruments have been identified and investigated by researchers to determine 
their effectiveness in the detection of perinatal depression (Boyd, Le, & Somberg, 2005; Gaynes et al., 
2005; Mann & Gilbody, 2011; E. R. Myers et al., 2013). Various screening tools have been validated 
for use in the perinatal period (Hewitt et al., 2009), however, there is insufficient evidence that a single 
tool has a high enough degree of both sensitivity and specificity to provide a positive predictive value 
(PPV = % of true positives/ all positive results on screening instrument) that warrants isolated use 
(Gaynes et al., 2005). Despite this, the screening tool most widely used in PND screening is the 
Edinburgh Postnatal Depression Scale (EPDS). The EPDS (Figure 1.1) is a 10-item self-report 
questionnaire with items scored 0-3, specifically designed and widely validated for use in postpartum 
depression (Cox, Holden, & Sagovsky, 1987). Research suggests (Hewitt & Gilbody, 2009) that the 
EPDS may, if enough care is used, be administered alone within screening protocols successfully. A 
separate approach to identification, outlined in NICE guidelines (NICE, 2007) suggests the use of 
verbal questions in an interview format based around two introductory questions (Whooley Questions) 
(Gjerdingen, Crow, McGovern, Miner, & Center, 2009; Mann & Gilbody, 2011) as an efficient way for 
healthcare professionals to quickly rule out PND and potentially reduce the number of women having 
to undertake the EPDS (Figure 1.2) 
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Table 1.1 The Edinburgh Postnatal Depression Scale (EPDS) (Cox et al., 1987) 
Item Response Format (Multiple Choice) 
1. I have been able to laugh and see the funny side of 
things. 
●  As much as I always could 
●  Not quite so much now 
●  Definitely not so much now 
●  Not at all 
2. I have looked forward with enjoyment to things. ●  As much as I ever did 
●  Rather less than I used to 
●  Definitely less than I used to 
●  Hardly at all 
3. I have blamed myself unnecessarily when things went 
wrong 
●  Yes, most of the time 
●  Yes, some of the time 
●  Not very often 
●  No, never 
4. I have been anxious or worried for no good reason. ● No not at all 
●  Hardly ever 
●  Yes, sometimes 
●  Yes, very often 
5. I have felt scared or panicky for no very good reason. ● Yes, quite a lot 
●  Yes, sometimes 
●  No, not much 
●  No, not at all 
6. Things have been getting on top of me. ●  Yes, most of the time I haven‘t been able to cope at 
all 
●  Yes, sometimes I haven‘t been coping as well as 
usual 
●  No, most of the time I have coped quite well 
●  No, I have been coping as well as ever 
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7. I have been so unhappy that I have had difficulty 
sleeping. 
● Yes, most of the time 
●  Yes, sometimes 
●  Not very often 
●  No, not at all 
8. I have felt sad or miserable. ●  Yes, most of the time 
●  Yes, sometimes 
●  Not very often 
●  No, not at all 
9. I have been so unhappy that I have been crying. 
 
●  Yes, most of the time 
●  Yes, quite often 
●  Only occasionally 
●  No, never 
10. The thought of harming myself has occurred to me. ●  Yes, quite often 
●  Sometimes 
●  Hardly ever 
●  Never 
Table 1.2 The Whooley Questions (NICE, 2007) 
 
NICE (2007) recommends that healthcare professionals ask these two questions at a woman‘s first 
contact with primary care and at 4-6 weeks and 3-4 months postpartum: 
● During the past month, have you often been bothered by feeling down, depressed, or 
hopeless? 
● During the past month, have you often been bothered by little interest or pleasure in doing 
things? 
A third question should be considered if the woman answers ―yes‖ to either of the initial questions: 
 
● Is this something you feel you need or want help with? 
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Although the EPDS may be administered from as early as three to five days after giving birth (Jardri et 
al., 2006), an optimal cut-off at 6-8 weeks postnatally (Boyce, Stubbs, & Todd, 1993; B. Harris, 
Huckle, Thomas, Johns, & Fung, 1989; Murray & Carothers, 1990; Zelkowitz & Milet, 1995) with a 
repeat screen at 3-6 months (Boyce et al., 1993; Cox et al., 1987; Elliott et al., 2000) is a widely 
recommended screening protocol, though there have been suggestions that the optimal time to 
initially conduct the EPDS is at 12 weeks when the initial sleep deprivation stage has been overcome 
(Downie et al., 2003). Very high scores in the early postpartum period can indicate a high risk of 
subsequent PPD (Dennis, Janssen, & Singer, 2004), however, conducting the EPDS at an early stage 
will also conflate the number of high-scorers artificially due to the ―postpartum blues‖ phenomenon. 
The widely accepted optimal cutoff point for detecting major depression is ≥13 (possible score range 
0-30), as referenced by the original validation study (Cox et al., 1987). However, a wide variety of 
cutoff points for the EPDS have been reported with research suggesting that the wide use of 
unvalidated cutoff scores in many studies may be a factor in the wide range of reported PND 
prevalence rates reported (Matthey, Henshaw, Elliott, & Barnett, 2006). An optimal cutoff of 10 for 
major and minor depression and 13 for major depression has been recommended (Hewitt et al., 2009) 
with EPDS sensitivity ranging from 0.60 - 0.96 (specificity 0.97 - 0.45) for major depression and 0.31 - 
0.91 (specificity 0.99 - 0.67) for major or minor depression (Hewitt et al., 2009). Notably, the cutoff 
point chosen for any particular study will affect the sensitivity - the lower the cutoff, the higher the 
sensitivity. Whilst a higher sensitivity means that fewer cases will go undetected, it also invariably 
decreases the specificity, thus resulting in an increased number of false-positives who are ultimately 
found not to be depressed (Paulden, Palmer, Hewitt, & Gilbody, 2009). A large Australian study 
(Milgrom, Ericksen, Negri, & Gemmill, 2005) demonstrated that the PPV of the EPDS at cutoff 11.5 
was 76% (min. 49%; max 84%), suggesting that three-quarters of high EPDS scores might be true-
positives. A similar PPV statistic was reported (Jevitt, Zapata, Harrington, & Berry, 2005), with 19.2% 
of 26 women clinically assessed after a high EPDS score found to be depressed and 53.85% of those 
found to be suffering from dysthymia (persistent depressive disorder as defined by the DSM-5) 
. Whilst this result appears to favour the EPDS, an analysis reported by Paulden et al. (2009) of 
formal postpartum depression identification studies found that due to the high number of false-
positives, such protocols were not deemed cost-effective enough to be implemented by the NHS 
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(National Health Service, UK), a finding corroborated by Hewitt et al. (2009). Miligrom et al. (2005) 
suggest a method of reducing false-positives based on a 2-step screening process: 1) administer the 
EPDS with an optimised cutoff of 12.5 and 2) then administer the Beck Depression Inventory (BDI) (a 
21-question self-report depression scale also with a depression cutoff at 12.5) to those who screen 
positive on the EPDS. Based on their data, a positive BDI score at this point will raise the PPV from 
76% by using the EPDS alone to 92% by administering both the EPDS and BDI. The Agency for 
Healthcare Research and Quality (AHRQ) (E. R. Myers et al., 2013) supports this finding, reporting 
that a 2-step screening process followed by a standardised questionnaire where necessary may 
represent the optimal approach to improving screening efficiency. 
 
It is important to note that high scores on the EPDS are only indicative that referral for further 
psychiatric assessment is warranted (Stewart et al., 2003a) but do not constitute a diagnosis of 
depression. The EPDS is not intended to replace a full diagnostic assessment of PND as it cannot 
diagnose PND nor can it indicate true severity (Stewart et al., 2003a). The EPDS is intended to pick 
up on major depression though it has also been found to inadvertently detect the presence of other 
mental health conditions, such as anxiety and bipolar disorder, with a sensitivity of 0.38-0.86 
(specificity 0.99-0.87) (Hewitt et al., 2009). Additionally, Item 10 on the EPDS questions the 
respondent about suicidal ideation and a positive response requires immediate attention. Health 
professionals administering the EPDS have often reported feeling uncomfortable when discussing the 
results of this question, or bringing up the issue altogether (Mason & Poole, 2008). Thus the question 
of acceptability of the EPDS amongst healthcare professionals and patients is a significant point to 
consider and has been found to vary. The acceptability of the EPDS within patient cohorts generally 
favour the EPDS, with a few exceptions. One study reported (Ciliska, 2004) that a significant number 
of the women they surveyed found the screening process involving the EPDS too simplistic and 
preferred an open discussion with their provider. These women indicated that the inadequacy of the 
screening process, the intrusiveness of the questions and the stigma around depression prevented 
them from giving reliable answers on the EPDS. Cultural factors may also play a role in acceptability 
with a systematic review on screening tools used with UK South-Asian women (Downe, Butler, & 
Hinder, 2007) and finding that these women generally prefer face-to-face interviews over self-reported 
questionnaires. In contrast, another study (Hewitt et al., 2009) reported that consumers accepted the 
Community-based perinatal depression recognition and management  |  June 2016  | University of Sydney  
11 
EPDS when conducted in the privacy of the home with a trained health visitor who was careful in 
administering Item 10 on the EPDS. Health providers have indicated their preference for the use of 
the EPDS, suggesting that it aids them ―get to the bottom of things‖ and uncovers issues that would 
not have been otherwise discussed (Vik, Aass, Willumsen, & Hafting, 2009). This low rate of detection 
by clinical assessment compared to EPDS detection is well-known amongst researchers (Holden, 
1994). A possible explanation for this low detection rate lies in the propensity for mothers to under-
report their depressive symptoms when directly questioned. This notion is also supported in another 
study (Horowitz, Murphy, Gregory, & Wojcik, 2011) that reported that EPDS positive screens were 
significantly higher when submitted by post than by telephone screening (19% positive screens by 
post, 11% by telephone EPDS screening). It may be argued then that autonomy should be respected 
by healthcare professionals when delivering a screening intervention and the EPDS administered at 
their discretion. 
 
Whilst the EPDS has been consistently validated for use in the postpartum period, a major problem 
faced by researchers lies in the ambivalence contained within the literature about the value of the 
EPDS during the antenatal period. Research findings in a sample of 9,028 screened women suggest 
(Evans, Heron, Francomb, Oke, & Golding, 2001) that depressive symptoms were more common 
during pregnancy than in the postpartum period, with peak incidence of depression occurring at 32 
weeks of pregnancy. A meta-analysis (Bennett, Einarson, Taddio, Koren, & Einarson, 2004) 
investigating the prevalence of depressive symptoms and depression in pregnancy reported that 
amongst the 19,284 women assessed, depression was found during the first trimester at a rate of 
7.4% (95% CI, 2.2%-12.6%), 12.8% during the second (95% CI, 10.7%-14.8%), and 12% during the 
third trimester (95% CI, 7.4%-16.7%). Women who reported a history of depression were five times 
more likely to exhibit depressive symptoms during pregnancy (Marcus, Flynn, Blow, & Barry, 2003), 
whilst a study of 188 primiparous women (Hayes, Muller, & Bradley, 2001) found that women were 
more depressed during pregnancy than in the first six months postpartum. Despite these findings, a 
Cochrane review (M. Austin, Priest, & Sullivan, 2008) concluded that there was insufficient evidence 
that routine antenatal psychosocial assessment led to improved perinatal mental health outcomes. 
Austin et al. (2003) found that no single screening tool had a high enough sensitivity and PPV to be 
included in routine antenatal care. Recent research has supported this notion suggesting that 
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screening tools such as the EPDS require further validation before they can be used routinely to 
screen for antenatal depression (Kozinszky & Dudas, 2015).  
 
Overall, screening instruments such as the EPDS form a significant part of community-based 
screening programs and whilst further studies are required to determine the validity of using the EPDS 
in the antenatal period, the use of the EPDS has been widely validated for use in screening for 
postpartum depression. Beyond the EPDS, community-based screening programs generally have 
been the subject of many research studies attempting to determine whether or not perinatal 
depression screening overall is useful (Gaynes et al., 2005; E. R. Myers et al., 2013; O‘Connor, 
Rossom, Henninger, Groom, & Burda, 2016; O‘Hara & McCabe, 2013). Whilst there is debate about 
the long-term effectiveness and benefits of universal PND screening programs (Thombs, Ziegelstein, 
et al., 2014), there is broad acknowledgement that screening practices are useful within primary care 
contexts where a condition is prevalent, detectable and a screening protocol is shown to be effective 
at detecting cases that may otherwise have been missed (UK National Screening Committee, 1998). 
For mothers with depression who may find it difficult to seek treatment for various reasons including 
social stigma, fear of having their baby taken away or not knowing where to seek help (Dennis & 
Chung-Lee, 2006; Goodman, 2009), being in contact with healthcare providers who are trained to 
detect possible cases of perinatal depression is crucial in enabling early detection and management 
of PND. 
 
1.2 Research problem  
Many clinical and practice guidelines globally (M. Austin, 2011; NICE, 2007; O‘Connor et al., 2016), 
encourage the implementation of screening protocols within established community-based care 
models for perinatal women, but as discussed in 1.1. the research that does exist consistently points 
to primary care models (O‘Connor et al., 2016), whether they are practice-based or home-based, as 
the preferred settings for screening women given the ease of access that women have to such 
venues and the extensive reach such settings provide. As mentioned previously, low levels of social 
support are a major predictor of PND (O‘Hara & Swain, 1996) with increased social support 
associated with a lower risk of developing  depression 6 to 8 weeks postpartum (Kritsotakis et al., 
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2013). These support structures extend to those acting within the mother‘s primary healthcare team 
who are likely to be aware of her previous mental health state and potentially be on the lookout for 
symptoms that indicate the onset of PND. Women with PND are unlikely to recognise and seek help 
for their depression (MacLennan, Wilson, & Taylor, 1996), necessitating the development of screening 
initiatives that can easily access such women within their immediate environment. A significant 
proportion of PND cases experience the condition silently and for protracted periods of time (Bennett 
et al., 2004) with few women who reported needing mental health support receiving either referral or 
treatment for their depression (Goodman & Tyer-Viola, 2010).  
 
Women routinely present to their family physicians (or general practitioners) throughout the course of 
their pregnancy and for infant health checkups in the postpartum period thus providing physicians with 
several opportunities to screen for the presence of PND. However, studies have suggested that the 
routine use of validated postpartum depression screening tools by family physicians is low (Seehusen, 
Baldwin, Runkle, & Clark, 2005) and that the reluctance to use them may in part be due to the 
perception that doing so would be time-consuming. This may be exacerbated by the perception that 
perinatal care in a clinical setting already requires a multitude of tests and activities, leaving little room 
for discussion of the mother‘s mental health state (Gordon, Cardone, Kim, Gordon, & Silver, 2006). 
Whilst many women may not hesitate to seek out general medical help during the perinatal period 
(Marcus et al., 2003), they are much less likely to seek out mental health support of their own accord. 
It may thus be argued that missed opportunities to screen women during routine perinatal checkups 
could be reclaimed by increasing the number of opportunities available to conduct such screening in 
the community health setting. Given the ubiquity of perinatal depression in the community, there is a 
compelling need to examine the benefits of implementing some form of PND screening across the 
spectrum of appropriate and accessible primary health care venues. Allied-health professionals who 
interact with women in the perinatal period but who are not considered to have an established role in 
perinatal care (as midwives and physicians do) are potentially well-placed to detect cases of PND 
during the usual course of their practice.       
 
Ideally, allied health providers interacting with a woman in the perinatal period would have an 
understanding of perinatal depression and the risk factors that predispose mothers to developing it. 
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However, this may not be the case given that allied health providers do not routinely interact with or 
are expected to treat childbearing women. If community-based avenues for the detection of perinatal 
depression were to include allied-health providers, an important factor would be to develop standard 
protocols to ensure that women suspected of having PND could be referred to the appropriate 
provider. In order to accomplish this, however, allied health providers need to be acknowledged as 
having a potential role to play in the detection of perinatal depression and strategies developed to 
investigate and better prepare them to detect and refer possible cases of PND.  
 
1.3 Research Objectives 
Pharmacists in particular are uniquely placed to engage with women in the perinatal period and 
potentially detect cases of PND. As one of the most easily accessible primary health professionals, 
pharmacists often interact with childbearing women who attend their local pharmacy for advice about 
medication use during pregnancy and breastfeeding or product requests for their infants (Edwards, 
2014). Where pharmacists have not been adequately prepared to screen for PND, these may 
represent missed opportunities to detect perinatal depression and refer appropriately. Community 
pharmacists are commonly identified as providing a significant and unique venue within the 
community to facilitate and broaden access to primary care services (Chapman, Zechel, Carter, & 
Abbott, 2004) and multiple research efforts have considered the feasibility of pharmacists conducting 
mental health screening for people at risk of major depression (Adler et al., 2004; Finley et al., 2002; 
O‘Reilly, Wong, & Chen, 2015a). It may be argued that community pharmacy represents an ideal 
venue to host perinatal screening programs and would provide an introductory model for other allied-
health professions also considering the possibility of conducting perinatal depression screening. 
  
Thus, the objectives of this study were to: 
 
1. Examine the literature to understand the current role of allied health providers in the detection 
and management of postpartum depression. 
2. Investigate the perspectives of pharmacists about their role in the detection and management 
of perinatal depression in primary care. 
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3. Develop, implement and evaluate an educational resource to improve the knowledge and 
attitudes of pharmacists around perinatal depression. 
1.4 Significance 
The presence of depression during the perinatal period is associated with severe consequences for 
affected mothers and their infants. Women are highly vulnerable to psychological distress during the 
perinatal period and given the high number of women that remain undiagnosed, implementing PND 
screening programs in a wide range of primary care venues may result in more cases of perinatal 
depression being detected and appropriately managed. Whilst studies have frequently considered the 
role of screening in secondary and tertiary settings and by physicians in primary care settings, few 
studies have considered the role of allied health providers conducting PND screening in a community 
setting. Hence the outcomes from this research will inform future research attempts to engage a wider 
variety of allied health providers, and pharmacists in particular, in PND screening efforts.  
 
1.5 Structure of thesis 
Chapter 1 of the dissertation provided an overview of the research background, problem, aims and 
significance. It described the presentation, prevalence, risk factors and consequences of perinatal 
depression. This led to a discussion about the importance of early PND detection and the role that 
PND screening programs, whether formal or informal, have to play in facilitating early detection and 
referral. This entailed a detailed discussion about the use of the EPDS in PND screening and a 
recognition that the EPDS is validated for use in the postpartum period but there is insufficient 
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evidence to support its use during the antenatal period. 
 
Figure 1.1  Thesis Structure 
 
Chapter 2 presents a literature review on existing research on the role of allied providers in PPD 
screening. The decision to focus on PPD literature rather than the entire perinatal period was made 
on the basis that the use of depression screening scales in the antenatal period requires further 
validation (Kozinszky & Dudas, 2015). The review, will examine the evidence pertaining to the data 
supporting feasibility of PPD screening by allied health providers using a scoping method.  
 
Chapter 3 describes the results of semi-structured phone interviews conducted with Australian 
pharmacists about their experiences with perinatal women and attitudes towards PND screening in 
the pharmacy (Phase 1). Though PPD was focused on in Chapter 2, the remaining chapters focus on 
PND (the entire antenatal and postpartum period) given the increasing emphasis in the literature on 
the importance of detecting depression during pregnancy as well as postpartum. Chapter 3 includes a 
description of the design, sample, data collection instrument used and data analysis efforts involved in 
Phase 1 of this study. The results of this phase of the research indicated that sample pharmacists 
were willing to conduct PND screening but required further training to do so. 
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Chapter 4 describes the development of an educational intervention (Phase 2) that aimed to assist 
pharmacists to understand perinatal depression, recognise factors that predispose women to PND, 
understand safe psychotropic use during pregnancy and lactation and to provide a rudimentary 
introduction to PND screening and referral pathways. The ADDIE (Assess-Design-Develop-
Implement-Evaluate) model of instructional design will be described as the framework used to design 
the educational intervention and details regarding the sample, procedures, content of the educational 
resources, data collection instruments and data analysis will also be described. The implications of 
the findings of Phase 2 of the study for pharmacy education around perinatal mental health are 
discussed and recommendations for future iterations of the training program developed are also 
presented. 
 
Chapter 5 will conclude by presenting an overall discussion of the findings from Phase 1 and Phase 2 
of this study in the broader context of PND screening in community pharmacy. Recommendations for 
pharmacy education, future research and practice will be discussed. Finally, this dissertation will draw 
conclusions about the key role that continuing professional education will play in the ability of 
pharmacists to conduct formal or informal PND screening during the course of their usual interactions 
with pregnant or postpartum women. 
Community-based perinatal depression recognition and management  |  June 2016  | University of Sydney  
18 
Chapter 2:  
Literature Review 
Postpartum depression screening by allied health professionals 
in primary care: a literature review 
 
Chapter 2 of this thesis has been submitted to the Journal of Mental Health (May 2016): 
 
Elkhodr, S., O’Reilly C.L., Okun M.L., Saini, B. Postpartum depression screening by allied 
health professionals in primary care: a literature review 
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Postpartum depression screening by allied health professionals 
in primary care: a literature review 
Elkhodr, S., O’Reilly C.L., Okun M.L., Saini, B.  
Abstract 
Background  
Postpartum depression (PPD) is a debilitating condition that affects a significant number of women. 
Primary-care based PPD screening programs offer a good chance of detection.  
Aim  
To review the literature on primary-care based PPD screening programs conducted by allied health 
professionals.  
Method  
The search was conducted between April and October 2014 in five databases. Key search terms 
included: allied health professionals, primary care, postpartum depression and screening. Inclusion 
criteria for article selection were that a) PPD screening constituted the focus of the research b) 
research based in primary-care setting c) focused on the screening outcomes, with/without an 
intervention and d) screening conducted by an allied health professional. Articles were excluded if 
they were not in the English language, focused on the antenatal period or based in secondary/tertiary 
settings.  
Results  
A total of 752 unique articles were obtained with eleven studies meeting the inclusion criteria. All 
articles reviewed described studies which used the Edinburgh Postnatal Depression Scale (EPDS) as 
the primary screening tool and all were led by nurses or midwives. Study results supported the 
feasibility of PPD-screening within primary care.    
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Conclusion  
 Further investigation into the feasibility of screening protocols within primary care is recommended 
given the prevalence of PPD.  
 
2.1 Introduction 
Depression is the second leading cause of global disability for women (Ferrari et al., 2013), with 
postpartum depression (PPD) affecting up to 13% of postpartum mothers. The DSM-5 (American 
Psychiatric Association, 2013) criteria stipulate that for a diagnosis of PPD, the onset of symptoms 
must have occurred within 4 weeks of birth, though this timeframe remains controversial with recent 
research suggesting that PPD onset can occur as late as 4 years postpartum (Woolhouse et al., 
2015). For the purpose of this review, PPD has been defined as the occurrence of depressive 
symptoms within 4 weeks of childbirth as per the DSM-5 criteria. Reported prevalence rates for PPD 
vary widely depending on the assessment method used, the timing of the assessment, and the 
population studied (Halbreich & Karkun, 2006). However, the widespread presence of PPD within 
various communities is a cause for concern and the subject of concerted public health efforts globally 
to mitigate its effects.  
 
The social and economic costs associated with PPD are significant yet it can often go undiagnosed 
and untreated (Gaynes et al., 2005). PPD has been strongly implicated in affecting the mother‘s 
relationship with her infant and the subsequent impact on the infant‘s long-term emotional 
development (Field et al., 2006), cognitive delays (Beardselee, Versage, & Giadstone, 1998) and 
increased risk of developing psychiatric disorders in adolescence (Pawlby, Sharp, Hay, & O‘Keane, 
2008). PPD is strongly implicated in cases of maternal suicide –it has been reported as a leading 
cause of maternal death (Hall, 2001) and infanticide, creating an understandable sense of urgency 
around developing methods to identify and treat PPD before it escalates to such fatal and preventable 
situations. 
 
Mothers with depression may not recognize or actively seek help for their depression (MacLennan et 
al., 1996). This may be due to a multitude of factors; fearing the stigma that they perceive to be 
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associated with PPD or feelings of shame and a fear that admitting to thoughts of self-harm or 
harming the baby may result in having the baby taken away from them (Mauthner, 2002). Such 
obstacles make it more difficult to detect PPD, necessitating the development of screening initiatives 
that women can easily access within their immediate environments and feel comfortable to engage 
with. Given the challenge PPD presents as a mental health disorder that may often go undetected by 
treating health providers and even the mothers themselves, the case for universal screening in 
primary care has been advocated by all levels of health governance - from primary health care 
authorities to the World Health Organisation (Wisner, Chambers, & Sit, 2006).  
 
Several published reviews (Baker et al., 2011; Gjerdingen & Yawn, 2007) have provided evidence that 
screening conducted by medical practitioners at scheduled well-baby visits and post-partum physician 
visits are useful in trying to identify cases of PPD yet these settings represent just a fraction of the 
avenues available within the primary care setting to undertake this task. Although medical 
practitioners are central in the management of PPD, allied health professionals are well-placed in 
primary care to assume roles that can help ease the immense pressure placed on community 
physicians. With up to 50% of PPD cases going undetected (Chaudron, 2003)  there exists a case for 
screening programs to exist in a multitude of allied-health directed, primary care settings. Primary-
care based screening models provide ideal settings for screening women, given the ease of access 
that women have to such venues and the extensive reach such settings provide. This review aimed to 
fill a gap in the literature by exploring the role of allied-health care professionals within current PPD 
screening research to determine the feasibility of delivering screening programs in allied-health 
directed avenues within primary care. The decision to focus on PPD rather than the entire perinatal 
period was made on the basis that screening tools are heavily utilised in PPD screening efforts 
(Stewart, Robertson, Dennis, Grace, & Wallington, 2003b) and that the use of depression screening 
scales in the antepartum period requires further validation (Kozinszky & Dudas, 2015).  
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2.2 Methods 
Search Strategy (search conducted April - October 2014) 
A strategic search was conducted using the following key terms (and related MeSH sub terms): allied 
health professionals, primary care, antenatal depression, postpartum depression and screening. The 
relevant search concepts and their related terms used were healthcare professional (OR/allied health, 
nurse, midwife, pharmacist, community worker, social worker) AND postnatal depression 
(OR/antenatal depression, perinatal depression, postpartum depression, postpartum blues, postnatal 
blues, maternal depression) AND screening (OR/referral, identification). Where appropriate, MeSH 
terms were utilized to increase search sensitivity. Five primary databases- Medline, Embase, Cinahl, 
PsycInfo, International Pharmaceutical Abstracts, and Scopus were used. Time limits were applied to 
search for articles published after 2000 and only articles in the English language were searched.  
 
The articles obtained were subsequently imported into the Endnote citation management software 
and duplicates were removed (Figure 2.1). The remaining articles (n=752) were screened. The key 
inclusion criteria for the initial screening was that that article must list postpartum depression 
screening as an essential aim of the research reported in the article. After initial screening, the full 
articles were read and subjected to detailed criteria which were that the research study must be based 
in a primary care setting (defined as a community-based venue that allows self-referral and no 
specialist intervention), focused on the screening outcomes in the postpartum period (where 
screening was conducted in isolation or as a precursor to identify eligible participants for a larger 
intervention study), that the screening process be conducted by an allied health professional (defined 
as any health provider who is not a medical practitioner) and finally, that screening protocols 
(population screened, tools used, criteria for ruling PPD in or out) be clearly defined. Research papers 
were excluded from this review if they were not in the English language, did not focus on the role of 
the allied health provider on screening outcomes as a major research objective, focused on screening 
by professionals that were not allied health care providers, conducted screening only in the antenatal 
period or conducted the screening in secondary or tertiary settings. Articles selected for review were 
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then analyzed against criteria in a modified version of the STAR-D checklist (Appendix A) and 
reported in Table 2.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.1 PRISMA flow diagram outlining the literature search strategy. 
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Records deemed relevant 
(n=223) 
 
Records screened after 
duplicates removed 
(n=752) 
EXCLUDED 
Screening outcomes not 
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Screening not conducted 
in primary care AND/OR 
not conducted by an 
allied health professional  
(n=151) 
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2.3 Results 
Search yield 
Eleven studies met the inclusion criteria that placed the allied health professional at the centre of the 
screening process and either directly focused on the screening outcomes themselves (n=4) or did so 
in the context of a larger intervention study (n=7) (Table 2.1).   
 
Screening Outcomes 
All studies measured the outcomes of a PPD screening program within primary care settings as at 
least one of their main research objectives and all studies which met the inclusion criteria for this 
review used the Edinburgh Postnatal Depression Scale (EPDS) as their primary screening tool. The 
EPDS is a self-administered 10-item questionnaire used for the purposes of identification of PPD in 
clinical and research settings. Values range from 0-30, with cut-off points for likelihood of depression 
differing between clinical protocols depending on the study methodology, language and diagnostic 
criteria used (Gibson, McKenzie-McHarg, Shakespeare, Price, & Gray, 2009). The EPDS has been 
the subject of many validation studies and the most recent systematic review reviewing EPDS 
validation studies (Gibson et al., 2009) noted that the thirty seven studies they analysed reported 
specificity values ranging from 44-100% and sensitivity from 34-100% depending on the cut-off values 
used.  
 
The studies reviewed reported outcomes differently. Some reported the PPV of the EPDS, whereas 
others tracked EPDS scores throughout a planned intervention. The interventions, EPDS cutoffs used 
in each study, professional  delivering the screening and other background information for each study 
is briefly described in Table 2.1
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Table 2.1 Summary of relevant information extracted from eleven studies meeting inclusion criteria 
Screening-only studies  
Reference EPDS 
Cutoff 
Study Protocol   Venue Participants Outcome Measures                Study results                       STAR-D 
 
Score                                      
Downie, J. et 
al. (2003) 
>=10 CHN;EPDS at 
6-8 weeks OR 
7-9 months 
postpartum 
child health 
centres; Western 
Australia 
mothers, 6 
weeks 
postpartum 
(n=167); 
mothers, 7-9 
months 
postpartum 
(n=91) 
to evaluate current 
practice outcomes from 
the use of the EPDS by 
child health nurses in 
child health clinics 
More women with depression at 
7-9 months (17.6%) than at 6 
weeks (13.8%);child health 
nurses referred several patients 
for possible PND based on 
observation despite normal 
scores on EPDS 
77% 
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Screening-only studies  
Reference EPDS 
Cutoff 
Study Protocol   Venue Participants Outcome Measures                Study results                       STAR-D 
 
Score                                      
Horowitz, J. A. 
et al. (2011) 
>=10 APRN; EPDS + 
SCID-1 at 4-6 
months 
postpartum 
EPDS 
(phone+mail);  
DSM IV 
interview (home) 
postpartum 
mothers 
(n=5169) 
to conduct a community-
based, PND screening 
initiative and 
recommend screening 
practices 
Screening by mail yielded a 
significantly higher percentage of 
mothers with elevated PND 
symptoms than screening by 
telephone suggesting that non-
direct screening methods 
improved chances of detection. 
64% 
Jevitt, C. et al. 
(2005).  
>=11 CHN + 
registered 
NM‘s; EPDS at 
72 hours and 6 
home visit; US pregnant 
(n=180); 
postpartum 
(n=77) 
to determine the 
feasibility of registered 
nurses screening for 
PND over time & making 
Women who appeared 
depressed were the least likely to 
agree to depression screening 
and/or a referral;10.6% of the 
77% 
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Screening-only studies  
Reference EPDS 
Cutoff 
Study Protocol   Venue Participants Outcome Measures                Study results                       STAR-D 
 
Score                                      
weeks 
postpartum 
referrals for further 
assessment in a 
primarily Black 
population 
screened sample received 
depression diagnosis, consistent 
with literature;  
Nishizono-
Maher, A. et 
al. (2004).  
>=9  CHNs; EPDS + 
clinical 
interview at 
 3-4 months 
postpartum 
community 
health centre; 
Japan 
mothers, 3-4 
months 
postpartum 
(n=96) 
to compare EPDS 
screening results with 
community nurses‘ 
clinical assessment  
51.1% of >9 EPDS scorers had 
not been detected by nurses for 
possible postnatal depression; 
nurses judgement significantly 
influenced by EPDS score when 
known 
 
77% 
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Screening & Intervention studies 
Reference EPDS 
Cutoff 
Study 
Protocol   
Venue Participants Outcome Measures                Study results                       STAR-D 
 
Score                                      
Brugha, T.S. 
et.al. (2011)  
>=12 HV‘s; EPDS at 
6 weeks, 6, 12 
and 18 months 
postpartum 
general 
practices in 
Trent, England 
mothers, 6 
weeks 
postpartum 
(n=2241) 
to study the effects of 
HV psychological 
intervention on EPDS 
outcomes at 6, 12 and 
18 months on women 
with an EPDS <12 at 6 
weeks 
At 6 months following childbirth, 
83 out of 767 (10.8%) control 
(CAU) women and 113 of 1474 
IG women (7.7%) scored >12 on 
the EPDS at 6 months, that is an 
absolute difference of 3.1% (95% 
CI 0.4–5.5) or a relative 
difference of 0.68 (95% CI0.50–
0.93, p=0.016) 
100% 
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Screening & Intervention studies 
Reference EPDS 
Cutoff 
Study 
Protocol   
Venue Participants Outcome Measures                Study results                       STAR-D 
 
Score                                      
Davies, B. R. 
et al. (2003). 
>=9  HV; CMH nurse                
EPDS at 1, 3, 
6, 12 & 18 
months 
postpartum 
Home visit; UK postpartum 
mothers (n=86) 
to improve the early 
detection and treatment 
of PND in the practice 
studied 
Use of the EPDS by health 
visitors enhanced the early 
detection of postnatal 
depression. 
46% 
Glavin, K. et 
al. (2010) 
>=10 PHN‘s; EPDS 
at 2 weeks, 6 
weeks, 3 
months and 6 
months 
postpartum 
home visits & 
well baby clinics; 
two 
municipalities in 
Norway 
mothers, 6 
weeks 
postpartum 
(n=228)  
to examine the effect of 
supportive counselling 
by public health nurses 
on PND 
Decrease in depression scores 
from baseline to 3 months (2.5 
point decrease, CI -4.0,-1.1) & 6 
months (2.7 point decrease, CI -
4.3, -1.2) in the intervention 
group. 
86% 
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Screening & Intervention studies 
Reference EPDS 
Cutoff 
Study 
Protocol   
Venue Participants Outcome Measures                Study results                       STAR-D 
 
Score                                      
Kuosmanen, 
L. et al. (2010) 
>=13 MHN‘s; EPDS 
at 8 weeks and 
after final 
mental health 
nurse visit 
three maternity 
and child health 
clinics in Vantaa, 
Finland. 
mothers, 8 
weeks post-
partum (n=166) 
to explore the impact of 
integrating mental health 
sessions into the 
everyday routines of 
MCH clinics  
Post-intervention, the mean 
EPDS score was 9.04; change 
from the beginning 
 -5.71, P = 0.062. 
43% 
Leung, S. S. L. 
et al. (2010). 
>=10  MCH Nurse; 
EPDS at 2 
months and 6 
months 
postpartum 
Maternal & Child 
Health Centres; 
Hong Kong 
mothers, 2 
month 
postpartum 
(n=462) 
to evaluate effectiveness 
of PND  screening 
program using EPDS  
Mothers undergoing PND 
screening programme using 
EPDS had better mental health 
outcomes than those screened 
by clinical assessment. 
85% 
Community-based perinatal depression recognition and management  |  June 2016  | University of Sydney  
32 
Screening & Intervention studies 
Reference EPDS 
Cutoff 
Study 
Protocol   
Venue Participants Outcome Measures                Study results                       STAR-D 
 
Score                                      
Macarthur, C. 
et al. (2002) 
no  
cut-off 
provided 
Midwives; 
EPDS at 4 
weeks, 10-12 
weeks & 4 
months 
postpartum. 
general 
practices; the 
West Midlands 
health region of 
the UK 
mothers, 4 
weeks 
postpartum 
(n=1503) 
to develop &  implement 
a new model of 
community postnatal 
care  
Mental health score (MCS) was 
significantly better in the 
intervention group than controls, 
as were mean EPDS scores and 
satisfaction amongst women who 
were assigned to the new model 
of care. 
85% 
Segre, L. et al. 
(2012) 
 >=12 CHN‘s 
screened with 
EPDS at ten 
possible 
home visits; Des 
Moines, Iowa  
postpartum 
mothers  
(n= 1800) 
to longitudinally assess 
the implementation and 
results of depression 
screening by the Des 
Depression scores significantly 
decreased amongst women who 
sought treatment after a positive 
screen; 63% of those seeking 
92% 
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Screening & Intervention studies 
Reference EPDS 
Cutoff 
Study 
Protocol   
Venue Participants Outcome Measures                Study results                       STAR-D 
 
Score                                      
occasions  
(depending on 
when subjects 
entered the 
study) 
Moine Healthy Start 
project 
treatment experienced at least a 
4-point improvement in EPDS 
score. Only 1% (n=8) of the total 
positive screens (n=581) were 
already seeking treatment. 
Abbreviations:  
MCH: Maternity And Child Health . 
MHN: Mental Health Nurse.  
CHN: Community Health Nurse.  
PHN: Public Health Nurse.  
HV: Home Visitor.  
NM: Nurse-Midwife.  
APRN: Advanced Practise Registered Nurse.  
CMH: Community Mental Health 
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Seven of these papers investigated the impact of counseling interventions following an initial 
screening process that were all integrated into the model of care (Brugha, Morrell, Slade, & Walters, 
2011; Davies, Howells, & Jenkins, 2003; Glavin, Smith, Sørum, & Ellefsen, 2010; Kuosmanen, 
Vuorilehto, Kumpuniemi, & Melartin, 2010; Leung et al., 2011; MacArthur et al., 2002; Segre, O‘Hara, 
Brock, & Taylor, 2012). All of the remaining four studies (Downie et al., 2003; Horowitz et al., 2011; 
Jevitt et al., 2005; Nishizono-Maher et al., 2004) that reported the outcomes of screening alone, 
included some mechanism for referral to an external treatment provider. None of the four studies 
reviewed reported follow up on the results of these referrals.  
 
In all seven studies where the design included initial screening followed by an intervention, the EPDS 
(Edinburgh Postnatal Depression Scale) was used as a screening tool as well as an outcome 
assessment tool to measure changes in depression scores after an intervention was implemented. 
However, the protocols for scoring and reporting the EPDS scores were different in each study. These 
studies used different methods to report changes in EPDS scores following an intervention (absolute 
score change, or threshold specified score change) as markers of depression. 
 
Six of the seven studies which applied a treatment intervention demonstrated significantly reduced 
EPDS scores following the intervention delivery. Glavin et al. (2010) noted that the intervention arm 
showed a 5.9 point average reduction in EPDS score compared to 3.4 points in the control arm, 
where the Reliable Change Index (a measure used to determine the clinical significance of change 
(Eisen, Ranganathan, Seal, & Spiro, 2007)) for the EPDS is calculated to be four points (Stephen 
Matthey, 2004). Davies et al. (2003) demonstrated that of 20 mothers classified as having depression 
according to their EPDS scores at 1 or 3 months, 75% were no longer depressed at 12 months, whilst 
Macarthur et al. (2002) showed a statistically significant reduction in EPDS scores of 1.66 in the 
intervention group. Segre et al. (2012) successfully referred 216 women with EPDS scores >12 for 
treatment with an on-site provider, where 63% of women (n=137) subsequently achieved at least a 4-
point reduction in EPDS scores after treatment, reporting that only 1% of those with a high EPDS 
score were already receiving treatment when screened. Leung et al. (2011) demonstrated a 41% 
reduction in the proportion of EPDS scores >10 in the intervention group at 6 months postpartum. 
Brugha et al. (2011) reported that the odds ratio for EPDS≥12 at 6 months for the 2241 subjects was 
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0.71 for the intervention group (7.7% EPDS score ≥12) compared to care as usual (10.8% EPDS 
score≥12). In contrast, Kuosmanen et al. (2011) did not find statistically significant changes in EPDS 
scores before and after the mental health intervention they studied. 
 
In the remaining four studies which focused on screening outcomes alone, the outcome measures 
used differed between studies. Some measured positive predictive value (PPV) of the EPDS as a 
primary outcome measure; Jevitt et al. (2005) found that of the 26 women in their study who received 
a mental health assessment following a positive screen, 19.2% (n=5) were diagnosed with 
depression, 53.9% (n=14) received a diagnosis of dysthymic disorder and 26.9% (n=7) were not 
classified as depressed, indicating a PPV of 73%. Horowitz et al. (2011) demonstrated a PPV of 
77.8%, with 144 out of the 185 mothers with EPDS scores >10 meeting the DSM-IV criteria for PPD. 
  
The remaining two studies did not report any diagnostic follow up to confirm the presence of 
depression so PPV could not be determined. However, they did conclude that their screening protocol 
was successful by virtue of the fact that the screening professional detected and referred cases that 
would otherwise have gone unnoticed. Downie et al. (2003) reported that 19.2% (n=50) of their 
screened subjects were at risk of developing depression based on their high EPDS scores with 11% 
of women in their study (n=29) receiving a follow-up referral. Nishizono-Maher et al. (2003) tested 
whether identification of mothers with PPD undertaken via clinical assessment by nurses yielded the 
same results as when the assessment was aided by use of the EPDS. In this Japanese study, 88/96 
subjects (total n= 693) who scored >9 on the EPDS and who were presenting to a clinic for 3 month 
postnatal check-up with their baby were provided with a nurse-delivered clinical assessment; the 
nurse was blinded to the EPDS score. Of these eligible cases, 51.1% (n=45) were not identified as 
depressed, by the nurse involved; this provides evidence for the clinical value of using a validated 
screening tool such as the EPDS in the course of nurse-directed postnatal depression screening.  
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2.4 Discussion 
This review described screening for postpartum depression (PPD) by allied health professionals in the 
primary care setting. To the best of our knowledge, this is the first review looking into this particular 
area of research. Primary care is a pivotal venue for PPD screening, thus clearly defined and 
implemented screening programs for depression could be particularly useful given the potential for 
healthcare professionals to miss cases of depression in the absence of such programs (Brealey, 
Hewitt, Green, Morrell, & Gilbody, 2010; Yonkers et al., 2001). It is important to note that despite 
casting a wide net to search for studies that included involvement of any type of primary-care based 
allied health professional in PPD screening, all research studies found that matched this inclusion 
criteria involved only nurse practitioners or midwives- none of the studies found involved any other 
type of allied health professional. Given the high prevalence of postpartum depression in the 
community, this is a particularly salient finding in light of the fact that there are multiple avenues within 
primary care that can be utilized to screen for PPD. Pharmacists are amongst the most easily 
accessible healthcare professionals within primary care and offer additional opportunities for mothers 
with PPD to be detected. In a recent study (O‘Reilly, Wong, & Chen, 2015b), it was demonstrated that 
pharmacists are capable and willing to perform depression screening and refer the patient to their 
physician where necessary.  This represents a critical area of future research which has the potential 
to significantly enhance the reach of PPD screening in primary care. However, our review indicates 
that although current community-based PPD screening programs have the potential to minimize the 
impact of PPD, the long-term success of such programs remains unclear due to a lack of long-term 
data. Despite this, the majority of studies reviewed concluded that screening in primary care provided 
a unique opportunity for healthcare professionals to detect PPD cases that could potentially go 
undiagnosed and untreated. 
 
Due to a lack of longitudinal studies on the topic, the long-term success of PPD screening programs 
could not be established. However, one of the key findings of this review was the universally 
recognised feasibility of PPD screening in primary care and the recurrent suggestion by authors that 
cases may have gone undiagnosed in the absence of the screening program utilized during the 
course of their study. The studies reviewed also suggest the utility of allied health professionals such 
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as nurse practitioners and midwives in PPD screening. This offers a significant opportunity to 
maximize existing resources; screening can be conducted and results referred to a specialist 
physician, sparing capacity in primary care. Mental health interventions by non-mental health 
specialist workers are already being implemented through the World Health Organisation‘s Mental 
Health Gap Action Programme (mhGAP). The mhGAP provides health professionals in low-middle 
income countries with the tools to deliver evidence-based mental health interventions in non-
specialised healthcare settings. This model could possibly inform future attempts to enable a wider 
variety of allied health workers to deliver PPD interventions in primary care.  
  
The availability of validated and widely known instruments such as the EPDS is a significant 
advantage in PPD screening. It was apparent in the studies reviewed that using an instrument such 
as the EPDS significantly enhanced clinical assessment of PPD and removed barriers that can lead 
women to underreport their symptoms when questioned directly by clinicians (Horowitz et al., 2011). 
This low rate of detection by clinical assessment alone compared to EPDS detection is well-known 
amongst researchers, with a review of the use of the EPDS by home visitors (Holden, 1994) indicating 
that the rate of detection of depression was as low as 40% using clinical judgment alone; a finding 
supported by Nishizono-Maher et al. (2003) and Leung et al. (2011). These findings appear to support 
research conducted within the broader area of depression which suggests that unassisted judgements 
of depression by clinicians lacks sensitivity when compared to standardised psychiatric measures 
used to screen for depression such as the Patient Health Questionnaire-9 (PHQ-9) (Carey et al., 
2014; Gilbody, Richards, Brealey, & Hewitt, 2007). The articles reviewed support the notion that 
where allied health professionals are involved in screening for postpartum depression in primary care, 
they would benefit from being trained in the use of instruments such as the EPDS as a standard 
screening tool within the course of their practice. 
  
Despite numerous studies exploring PPD screening in primary care, this area of research is limited by 
a diverse set of factors that complicate our ability to define a ―successful‖ PPD screening program or 
construct best practice recommendations for PPD screening in primary care. The lack of consistency 
in the reporting of screening outcomes is one of these factors. In the studies reviewed, multiple 
outcome descriptors were used to answer what was essentially the same question across the board: 
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how effective is screening by allied health professionals in primary care? In the four studies reviewed 
that conducted screening alone, the outcomes measured were either PPV of the EPDS or more 
simply, the number of positive screens elicited by EPDS screening (Downie et al., 2003; Horowitz et 
al., 2011; Jevitt et al., 2005; Nishizono-Maher et al., 2004). The underlying assumption- that detection 
equates with a positive outcome- is flawed given that case detection is simply the first step on a long 
road to recovery (ultimate recovery being the goal of screening in the first place). Despite all four 
studies including some mechanism for referral as part of their study, they did not report long-term 
follow up to determine PPD progression and the outcome of referral. Seven of the studies reviewed 
attempted to fill that gap by implementing an intervention following on from their screening protocol 
(Brugha et al., 2011; Davies et al., 2003; Glavin et al., 2010; Kuosmanen et al., 2010; Leung et al., 
2011; MacArthur et al., 2002; Segre et al., 2012). These studies mostly analysed EPDS score 
changes from baseline to post-intervention as an outcome to measure the effect of the intervention 
compared with controls. Six out of these seven reported improvements on baseline EPDS scores after 
the intervention; in one case the EPDS scores did not improve post intervention (Kuosmanen et al., 
2010). Although the results of these intervention-based studies are promising, they highlight the need 
for further, high quality research that quantitatively assesses the long-term impact of primary care 
PPD screening using consistent outcome measures. 
  
Another factor limiting the available evidence in these studies was the lack of standardized EPDS cut-
off scores used across the research spectrum. The literature (and indeed, the studies included in our 
review) shows a highly scattered approach to determining the EPDS cut-off for each study. The widely 
accepted optimal cut-off point for major depression is 13, as referenced by the original validation 
study, which indicates the likely presence of major depression (Cox et al., 1987). However, a wide 
variety of cut-off points for the EPDS (Stewart, Robertson, Dennis, Grace, & Wallington, 2003c) have 
since been reported. A meta-analysis of over 40 studies (Paulden et al., 2009) demonstrated an 
optimal cut-off of 10 for both major and minor depression and 13 as a cut off for major depression. 
Whilst a cut-off of 13 suggests the presence of major depression, a lower threshold of 10 will increase 
screening sensitivity and thus the number of potential cases of PPD identified. One study (Chaudron 
et al., 2010) suggested that the optimal cut-off of the EPDS may be as low as 9, several points below 
the traditional cut-off of 13. Regardless of cut-off scores, Davies et al. (2003) provide some evidence 
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to suggest that breaking away from study protocols is sometimes necessary when the clinicians 
involved suspect PPD despite a low EPDS score.  The variance in EPDS cutoff scores between 
studies highlights the need to standardise EPDS cut-off scores in research protocols to ensure that 
cutoffs used in primary-care based screening programs are backed by a strong body of evidence. 
Further research into key protocols in the use of EPDS for PPD screening is recommended to assess 
the factors that drive EPDS cut-off inconsistencies and to help shape a defined set of cut-off scores 
that inform future research studies. 
  
There is a growing sense amongst PPD researchers (Chaudron & Wisner, 2014) that future research 
must pivot around effective ways of bridging the gap between screening and treatment engagement to 
give an accurate picture of screening outcomes that can inform the development of clinical guidelines. 
Screening programs implemented in the absence of well-established and well-resourced referral and 
treatment programs to funnel positive screens are invariably found to be ineffective (Nishizono-Maher 
et al., 2004). Three randomised cluster trials studying the implementation of a training program that 
equips primary healthcare professionals with the skills to recognize, identify and treat PPD (Brugha et 
al., 2011; Leung et al., 2011; Yawn et al., 2012) collectively indicate that screening is most effective 
when integrated into a stepped-care model that begins with screening and ends with treatment  
(Gjerdingen, Katon, & Rich, 2008). The most recent systematic review (E. R. Myers et al., 2013) 
prepared for the Agency for Healthcare Research and Quality (AHRQ) in the United States suggests 
that where screening and treatment is offered by the same provider or practice, outcomes are 
considerably better and depressive symptoms significantly improve. This is particularly true for women 
who are more likely to decline referral to another service for treatment, as reported by nurse 
practitioners in the study by Jevitt et al. (2005) who observed that women that appeared depressed 
were the least likely to agree to referral. Further research on integrated care models in various 
primary care settings is required to bridge this research gap and provide policymakers with the 
confidence they need to implement such programs universally. 
 
However, despite evidence that stepped-care models appear to provide promising results, there have 
been limited attempts to determine the overall effectiveness of a screening program from detection 
right through to referral and treatment. Only one randomised controlled trial (Leung et al., 2011) has 
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been conducted to the knowledge of the authors that attempts to fill this research gap. However, 
significant limitations have limited its generalizability, leading some researchers (Thombs, Arthurs, et 
al., 2014) to argue that there is insufficient evidence to prove a benefit to women from established 
screening programs and that clinical guidelines should reconsider supporting costly universal 
depression screening programs. This conclusion correctly identifies a gap in the research exclusively 
linking screening to depression outcomes through high-quality randomised controlled trials. Some 
researchers lament the implementation of universal screening programs (L. Harris, 2016; Thombs, 
Ziegelstein, et al., 2014) citing lack of evidence of long-term benefit to PPD-affected women, 
exorbitant costs and potential harm to women as justifications for their stance. However, given the 
immense social risk and undiagnosed maternal suffering associated with not implementing some form 
of universal screening (Gjerdingen & Yawn, 2007), it may be suggested that these findings strengthen 
the imperative to conduct further high-quality randomised controlled trials to determine the long-term 
success rates of PPD screening programs. Further research is also required to determine whether 
extending such programs into allied-health directed avenues would result in a significantly higher 
number of women with PPD receiving diagnosis and treatment.   
2.5 Limitations 
Although great care has been taken to ensure the validity of this review, it contains several limitations. 
Firstly, the literature review was undertaken and synthesised by one author, increasing the chance of 
errors in determining eligibility of papers to be included in the review. This limitation was exacerbated 
by the tendency of some authors within the literature to implicitly suggest that their study measured 
primary-care screening outcomes when on closer examination, they didn‘t include this as a research 
objective. Preliminary screening of the literature was undertaken by secondary authors to reduce the 
effect of this limitation. Secondly, the authors were unable to ascertain the generalisability of the 
findings presented in the papers reviewed due to factors presented in the discussion. Despite these 
limitations, this review provides a unique perspective on PPD screening in primary care and delivers 
new insights about the application of screening protocols in settings beyond that which is current 
practice.   
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2.6 Conclusion 
Screening for PPD by allied health professionals with the EPDS is feasible and can help detect 
hitherto undiagnosed disease. While much research has been conducted, inconsistencies in defined 
outcomes and cut off thresholds for the EPDS within published screening studies limit effective 
translation of research into practice. Ease of access to healthcare professionals is vital for such 
screening programs to be effective. The findings of this review support the possibility that postpartum 
depression screening can be extended into multiple facets within primary care. However further 
research is required into the feasibility of training a wider scope of allied health providers within 
primary care to maximize PPD detection and improve depression outcomes. There is also an urgent 
need for further high-quality randomised-controlled trials that examine the long-term impact of 
screening and intervention on PPD outcomes within the context of stepped-care models.  
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Pharmacist perspectives on pharmacy-based perinatal 
depression screening: a qualitative study. 
Elkhodr, S., O’Reilly C.L., Saini, B.  
 
3.1 Introduction 
Perinatal depression (PND) affects up to 13% of mothers (Halbreich & Karkun, 2006) and is 
characterised by a non-psychotic depressive episode occurring during pregnancy or after birth. 
Distinct from the ‗postpartum blues‘, which occur in up to 70% of all new mothers and usually resolve 
within two weeks of birth (Marcus & Heringhausen, 2009), PND onset can occur as late as four years 
postpartum (Woolhouse et al., 2015) and can have far-reaching consequences on families affected by 
the disorder (Letourneau et al., 2012). With heightened global awareness about mental health and the 
recognition that PND often remains undetected, the implementation of universal screening programs 
to detect PND has been widespread and broadly advocated (Milgrom & Gemmill, 2014). 
 
According to a new statement from the US Preventive Services Task Force (USPSTF), all pregnant 
and postpartum women should be routinely screened for depression (L. Harris, 2016). However, the 
lack of randomised controlled trials (RCT‘s) providing evidence that universal screening programs 
improve depression outcomes has called the utility of such programs into question (Thombs, 
Ziegelstein, et al., 2014). A frequently cited criticism in the literature (Chaudron & Wisner, 2014; 
Gjerdingen & Yawn, 2007) is that comprehensive systems are required to ensure that suspected PND 
cases are funneled through to appropriate diagnostic and management services; that screening is just 
the first step of many and must necessarily precede a well-structured, collaborative system of care. 
Advisory bodies such as the Agency for Healthcare Research and Quality (AHRQ) have suggested 
that universal screening be reserved for situations where sturdy referral systems have been 
established to deal with screening results. Regardless, numerous studies have suggested that routine 
screening initiatives successfully increase the detection rate of PND in the community setting (Brugha 
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et al., 2011; Downie et al., 2003; Evins, Theofrastous, & Galvin, 2000; Horowitz et al., 2011; Jevitt et 
al., 2005; Segre et al., 2012).  
 
Given their routine contact with perinatal mothers, nurses and midwives are often the first health 
professionals to suspect that a woman is experiencing PND (Segre, O‘Hara, Arndt, & Beck, 2010) and 
although these visits present key opportunities to recognise and refer PND cases, they represent just 
a fraction of the avenues available within the primary care sphere to undertake this task. PND 
screening by allied health professionals who deal with perinatal women in primary care could 
theoretically increase the likelihood of detecting cases of PND. They are highly accessible to pregnant 
and postpartum women, operate within numerous venues in the community and are well-placed to 
assume roles that can help ease the immense pressure placed on community physicians.  
 
Pharmacists are one of the most accessible healthcare professionals within a mother‘s health care 
team and are well-placed in the community to identify potential cases of PND through the daily, casual 
conversations they encounter with women at risk. There are numerous examples of successful 
pharmacist-led, community-based screening programs that screen for conditions such as depression 
(O‘Reilly et al., 2015a; Rubio-Valera, Pons-Vigués et al., 2014), COPD (Castillo et al., 2009; L. Fuller 
et al., 2012; Soriano, Zielinski, & Price, 2009), sleep disorders (J. M. Fuller, Wong, Krass, Grunstein, 
& Saini, 2011; Perraudin, Le Vaillant, & Pelletier-Fleury, 2013; Tran et al., 2009), diabetes (Snella et 
al., 2006) and hypertension (Mangum, Kraenow, & Narducci, 2003) which support the notion that PND 
could also potentially be screened for in a pharmacy setting. Increasingly, the role of pharmacists in 
detecting and managing mental health disorders is becoming more accepted as emerging evidence 
points to their professional pertinence (Bell, Whitehead, Aslani, Sacker, & Chen, 2006; Rubio-Valera, 
Chen, & O‘Reilly, 2014) and feasibility within mental health care teams. Pharmacists may be 
instrumental in supporting early detection, forward referrals and interventions by other trained 
professionals (Finley, Crismon, & Rush, 2003) and recommendations have been made to include 
pharmacists as part of primary mental health care teams (Brophy, Hodges, Halloran, Grigg, & Swift, 
2014). Such involvement could reasonably be extended to accommodate the mental health needs of 
perinatal women though there appears to be very little in the literature to suggest this potentiality has 
been explored. Pharmacists already play a significant role in facilitating optimal perinatal health, 
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ranging from providing breastfeeding support (Edwards, 2014; Ruddock, 2004) and contraception 
counselling (Schatz, Chapman, & Chang, 2014) to nutrition advice (Philpott et al., 2014) and minor 
ailments in childhood. However, there are no studies that elucidate the perspectives or experiences of 
community pharmacists in PND, representing a significant gap in the literature about PND screening 
in the primary care context. 
3.2 Aim of the study 
The purpose of this study was to explore community pharmacist‘s current involvement in supporting 
perinatal women‘s mental health, their perspectives on the future role pharmacists‘ can play in health 
promotion (screening and health education) for perinatal depression in community practice and the 
barriers preventing them from currently doing so.  
3.3 Ethical Approval 
The study was approved by the Human Research Ethics Committee at the University of Sydney 
(project number 2015/683) (Appendix B). 
3.4 Methods 
A qualitative method of data collection and inductive analysis using a semi-structured interview guide 
to gather the data was deemed the most appropriate research design for this study, particularly as the 
research is exploratory  
 
Participant recruitment 
Purposive recruitment methods were employed to build a convenience-based sample of practicing 
pharmacists from the western/south western regions of the city of Sydney, New South Wales. The 
decision to focus on pharmacies in this area was based on data obtained from the Australian Bureau 
of Statistics (ABS 2014) which suggested that the fertility rate in this region was higher than the NSW 
average. Invitation letters, participant information sheets and consent forms were mailed out to thirty 
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two pharmacies in south-western Sydney in addition to practicing pharmacists known to the research 
team who were not necessarily located within the study catchment area of south-western Sydney. 
This was followed up with a phone call ten days later to elicit interest in participating in the study. 
Passive snowballing methods were subsequently employed to enhance the sample variation and size. 
Study inclusion criteria included participants who were pharmacists, English speaking and had 
practiced or were currently practicing within community pharmacy. Upon completion of the interview, 
participants were reimbursed with a thirty dollar gift voucher for their time and contribution. 
Recruitment continued until thematic data saturation was reached with respect to pharmacist 
experiences with perinatal depression. 
Interviews 
All semi-structured interviews were conducted over the phone by the first author in lieu of face to face 
interviews. This operating decision was made to enable convenience and higher response rates for 
pharmacists who cite ―lack of time‖ as a primary barrier to research participation (Awaisu & Alsalimy, 
2015). Although there was scarce literature related to pharmacist perspectives on PND, general 
reading about PND and primary care, as well as the collective pharmacy practice experiences of the 
research team were used to construct a good-quality semi-structured topic guide. The interview was 
structured to extract relevant participant demographic data and basic experiences with new mothers 
through simple, opening questions that became progressively detailed as the interview continued as 
outlined in Table 3.1 (see Appendix C for full questionnaire entitled ―Interview Topic Guide‖). Using 
this funnel approach, factual questions were used initially, followed by opinion and self-reported 
practice behaviour questions whilst allowing for reflective open ended comments if volunteered. To 
provide context, two brief, hypothetical vignettes related to mothers presenting with PND symptoms 
were used to lead interviewees onto questions around current and future practice. The guide was pilot 
tested with three practicing pharmacists prior to research interviews commencing both for the 
appropriateness of the interview guide and for the training of the main interviewer (SE). All interviews 
were digitally recorded and then transcribed verbatim by an independent transcriber for subsequent 
analysis. All transcriptions were cross-checked by the first author for accuracy and assigned identifier 
numbers. 
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Table 3.1: Semi-structured Interview Guide outline 
General Professional Characteristics 
 
seniority, size of pharmacy, location of pharmacy, years in practice, frequency of practice 
Pregnancy and postpartum in the pharmacy 
 
types of product queries, special Issues encountered, common counseling points to this patient 
group, general services offered to this group, observations about this patient group 
 
Perinatal Depression in the Pharmacy: Current Practice 
 
frequency of contact with postpartum mothers, gauging emotional problems, approaching 
suspected PND, current referral practices, confidence with referral 
 
Perinatal Depression in the Pharmacy: Future Practice 
 
community pharmacy‘s capacity to screen for postpartum depression, steps before PND screening 
can become professional service, tools required to screen for PND and incorporating them into the 
counseling session, potential barriers that need to be addressed before PND screening 
implemented, perceived stigma around PND, patient privacy and PND screening, acceptability of 
PND screening being conducted by pharmacists, cost issues, pharmacy owners willingness to 
implement PND screening, need for training. 
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Data Analysis  
Given that the objective of the semi-structured interviews  was to seek the perspectives of 
pharmacists concerning their experiences with PND and the lack of existing data on the topic, a 
constructivist approach was chosen to underpin data analysis. This approach recognises the 
subjective interplay between participant and researcher in deriving meaning from data (Mills, Bonner, 
& Francis, 2008), subjecting the research notes to a process of ―analytic induction‖ (Pope, Ziebland, & 
Mays, 2000) as a way of iteratively ―testing and retesting theoretical ideas‖ emerging from the data. 
Transcribed data were systematically coded using NVivo 10 software (QSR International Pty Ltd, 
2012). The research team first familiarised themselves with the transcripts before conceptualising 
presenting themes using open and axial coding techniques into a coding framework which was 
utilised in the analysis of further transcripts. Codes were integrated into this framework as they 
emerged. To improve the reliability of the data, 20% (n=4) transcripts were independently coded by 
two members of the research team and coding structures compared to achieve consensus. 
3.5 Results 
Of thirty two pharmacies contacted by mail and phone to participate, eleven responded (34% 
response rate). A further seven pharmacists in Sydney and two in the ACT were recruited through 
snowballing methods. Thus, a total of eighteen semi-structured phone interviews were conducted with 
practicing pharmacists in New South Wales and two in the ACT (twenty interviews in total) between 
September 2015 and January 2016. Table 3.2 summarises the general demographic and practice 
characteristics of participants. The interviews ranged between 18 and 43 minutes. The number of 
years participants had been in practice ranged between one to thirty. Three participants were 
registered but not currently practicing; these pharmacists were on maternity leave at the time but 
usually practised within community pharmacy. Participants reported their frequency of contact with 
perinatal women as ranging from ten per day to once every six months. A thematic content analysis of 
the interview transcripts revealed three umbrella themes  – role perceptions, patient-pharmacist 
relationship and practice issues, and eight sub themes summarised in Table 3.3 with relevant quotes 
provided beneath each sub-theme. Where direct participant quotes are used, the code P refers to the 
pharmacist followed by a number indicating the participant who provided the quote. 
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Table 3.2. Participant professional characteristics 
 
Participant Characteristics Proportion (n=20) 
Gender 
Female 
Male 
 
14 
6 
Time in Practice 
<5 years 
5-10 years 
>10 years 
 
5 
11 
4 
Seniority 
Employee 
Manager 
Owner 
Not currently practising 
 
10 
3 
4 
3 
Frequency of practice  
1-2 days/week 
3-4 days/week 
5+  days per/week 
Not currently practising 
 
 
3 
2 
12 
3 
Location of pharmacy 
Shopping strip 
Shopping centre 
 
12 
5 
 
 
Role Perceptions 
All participants expressed that pharmacists were ideally placed in the community to screen for PND 
and had the capacity and willingness to screen given the right circumstances but emphasised that 
diagnosis was beyond their scope of practice.  
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Accessibility 
 Participants identified several key parameters defining their role in the context of perinatal mental 
health, all underpinned by the ease with which mothers are able to access their pharmacists.  
“I think the beauty of community pharmacy, is the accessibility of it. So the fact that 
there’s always a pharmacist that you can speak to… rather than other medical 
settings, that require the customer to take that first step of, “I’m going to go and 
speak to someone about this.” which is quite often the biggest hurdle that people 
face…” P15 
 
“Sitting down and showing her that as a pharmacist, I’m on her side and for her to call 
me up whenever she’s feeling down .. show her that I’m part of her support system 
and that I’m there for her.. some patients do feel like the pharmacist is the first point 
of contact for anything, they just come into the pharmacy, which is ideally 
accessible.” P2 
 
“Always make sure that they know, they can come back in...make sure those doors 
are open…we are the most accessible health care professional you can just pop in 
and see the pharmacist, you don’t need to have an appointment.” P10 
 
 
Participants frequently noted that key to this supportive role was the imperative to de-stigmatize 
perinatal depression and reassure women that their experiences were relatively common.  
“Just informing the mother that it is quite normal..so a lot of them feel like they are 
the only one, as if it’s not normal to be feeling this way… but just inform them that 
there is help.. it’s something that still is not understood very well and that’s where the 
pharmacist can help change their views. 
.” P5 
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Most participants pointed out that overcoming this stigma was crucial to encouraging patients to open 
up about their depression. 
 
“The patient might perceive it as stigma (sic) and so she might be unwilling to 
disclose this sort of stuff in a pharmacy setting…so getting the patient to talk about 
these things that’s going to be the tricky part… I would reassure her that’s a very 
common experience after giving birth.” P6 
 
“It‟s a case of trying to put the person who you are talking to at ease, so you can try to 
overcome that stigma… and just reassuring people that what they‟re experiencing is 
completely normal.” P15 
 
 
Preparedness for roles in PND 
Although most participants identified their role as being primarily concerned with the provision of 
medication advice & counselling, some participants voiced concerns that community pharmacists are 
not currently well-equipped to advise on medication use while pregnant or breastfeeding.  
“I think pharmacists in the community will often get asked - is it safe to take 
antidepressants while you’re pregnant and while you’re breastfeeding and I think that 
are a lot of pharmacists out there who don’t know how to use the information in the 
best interests of the patient… I’ve seen it where pharmacists would scare women, 
about taking medication and that would result in them not wanting to get diagnosed, 
and not taking any treatment. ” P13 
 
“it‟s not particularly an easy thing to do because available resources for pharmacists to be 
able to make informed decisions about drugs aren‟t easy to come by... it‟s not easy for 
pharmacists to deal with” P18 
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All participants‘ noted the imperative to refer suspected cases of PND to appropriate professionals as 
their professional duty though were unfamiliar with local referral pathways for PND.  
 
Professional Boundaries 
A prevailing notion amongst a majority of the participants was that pharmacist-led PND screening 
would encounter resistance from primary care physicians (or general Practitioners-GPs). This was 
thought to occur as GPs may perceive that pharmacists were either not trained to screen, did not 
have the time in the pharmacy to explore sensitive mental health issues or believed that pharmacists 
would be stepping onto GP professional boundaries by conducting PND screening.  
“I think some doctors may raise their brows thinking (pharmacists) haven‟t been trained 
enough to be able to detect or screen for patients with mental health problems and I would 
agree to a certain extent. We are not doctors. We are only trained to a certain point where 
we had to say we need to refer you...if we can‟t detect patients that are going through that 
we‟re lacking in our professional duty to them” P11 
 
“I know with previous services, the doctors weren‟t taking on it, because they felt in a way 
that pharmacists were taking over the GP‟s job, but showing them it‟s actually more of a 
team work, the pharmacist referring rather than diagnosing, that will sort of help break down 
the barrier.” P2 
 
Suggestions were made that the key to overcoming some of this resistance would be through 
relationship-building and proving the value of the pharmacy based service.  
“I think a lot of it comes down to the relationships that you have with medical practitioners in 
your own area. A lot of medical practitioners really appreciate the fact that we ‟re referring 
people for other medical conditions already...the doctor‟s generally very appreciative of the 
fact that we‟ve sent that person back to them.” P15 
 
“The more people we screened and referred particularly if they turned out to be legitimate 
cases of concern then I think well the results are going to speak for themselves.” P19 
 
Furthermore, pharmacists noted that cultivating strong, interprofessional networks across the perinatal 
depression care landscape would allow for more robust referral and management strategies.  
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You don’t want to be overstepping anyone’s professional boundaries, but at the same 
time I think having recognition and the confidence of other healthcare professionals 
would definitely help. Because if we do get access to that kind of delivery of service 
but then get resistance from healthcare professionals then I don’t think we’ve 
accomplished anything” P7 
 
“For a diagnosis of depression, you need a medical practitioner, diagnosis cannot be 
made in a pharmacy, it can only be detected...you can suspect, but certainly you can’t 
diagnose it.” P6 
 
“I think screening and referring them on is definitely our role, but would have to be careful to 
stick within our realm and our field of expertise and not step outside that” P10 
 
 
The possibility of delivering PND training with GPs and pharmacists attending together was also 
raised by one participant. 
Pharmacist-patient relationship 
Patient Trust 
Pharmacists emphasised that nurturing patient trust was a prerequisite to initiating conversations 
around sensitive mental health issues. Moreover, pharmacists believed that the rapport they build with 
their patients through casual, non-threatening conversations allows them to pick up on nonverbal cues 
that may indicate the presence of a mental health disorder.  
I find that with my patients. I mean I tend to find out all about them just from chit-
chatting. It doesn’t have to be direct questions. You could just be discussing life in 
general & you’ll just pick up on these things. p11 
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The more you can get people talking the more cues you see, like both verbal and 
nonverbal cues you will start to see. And also people start to open up the longer the 
conversation goes on. So you tend to be able to get a good gauge on what the real 
issue is rather than the initial thing that the person is talking to you about. P15 
 
An interesting observation was made by several pharmacists that a patient‘s trust was predicated on 
the pharmacist‘s perceived ability to relate to the mother in question; namely that they are either 
female or a father and thus able to empathize.  
“I was always very wary, when I first got registered about being a young male 
pharmacist and having these conversations with women...I always talk about personal 
experience whenever I talk to customers, about my own kids...I think it makes you 
much more relatable” P15 
 
“If you guide them in that direction, but also show them that – I‟ve been through something 
similar and this is what I did, I think they would be more prone to accepting that advice. 
There‟s that fine line and it really depends on the pharmacist ...if it was a male, some women 
might get offended.” P12 
 
The difficulties associated with maintaining patient privacy in an open pharmacy was also frequently 
cited as a potential barrier to earning patient trust. 
“There‟s also the whole issue of pharmacy being such an open space and if you don‟t have 
that area or counseling room where you can spend that time with the patient then the patient 
would be less likely to tell you what‟s going on because they will always have that feeling of 
someone listening in” P11 
 
Patient Autonomy 
Participants noted that patients are often hesitant to disclose that they are struggling emotionally.  
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“They’re often trying to shrug it off, they say I’m tired, it’s because I haven’t slept 
properly, because I’m not eating properly. So they’re not wanting to name how they’re 
feeling..as a mum, you would never talk about how you weren’t coping.” p13 
 
Pharmacists asserted that in such cases, respecting patient autonomy transcended their professional 
mandate to refer cases that they believed warranted additional investigation, except where immediate 
risk to the mother or child was apparent.  
“If in fact, if they outright say that they‟re really depressed and they want to hurt themselves, 
then patient confidentiality isn‟t much of an issue in those cases, but it is your responsibility 
as a pharmacist to get somebody involved, who might be in a better position to actually 
manage that.” P10 
 
They were also careful to maintain this autonomy when following up on mental health referrals with 
the patient‘s medical practitioner by ensuring they receive consent first.  
 
“I would encourage the patient, yeah just go and have a chat to your doctor. If there was no 
improvement that‟s when I might be considering having a conversation with the prescriber 
but I‟d get the patient‟s consent first because you don‟t want to sort of stir things around that 
way.” P19 
 
Clinical Practice Issues 
Training 
Pharmacists cited a lack of confidence when dealing with sensitive mental health issues.  
“If I knew more about the condition and knew how to pick up on it in pharmacy that would 
make me more confident. If am confident that she does have possibly have it or if she thinks 
that she might have it that‟s easier to refer.” P1 
 
Most participants acknowledged that their current level of expertise was inadequate to deal with the 
complexities associated with perinatal depression and expressed frustration at the lack of clear 
guidance available to pharmacists regarding appropriate referral pathways. They unanimously stated 
a desire to engage in further education to gain these skills and knowledge.  
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“The perceptions of pharmacists themselves could be a barrier because, you know, 
there is a stigma is dealing with general depression let alone postpartum depression. 
That could be resolved with education to empower pharmacists, I guess and training 
to sort of make it normalized that dealing with patients with depression and 
postpartum depression is not only essential but it is possible.” P7 
 
“I definitely want training because as I said as a pharmacist, we just know the general 
side. We don’t have training on how to approach something as sensitive as mental 
health. So probably more in-depth training and techniques on how to approach the 
situation that would definitely give you more confidence in dealing with it.” P2 
 
When queried about the format they would like the training to take, the majority stated that they would 
prefer online modules but that a face-to-face component was also necessary to simulate possible 
interactions with patients who may have PND. 
“I think it would probably have to be a combination of pre-learning online. And then probably 
some face-to-face stuff. Because I think when you‟re talking about how you interact with the 
customer, which is really the key to whether or not it‟s going to be successful. There has to 
be some face-to-face time, because you need to be able to present those scenarios in a 
more personal way.” P15 
 
Conflicting priorities 
Pharmacists frequently cited a lack of time as the primary barrier to conducting PND screening in 
community pharmacy. Participants expressed that competing demands in the pharmacy created a 
perplexing dilemma where they had to choose between providing patients with focused attention or to 
get through the heavy foot traffic that flows through their pharmacy. Such conflicts were described as 
a compelling reason to thoroughly consider whether PND screening, a time-intensive endeavour, is 
appropriate in community pharmacy. 
“Times always a barrier, the pharmacist is always very busy... It‟s unfortunate but that‟s just 
the whole changing face of pharmacy. It has become hard to spend time with patients. If that 
was to take place I think it would be necessary to employ more staff especially employ 
another pharmacy dispensary checker or another pharmacist so you could have enough 
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time to be able to go through with these processes and put them in place and to use them 
sufficiently.” P11 
 
It was pointed out however, that if a given pharmacy was intent on providing this service, such 
conflicts could be resolved. 
“I guess you can always get around with that if you really generally want to adopt that 
service. I think that wouldn‟t stop anyone if that‟s the mission and the priority the pharmacy 
wants to adopt and instill.” P7 
 
Remuneration 
Suggestions were made that time constraints could be resolved by securing funding that would allow 
for more pharmacists to be on staff thus giving them time to have in-depth mental health discussions 
with patients.  
 “Time means money so if it‟s going to be a free service most pharmacy owners will be 
hesitant because they are paying for that extra pharmacist to do that extra work so there has 
to be something in return.” P11 
 
Some pharmacists believed that PND screening counts as a professional service they should be 
financially remunerated for. Some participants felt that pharmacy owners would be more partial to 
adopting PND screening in their pharmacy if remuneration was provided.  
“The issue with pharmacy, the big issue is actually funding.There should be some kind of 
reimbursement for that because this is not just dispensing a prescription. It‟s more of an in-
depth session. So something along the lines of the Medcheck program for example...some 
kind of reimbursement, should really be there, to motivate the pharmacists to give that extra 
time for the patient.” P2 
 
The pharmacy owners interviewed all agreed that the value provided by pharmacists in the context of 
PND screening needed to be recognised but differed on whether that value should be financially 
compensated.  
“I honestly believe, that us providing this service to our community, creates 
customers for life...I don’t believe you could charge for mental health screening. ” P13 
 
“I think going forward the bottom‟s fallen out of the margin of dispensing. Most pharmacies 
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depend on dispensing...so services that are being rolled out need to have some kind of 
value.” P20 
 
Not all pharmacists however believed that they needed to be remunerated to screen for PND. These 
participants either felt that the costs associated with screening would be so low as to not warrant 
remuneration or they believed that screening was simply another facet of their role as pharmacists. 
 
“ I don‟t think there‟s much cost involved in screening, unless it‟s a you know, full blown 
screen, where they come in at a scheduled time – I think if you‟re just picking up on that with 
the perinatal patients coming into the pharmacy, I dont think there actually needs to be any 
funding for that; just part of our role.” P10 
63 
 
3.6 Discussion 
This study represented the first qualitative study conducted to evaluate the concerns, beliefs and 
needs of pharmacists in the context of perinatal depression screening. Quantitative reviews have 
been undertaken to assess the acceptability of perinatal depression screening to healthcare 
professionals (El-Den, O‘Reilly, & Chen, 2015) however much of the research conducted in the area 
of perinatal depression has centered around the experiences of medical practitioners, nurses and 
midwives. There is little evidence in the literature to suggest that the feasibility of pharmacist-led PND 
screening has yet been explored. On the other hand, there is reasonable evidence to suggest that 
pharmacists have a role to play in the detection and management of mental health issues (Finley et 
al., 2003; Rubio-Valera, Chen et al., 2014) and the feasibility of implementing depression screening 
services in pharmacy has been demonstrated (O‘Reilly et al., 2015a). This study bridges a significant 
investigative gap that opens the possibility of trialing perinatal depression screening programs in 
community pharmacy. The results of this study indicate that pharmacists are willing to expand the 
professional scope of their practice to incorporate such a role. However, participants voiced salient 
points for consideration before the feasibility of such a program can be explored. Their main areas of 
concern centered around establishing patient trust, handling conflicting priorities, access to 
educational resources, and enhancing interprofessional collaboration. 
 
The importance of establishing patient trust and rapport was raised in this study as a significant 
consideration in the provision of perinatal depression screening services. Many studies have 
confirmed that patient trust is a critical factor in treatment compliance (Kerse et al., 2004; Piette, 
Heisler, Krein, & Kerr, 2005; Zolnierek & DiMatteo, 2009). Ensuring patient privacy is paramount to 
establishing this trust, participants stated, though guaranteeing this privacy in the context of a busy 
pharmacy was difficult. Lack of privacy in community pharmacy has been a long-standing issue for 
pharmacists (Raisch, 1993). However, consultation rooms in pharmacies are becoming more 
commonplace and may encourage patients to discuss sensitive issues with their pharmacist, such as 
PND, in private when they are aware of their availability (Mobach, 2008; Saramunee et al., 2014).  
 
Community-based perinatal depression recognition and management  |  June 2016  | University of Sydney  
64 
In addition to challenges associated with maintaining patient privacy, pharmacists acknowledged that 
they struggled to prioritise in-depth mental health discussions with mothers in the pharmacy due to 
significant time-pressures. Such pressures are well-documented (Eades, Ferguson, & O‘Carroll, 2011; 
Eden, Schafheutle, & Hassell, 2009; Gert Scheerder, Iris De Coster, & Chantal Van Audenhove, 
2008; Saramunee et al., 2014). Participant suggestions that remuneration for a PND screening 
service to employ extra pharmacists may be justified given pharmacist performance, job satisfaction 
and time spent with patients is associated with staffing adequacy (Chui, Look, & Mott, 2014; Kreling et 
al., 2006). Pharmacy stakeholders have long been championing the expansion of professional 
pharmacy services but without adequate financial support to reduce associated pharmacist workload 
increases, pharmacists are far less inclined to adopt such services (Bush, Langley, & Wilson, 2009). If 
future research deems PND screening in pharmacy feasible, then government remuneration schemes 
may be required to support the wide rollout of such a program.  
  
Whilst lack of privacy and time to explore the mental health state of perinatal patients were cited as 
major barriers, a more urgent concern appeared to be lack of adequate training to detect or refer 
cases of PND. Pharmacists in this study frequently commented on the need for further training in 
perinatal depression detection, referral and management and the lack of clarity in current guidelines 
for directing patients to appropriate care. These suggestions align with previous research (Scheerder 
& Iris De Coster, 2015) suggesting lack of training as the most important barrier to implementing 
depression services in pharmacy. Given they are often the first point of contact for patients with 
depressive symptoms (Linden, Wurzendorf, Ploch, & Schaefer, 2008), the imperative to adequately 
prepare pharmacists to detect and appropriately refer cases of suspected PND is high. Study 
participants expressed that they lack the confidence to approach sensitive mental health issues, 
corroborating previous research suggesting pharmacists are more comfortable dealing with physical 
illnesses than mental illnesses (Rickles, Dube, McCarter, & Olshan, 2010) and lack sufficient 
confidence to conduct public health services (Eades et al., 2011). The suggestion that a priority for 
such training would be to overcome stigma and build mental health literacy amongst pharmacists is 
not unwarranted. Findings from previous studies with pharmacists (O‘Reilly, Bell, Kelly, & Chen, 2013) 
indicates that lower levels of mental health stigma results in pharmacists being more willing to provide 
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medication counseling for consumers with schizophrenia and that pharmacy students (Bell, Johns, 
Rose, & Chen, 2006; Linden et al., 2008) had a significant reduction in stigma after attending mental 
health education programs.  
 
 However an interesting finding was the suggestion that pharmacists also require further training in 
medication use during pregnancy and lactation. Previous studies indicate that whilst the majority of 
pharmacists feel confident providing medication counselling during the perinatal period, their 
knowledge is variable and may require further training (de Ponti, Stewart, Amir, & Hussainy, 2015). 
Participants repeatedly emphasized that their primary role in the context of perinatal care is to 
facilitate safe use of medicines and provide important medicine information, a notion commonly 
expressed amongst pharmacists in research studies (Eades et al., 2011; Worley et al., 2007). As 
such, any attempts to develop pharmacist-specific, PND training modules would need to examine and 
address knowledge gaps since medication counselling is primarily within the purview of pharmacists. 
In terms of training format, views collected from pharmacists during this study are consistent with a 
solid body of evidence suggesting that digital learning approaches are an effective means of 
delivering health training to healthcare professionals (Davis, Sollecito, Shay, & Williamson, 2004; 
Hollis et al., 2015; Manning & Frisby, 2011; Peters, Kimura, Ladden, March, & Moore, 2008). Digital 
learning is becoming an indispensable tool in the mental health education repertoire with many 
healthcare professionals engaging in continuing professional development activities online. This 
pedagogical transition however does not negate the need to deliver at least some content vis-a-vis. 
This is primarily true when attempting to train pharmacists to improve their communication 
approaches to people with mental illness (Bell, Whitehead, et al., 2006) where role plays and patient 
interactions are vital to the learning process. Further research into the format and feasibility of training 
pharmacists to understand, detect and refer cases of PND is recommended. 
 
Interprofessional collaboration, particularly between pharmacists and general practitioners (GP‘s), 
was frequently mentioned by participants as necessary to the successful implementation of PND 
screening, supporting previous research stating the same (Bradley et al., 2008; Bradley, Ashcroft, & 
Noyce, 2012; Laubscher, Evans, Blackburn, Taylor, & McKay, 2009; Zwarenstein, Goldman, & 
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Reeves, 2009). Cooperation between pharmacists and GP‘s is vital to ensuring continuity of care, 
although collaboration between these two professions in the context of depression is uncommon (Bell, 
Aslani, McLachlan, Whitehead, & Chen, 2007). Both GP‘s and pharmacists report interprofessional 
collaboration as an essential component to successful pharmacist-delivered public health services 
(Bryant, Coster, Gamble, & McCormick, 2009; Scheerder et al., 2008) however GP‘s have often 
expressed doubt in pharmacist‘s abilities to deliver services beyond their roles as medication experts 
(Hughes & McCann, 2003). One participant‘s suggestion about interprofessional learning i.e. involving 
GP‘s in pharmacist PND training echoes previous research (Hughes & McCann, 2003; Scheerder & 
Iris De Coster, 2015) suggesting this may encourage cross-sector discussions about how to jointly 
manage PND patients, ensuring adequate pharmacy utilisation, efficient referral systems and avoiding 
duplication of care. Participant‘s perceptions that GP‘s are not comfortable with pharmacists 
managing the PND screening process has been mirrored by research suggesting GP‘s do not believe 
pharmacists are as equipped to deliver some health services as GP‘s are (Blenkinsopp, Tann, Evans, 
& Grime, 2008; Edmunds & Calnan, 2001; Hughes & McCann, 2003). Bradley et.al (2012) propose a 
model of collaboration that takes these attitude discrepancies into account and moves through three 
stages of interaction (isolation, communication and collaboration) before meaningful professional 
alliances can occur. For PND screening in the pharmacy to be useful, consistent referral systems to 
GP‘s must be installed and this requires harmonious cooperation between both professional sectors.  
3.7 Conclusion 
Pharmacists are willing and able to reinforce their involvement in mental health promotion activities by 
developing systems to implement perinatal depression screening in the community pharmacy context. 
The main barriers that must be overcome to facilitate such a program include inadequate training, lack 
of patient privacy and time and perceived GP hesitation to support pharmacist-led PND screening. 
Further research into the feasibility, economic viability and benefit of such screening initiatives is 
recommended.  
This manuscript does not contain clinical studies or patient data. 
The authors declare that they have no conflict of interest. 
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Chapter 4: 
Phase 2 Study 
Developing and implementing the Perinatal Mental Health in 
the Pharmacy (PMHP) training program 
 
4.1 Plan of Chapter 
Research findings from the first phase of this research described in Chapter 3 indicated a need for a 
training intervention to augment pharmacists existing understanding of perinatal mental health 
disorders and to prepare them for the possibility of undertaking perinatal depression screening. This 
chapter will describe the development, implementation and evaluation of a pilot perinatal depression 
educational training program delivered to pharmacists (Phase 2). The development of this training 
program was based on a thorough evaluation of adult education methodologies and the approach 
taken to plan, design and deliver the program will be discussed in depth in this chapter. Phase 2 
findings will be discussed in the context of a broader discussion around mental health education 
programs delivered to pharmacists with particular attention focused on the feedback provided by 
Phase 2 participants.  
 
4.2 Introduction 
The recognition of the role of primary health practitioners in the delivery of mental health services has 
been growing steadily and as one of the most accessible primary health professionals, pharmacists 
have been increasingly studied as potential drivers of mental health care in the community setting 
(Rubio-Valera, Chen et al., 2014). With the increasing emphasis placed on the pharmacist‘s role in 
mental health care delivery, there is a need to continue to research appropriate and effective ways of 
preparing pharmacists to collaborate within a team of health professionals to detect, refer and 
manage patients with mental health disorders. With perinatal depression (PND) affecting up to 13% of 
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women in the perinatal period (Gaynes et al., 2005), pharmacists are in an ideal position to screen for 
this disorder. As discussed in Chapter 3, pharmacists acknowledge the important role they have to 
play in supporting mothers through this vulnerable and often difficult time in their lives. However, 
pharmacists in Phase 1 of this study consistently stated that whilst they acknowledged their role in the 
provision of perinatal care, they were not equipped to handle perinatal mental health issues as they 
were not adequately trained in this area. Research has shown that pharmacists who undertake mental 
health training often report lowered levels of stigma attached to mental health issues, an improved 
ability to detect mental health disorders and increased confidence in providing services to consumers 
with mental illness (McGuire, Bynum, & Wright, 2016; O‘Reilly, Bell, Kelly, & Chen, 2011). A thorough 
review of the literature suggested that an educational intervention for pharmacists on the subject of 
perinatal mental health has not been reported. With a need for pharmacist-specific perinatal mental 
health training clearly identified in Phase 1 of this study, the research team decided to develop and 
pilot test a perinatal mental health training program with a small group of community pharmacists to 
inform future attempts to train pharmacists in this important area. 
4.3 Objectives 
The primary objectives of Phase 2 were to: 
 
1. Pilot test a perinatal mental health training program with pharmacists 
2. Identify an appropriate training methodology to inform the development of a perinatal mental 
health training program relevant to pharmacy practice 
3. Fulfill the training needs articulated by community pharmacists in Phase 1 (Chapter 3) 
through a pilot perinatal mental health training program 
4. Gather feedback from pilot participants to inform future iterations of this newly developed 
training program. 
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4.4 Method 
4.4.1 Design 
Phase 2 utilised a single-group, pre-post experimental design to pilot test an educational program on 
the topic of perinatal mental health. A mixed format approach was employed, encompassing self-
study and face-to-face components. The educational intervention consisted of a three-hour face-to-
face workshop which was preceded by the dissemination of relevant pre-reading to all registered 
participants. Pre- and post-workshop analyses of participant attitudes and confidence levels with 
respect to perinatal depression screening as well as training program evaluation were investigated 
through an online survey sent to participants. Participants were expected to complete a self-reflection 
activity within three weeks of completing the workshop to satisfy continuing professional development 
requirements attached to this program.  
4.4.2 Sample 
Community pharmacists practising in Sydney, Australia (n=15) were recruited to participate in the 
―Perinatal Mental Health in the Pharmacy” (PMHP) educational program. Recruitment was conducted 
through a non-paid advertisement posted in a popular Australian pharmacist‘s social media group 
inviting pharmacists to participate by registering online. One of the inclusion criteria for participation 
was that participants must be registered pharmacists with community pharmacy experience. Twenty- 
nine pharmacists who met this inclusion criterion registered to attend the training program, however, 
only 52% (n=15) of registered and eligible participants attended the workshop. Given the purpose of 
the research was to pilot test and gather participant responses to the training program, the small 
sample size was deemed adequate for the purposes of Phase 2. Participants were advised on 
multiple occasions throughout their involvement with the program that the purpose of the pilot was to 
gather feedback and insights that may inform future research about PND training for pharmacists. 
Their completion of the pre- and post-workshop surveys was taken as confirmation of their consent to 
be involved in the pilot test. Participants were advised that pending completion of all components of 
the program, they would receive a certificate which could contribute to their continuing professional 
development portfolio.  
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4.4.3 Educational Program  
A review of adult training methodologies used in the development of pharmacy programs was 
conducted in consultation with senior members of the research team. Various models were 
investigated for the development of PMHP and two models in particular were deemed appropriate for 
use in the PMHP program - the ADDIE (Assess-Design-Develop-Implement-Evaluate) model and the 
Dick and Carey Systems Approach model. 
 
The ADDIE model (Branson, Rayner, Cox, Furman, & King, 1975) is at the core of Instructional 
System Design models with wide applicability across disciplines including the health sciences (Duffy & 
Robins, 2011; Pittenger, Janke, & Bumgardner, 2009; Robinson & Dearmon,2013). It provides a lean 
and unencumbered view of all necessary components of an instructional program and provides a 
clean, linear and simple-to-use framework for novice instructors to follow. It does not prescribe the 
use of specific learning theories but rather serves as a device to assist instructors to visualise and 
plan course design. The ADDIE model postulates that learners‘ needs and the context in which they 
are to be taught should be analysed (Assess) which sets the stage for learner expectations and 
learning goals to be constructed in the Design phase. Here, learning goals and objectives, 
communication and technology strategies and overall class design are defined. Once a blueprint for 
the program is established, instructors then develop program materials in line with the learning 
objectives in preparation for implementation within a class environment. Finally, the course instructors 
evaluate the program through the delivery of feedback and assessment mechanisms intended to 
measure the outcomes of the program to inform future iterations (Shelton & Saltsman, 2006) 
 
In contrast, the Dick and Carey Systems Approach Model (D. C. Myers, Dick, & Carey, 1978) (Figure 
4.1) postulates a systems view whereby instruction is conceived as a complex, interconnected 
structure rather than the sum of isolated parts as described in the ADDIE model. The model describes 
the interdependence between content, context and instruction and assumes an iterative rather than a 
linear execution of each step. The evaluation process in the Dick and Carey model stands in contrast 
to the ADDIE model. The ADDIE model places the evaluation phase in the final stage of the 
instructional process whereas a key component of the Dick and Carey model is that evaluation occurs 
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throughout each step of the method. Revisions are made continuously and constant iterations of the 
instructional program are to be expected (Keenan, 2013).  
 
 
Figure 4.1 The Dick and Carey Systems Approach Model (Dick et al., 2001) 
 
After careful consideration, the ADDIE (Assess-Design-Develop-Implement-Evaluate) model was 
chosen as the most appropriate framework to utilise in the development of the PMHP program 
(Mayfield, 2011; Shelton & Saltsman, 2006). The primary driver behind this decision was the 
recognition that the inherent flexibility and linearity of the ADDIE model conferred a level of simplicity 
that was appropriate for the purposes of a pilot test. As such, this section will be organised in 
accordance with the ADDIE framework to allow for a coherent overview of the process followed by the 
research team in the development of the PMHP program. 
4.4.3.1 Defining the context (ASSESS) 
The research findings in Phase 1 of this study provided enough scope to justify an investigation into 
the training needs of the target demographic - community pharmacists. The ASSESS phase of the 
ADDIE framework requires that the instructional problem is defined, training goals clarified and that 
existing gaps in the knowledge/awareness of the target demographics are elucidated. 
Community-based perinatal depression recognition and management  |  June 2016  | University of Sydney  
72 
Needs analysis 
The process of determining an educational need (or clarifying the discrepancy between current and 
desired knowledge levels) is usually considered to be the first step in instructional design (Burton & 
Merrill, 1991). Qualitative findings discussed in Chapter 3 clearly identified a gap between 
pharmacist‘s existing knowledge about perinatal mental health and their level of expected knowledge. 
Pharmacists interviewed felt that while they were willing to screen for perinatal mental health 
disorders, they were not trained well enough to do so. Participants frequently suggested that their 
understanding of safe medication use in pregnancy and lactation was not adequate and that they 
were not comfortable counselling pregnant or lactating patients about safe psychotropic use.  
 
Furthermore, analysis of the interviews conducted in Phase 1 revealed a sense of reticence amongst 
participants to engage in discussions about mental health with women in the perinatal period due to a 
lack of confidence in approaching what is perceived to be a sensitive issue. Pharmacists have 
frequently reported a lack of confidence in counselling patients with mental illness (Badger, Kingscote-
Davies, & Nolan, 2002; Bell, Rosen, Aslani, Whitehead, & Chen, 2007; Bell, Whitehead et al., 2006) 
although they are usually interested in providing services to mentally ill patients (Cates, Burton, & 
Woolley, 2005). Although there does not appear to be published data specifically discussing the 
impact of pharmacist confidence levels on the ability to screen for perinatal depression, it may be 
inferred that a similar level of reticence exists particularly in light of the findings in Phase 1 of our 
study.   
Review of existing resources  
A comprehensive review of existing perinatal depression training programs that were easily 
accessible to pharmacists was conducted. A thorough search of published literature was conducted 
using the search terms education (/OR training OR teaching) AND primary care 
 (/OR allied health OR pharmacy) AND perinatal depression (/OR postpartum depression OR 
postnatal depression OR antenatal depression). Where appropriate, MeSH terms were utilised to 
increase search sensitivity. Five primary databases - Medline, Embase, Cinahl, PsycInfo, International 
Pharmaceutical Abstracts and Scopus were used. Time limits were applied to search for articles 
published after 2000 and only articles in the English language were searched.  
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In addition, three online search engines - Google, Yahoo and Bing - were used to search for perinatal 
mental health training programs used in practice. Filters were set by language and geographical 
location so that only results in the English language and in Australia were found, since the focus of 
this search was primarily on Australian-based programs (given our target demographic consisted 
solely of Australian pharmacists). Programs which did not list allied health-care professionals in their 
target audience groups, aimed specifically at one group of health professionals or patients (e.g. 
midwives, rural health providers, Indigenous patients, etc.) or listed pre-requisites were excluded from 
the review. Programs which were held as one-off events or did not publicly advertise the training were 
also excluded. Several training providers were identified which hosted training programs of various 
formats and target audiences (Table 4.1).  
 
These training programs ranged from a one and a half hour online training program to a Masters 
degree focusing purely on perinatal and infant care. Many of the specialised perinatal mental health 
training programs whose details were published online (that were geared solely at healthcare 
professionals) focused on providing training to medical and nurse/midwife practitioners though they 
did also suggest that they were available for ―allied health professionals‖. The only comprehensive 
training program which appeared to be freely and easily available to all healthcare professionals 
across Australia was the six-part online perinatal mental health training program provided by 
BeyondBlue, Australia‘s leading mental health advocacy organisation. The training program offered is 
an online learning program which incorporates case studies and clinical advice from leading perinatal 
mental health experts. BeyondBlue has also developed the Clinical Practice Guidelines for the 
treatment of perinatal mental health disorders which is intended to be used as a reference resource 
by health professionals. One member of the research team completed this online training program to 
determine its suitability for pharmacists and determine whether there was a need for developing the 
PMHP program if this program could sufficiently address the training needs espoused by pharmacist 
participants in Phase 1.
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Table 4.1 Review of existing PND training resources 
 
Name of 
training 
provider  
Duration and 
mode 
Program Overview Target 
audience  
Accrediting bodies Reference 
 
BeyondBlue 
 
 
(national) 
6 x 1 hour 
modules 
 
Online  
 ―Detecting and managing perinatal 
mental health disorders in primary 
care― 
 
Covers: 
 
- Perinatal mental health  
- Edinburgh Postnatal Depression 
Scale (EPDS) 
-Broader psychosocial assessment 
-Counselling skills and client-centred 
communication 
-Evidence-based interventions for 
anxiety and depression 
All health 
professionals 
Royal Australasian 
College of General 
Practitioners (RACGP); 
Australian College of 
Rural and Remote 
Medicine (ACRRM) and 
the  
Royal College of Nursing 
Australia (RCNA) 
https://www.beyondblue.org.au/health-
professionals/perinatal-mental-
health/perinatal-mental-health-training 
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Name of 
training 
provider  
Duration and 
mode 
Program Overview Target 
audience  
Accrediting bodies Reference 
-Refer to relevant pathways and 
existing treatments 
Women‘s 
Health Clinical 
Support 
Programs 
(WHCSP) 
 
 
(WA) 
 
Face-to-face 
workshop 
 
4 hours 
―Edinburgh Postnatal Depression Scale 
(EPDS) training‖ 
 
Covers: 
 
-Perinatal mental health 
-EPDS overview 
-Using the EPDS to screen 
-Referral pathways 
 
Health 
professionals 
working with 
families during 
the antenatal 
and postnatal 
periods 
n/a http://www.wnhs.health.wa.gov.au/health_pro
fessionals/WHCSP/index.php 
The Black Dog 
Institute 
 
(SA and Tas) 
 
Face-to-face 
workshop; 
various times 
during the year 
 
―Perinatal in practice‖ 
 
This workshop aims to introduce health 
professionals to the current 
understanding of perinatal mood 
All health 
professionals 
Australian College of 
Rural and Remote 
Medicine (ACRRM) 
 
 
http://www.blackdoginstitute.org.au/docs/Peri
natalProgramDescription.pdf 
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Name of 
training 
provider  
Duration and 
mode 
Program Overview Target 
audience  
Accrediting bodies Reference 
8 hours disorders and its management, using 
lecture, case studies and interactive 
exercises. 
 
 
 
NSW Institute 
of Psychiatry 
 
 (NSW) 
 
 
Eight units of 
study + one 
week residential 
block per 
semester 
 
Graduate Diploma in Mental Health 
(Perinatal and Infant) 
 
 
Allied Health 
Professionals 
working with 
families who 
have infants  
 
 
Accredited with 
Department of Education 
and Training (DET) 
 
 
http://www.nswiop.nsw.edu.au/future-
students/postgraduate-study/pimh 
Australian 
Psychological 
Society 
 
 
(national) 
3 hour online 
training program 
 
―Perinatal Non-Directive Counselling 
Training‖ 
 
Covers:  -Review of non-directive 
counselling skills -Perinatal-related 
counselling issues -Perinatal-related 
Psychologists, 
Social Workers, 
Midwives, Child 
& Family Health 
Nurses/ 
Maternal & 
n/a https://www.psychology.org.au/Events/Event
View.aspx?EventID=8570 
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Name of 
training 
provider  
Duration and 
mode 
Program Overview Target 
audience  
Accrediting bodies Reference 
information resources  Child Health 
Nurses, Allied 
Health, Nurses, 
Obstetricians 
NSW Institute 
of Psychiatry 
 
 (NSW) 
Twelve units of 
study + one 
week residential 
block per 
semester 
―Master of Mental Health (Perinatal and 
Infant)‖ 
 
The course is designed to equip 
professionals working in the area of 
Perinatal and Infant Mental Health with 
appropriate, comprehensive, clinical 
and academic skills for providing 
leadership within the discipline.  
All Health 
Professionals  
Accredited with DET http://www.nswiop.nsw.edu.au/future-
students/postgraduate-study/pimh 
The Victorian 
Transcultural 
Psychiatry Unit 
(VTPU)  
Online program; 
90 minutes 
―Cultural responsiveness in perinatal 
mental health: Working effectively with 
women and their families from culturally 
and linguistically diverse (CaLD) 
GPs, Midwives, 
Maternal Child 
Health Nurses, 
Psychologists, 
n/a http://dev.professorlang.com/node/1532 
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Name of 
training 
provider  
Duration and 
mode 
Program Overview Target 
audience  
Accrediting bodies Reference 
 
(national) 
backgrounds‖  
 
Covers: 
- Culturally responsive service delivery   
-Working with interpreters in mental 
health settings  -Frameworks for 
culturally sensitive perinatal mental 
health service delivery 
Social workers, 
Mental Health 
Nurses, Case 
Managers/Clinic
ians 
Monash 
University 
(Vic) 
1.5 hour online 
training 
―Perinatal & Infant Mental Health 
Training‖ 
 
Training program to increase 
understanding of perinatal & infant 
mental health issues. 
Community/allie
d health 
n/a http://med.monash.edu.au/nursing/profession
al-development/perinatal-intro.html 
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Identifying training gaps for pharmacists 
Whilst the BeyondBlue online training program was indeed comprehensive and suitable for 
pharmacists, the research team felt that the program was developed under the assumption that 
general practitioners would be the main audience. Whilst module one (Overview of Perinatal 
Depression), two (Depression screening using the EPDS) and six (Management of Perinatal 
Depression) were found to be highly pertinent for a pharmacist audience, the remaining three 
modules (which focused on diagnostic assessment, mental health care plans and secondary referral 
pathways) were not felt to be relevant to the pharmacy context. Based on these considerations, a 
decision was made by the research team to continue with plans to develop the PMHP program.  
 
The research team drew upon their collective practice experience and findings from Phase 1 of this 
study to identify gaps in pharmacists‘ understanding of perinatal mental health to inform the 
development of PMHP. It was recognised that while the BeyondBlue training program provided a 
rough outline suitable for the PMHP program, key topics needed to be covered which were particularly 
relevant for a pharmacist audience. One of these topics was the use of psychotropic medication 
during pregnancy and lactation. Several participants in Phase 1 mentioned that they felt they lacked a 
thorough understanding of psychotropic medication use in the perinatal period - a finding which is 
corroborated by research suggesting that pharmacists required further training with respect to 
pharmacotherapy use in the perinatal period (Byatt et al., 2013). 
4.4.3.2 Designing the program (DESIGN) 
In the DESIGN phase of the PMHP program, the research team endeavored to answer the following 
question: what will the program look like? In this section, we set the learning objectives, determine an 
appropriate structure and format for the program, develop a content framework and set the evaluation 
criteria. 
Setting the learning objectives 
To inform the development of the learning objectives of the PMHP program, the research team 
utilised the Matrix Framework of Perinatal Depression and Related Disorders as the basic framework 
(NPDI, 2011). The Framework was developed by the National Perinatal Depression Initiative‟s (NPDI) 
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Workforce Training and Development Committee (Australia) and the aim is to provide guidance on the 
core skills required by health practitioners working with perinatal women and ensure uniform 
standards of care across the healthcare spectrum. The NPDI committee responsible for developing 
the Framework was made up of experts from a range of disciplines in perinatal mental health 
including representatives from the Australian General Practice Network, Australian College of 
Midwives, Royal Australian College of General Practitioners, Australian Psychological Society and the 
Australian Association of Maternal and Child Family Health Nurses. Furthermore, the team was made 
up of perinatal psychiatrists, obstetricians, rural/remote practitioners and consumer and carer 
representatives to bring practice experience to the development of the Framework (M. Austin, 2011). 
As such, it was deemed to be a robust and appropriate training framework to inform the development 
of learning outcomes for the PMHP.  
 
The Framework defines five levels of training and associated learning objectives, graded by the level 
of involvement and complexity of care provided by stakeholders in each tier. The five levels, from 
lowest complexity to highest are Awareness/Health Promotion, Basic Skills, Basic Skills Plus, 
Intermediate Skills and Advanced Assessment and Intervention. The Framework provides guidance 
on which groups of professionals are likely to fall under each category based on their level of 
involvement in postnatal care. ―Allied health‖ falls under the Basic Skills category and after a close 
examination of the learning objectives assigned to this category, the research team deemed that 
these objectives were an appropriate basis for the development of the learning objectives in the 
PMHP program. The modified learning objectives and strategies used to achieve these objectives will 
be described in the next section. 
Structure & format of the program 
Another important consideration in the development of PMHP was the structure and format of the 
program. The majority of participants in Phase 1 of this study stated that they would prefer a blended 
learning approach with both online and face-to-face components. This approach has been shown to 
be effective previously. For example, in a meta-analysis looking at the effectiveness of online vs 
blended learning (Means, Toyama, Murphy, & Baki, 2013), blended learning approaches were found 
to be superior in studies contrasting blended approaches with purely face-to-face teaching methods. 
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One of the interview topics in Phase 1 was to enquire from participants the length of training they 
would feel appropriate should a training program on PND be designed specifically for them. The 
response was mixed, with preferred face-to-face time ranging from nothing at all to a complete 
weekend course. However, the most common response was that a half-day/evening workshop would 
be most appropriate. Given that lack of time is a common complaint by pharmacists in a community 
setting (Eden et al., 2009), ensuring that the PMHP allocated an adequate amount of time to meeting 
the learning objectives without becoming a burden on participants was deemed critical. As such, it 
was decided that the format of the program would be divided into two components: a training manual 
(pre-reading) that would be delivered to each participant via email before the delivery of a face-to-face 
3-hour evening workshop.  
 
In terms of program structure, Experiential Learning Theory informed the development of PMHP in 
recognition of the diverse sets of learning styles likely to be represented by participants. Kolb‘s 
Experiential Learning Model (Wolfe & Kolb, 1984) defines learning as "the process whereby 
knowledge is created through the transformation of experience. Knowledge results from the 
combination of grasping and transforming experience".  As depicted in the four-stage continuous 
learning cycle (Figure 4.2), the learner must use analytical skills to conceptualise and be actively 
involved in an experience in order to reflect upon the experience and be able to use the new ideas 
gained to inform future behaviour. Each dimension of the Model (represented by the Abstract-
Concrete axis and the Active-Reflective axis) represent conflicting yet connected modes of learning 
which assimilate into four major learning styles depicted in Figure 4.1. Several studies conducted with 
health science students (Z. Austin, 2004; Williams, Brown, & Etherington, 2013/4; Zoghi et al., 2010) 
have demonstrated a strong leaning towards the Converger learning style though research (Smith, 
Krass, Sainsbury, & Rose, 2010) has shown that undergraduate pharmacy students prefer 
application-directed approaches whereas postgraduate students prefer the deep processing 
opportunities that a meaning-directed learning approach provides.  
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Figure 4.2 Kolb‟s Experiential Learning Model (Wolfe & Kolb, 1984) 
 
These considerations were taken into account in the design stage of the PMHP program leading the 
research team to devise a program strategy that would incorporate both didactic and experiential 
learning elements into the instructional framework in an attempt to maximise learning opportunities for 
participants with differing learning styles. The online component, a training manual intended to contain 
all content relating to PMHP learning objectives, constituted the required reading for all participants 
before attendance at the workshop. This passive learning approach was intended to provide 
participants with necessary background information about perinatal depression and fulfill the Abstract 
Conceptualisation component of the Kolb Learning Model. Armed with required background 
knowledge, participants would then be led into a workshop environment that would be focused entirely 
on the application of that knowledge through Active Experimentation. The decision was made to 
eschew any attempt to deliver content during the workshops. Instead, the team favoured creating a 
learning environment that built upon and contextualised background knowledge through the facilitation 
 
 
Accommodators 
 
 
Divergers 
 
 
Convergers 
 
 
Assimilators 
 
 
Learning Style 
preferences 
Concrete Experience (CE) 
Reflective Observation 
(RO) 
Abstract Conceptualisation (AC) 
Active Experimentation 
(AE) 
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of structured activities. Upon completion of the workshop, participants would then be expected to 
apply workshop learnings in their professional practice to gain Concrete Experience by engaging in a 
conversation with perinatal women. Participants would then be expected to complete a written 
exercise through an online survey platform asking them to reflect upon the experience (Reflective 
Observation).  
Alignment of learning objectives with program design 
With the structure and format of the program decided, the research team engaged with andragogical 
literature to determine appropriate methods to align program collateral with the assigned learning 
objectives. The training manual, entitled ―Perinatal Mental Health: A Guide for Australian Pharmacists‖ 
(hereby known as the Guide) (Appendix D), would match evidence-based content with the learning 
objectives to ensure alignment with learning outcomes (Table 4.2 below). The development of 
activities for the workshop, however, required deeper investigation and a more creative approach to 
ensuring that learning outcomes are achieved. Adult learning principles, borrowed from andragogy 
theories, were utilised in the development of the workshop activities. This will be discussed further in 
4.4.3.3
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Table 4.2 Strategies used to ensure fulfillment of learning objectives 
 
Learning objectives- at the end of the PMHP 
program, pharmacists would be able to: 
Strategy 
To know the key features and prevalence rates of the 
most common perinatal mental health disorders; know 
how to differentiate between the various disorders and 
understand the impact on infant health and well-being 
● Provision of a section in the Guide covering 
relevant information  
● Development of an infographic activity in the 
workshop to consolidate learnings 
Understand the importance of conducting a broader 
psychosocial assessment, including risk assessment, 
for comprehensive clinical care in patients with possible 
PND 
● Provision of a section in the Guide covering 
relevant information 
● Delivery of a presentation by a mental health 
educator (patient) 
● Discussion of a case study in the workshop 
addressing risk factors and psychosocial 
assessment  
Understand the background, purpose and importance 
of screening, its application and limitations & implement 
screening (using the EPDS)    
 
● Provision of a section in the Guide covering 
relevant information 
● Initiation of a workshop discussion about the 
importance of screening and integration of 
screening into the pharmacy workflow 
Interpret the EPDS scores and integrate with other 
assessment material as well as communicate these 
results to women using basic counselling skills and 
client-centred communication  
● Role play activity during the delivery of the 
workshop with various possible scenarios 
● Provision of sample EPDS forms 
 
Understand the importance of knowing where and how 
to refer to relevant referral pathways and existing 
treatments, interventions and support  
 
● Provision of a section in the Guide covering 
relevant information 
● Initiation of workshop discussion about 
referral procedures, networks and the 
integration of referral protocols into the 
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Learning objectives- at the end of the PMHP 
program, pharmacists would be able to: 
Strategy 
pharmacy workflow 
● Development of pharmacy screening service  
(including referral protocols) as workshop 
activity 
● Provision of a template referral letter to GPs 
Have awareness of evidence-based interventions for 
anxiety, depression and related disorders in the 
perinatal period.  
● Provision of a section in the Guide covering 
relevant information 
 
● Discussion of a case study relating to 
psychotropic use whilst breastfeeding during 
workshop 
Have knowledge of Clinical Practice Guidelines for 
mental health disorders in the perinatal period.  
Provision of the Clinical Practice Guidelines in print 
and digital versions 
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Assessment model 
The research undertook an exhaustive search of the literature to determine an adequate model to use 
for the evaluation of the PMHP program. Kirkpatrick‘s Four-Level Evaluation model (Reaction-
Learning-Behaviour-Results) (D. L. Kirkpatrick, 1975) was deemed the most appropriate to use for the 
purposes of Phase 2. The Kirkpatrick Model is a commonly used standard for evaluating the 
effectiveness of training and considers the value of training across four, stepped levels: 
 
● Level 1 - Reaction- evaluates participants response to the training and their perception of its 
value 
● Level 2 - Learning- evaluates whether or not participants have understood and learned the 
material 
● Level 3 – Behaviour - measures the application of those learnings and whether participants 
have been able to put their understanding into practice 
● Level 4 – Results - evaluates the broader impact of the training on the organisation or an 
external stakeholder.  
 
Whilst there has been criticism of the model for presenting the evaluation process as a simplified set 
of hierarchical outcomes that does not consider the impact of intervening variables on training results 
(Holton, 1996), the research team did not consider that the effects of such variables on PMHP 
evaluation outcomes would justify the use of an elaborate evaluation model. In fact, the power of the 
Kirkpatrick Model has often been attributed to its simplicity and ability to help trainers think clearly 
about their evaluation criteria (Alliger & Janak, 1989); characteristics that were considered important 
in this pilot test given the small sample size and modest aims of the project. Given that the primary 
objective of Phase 2 of this study was to identify and gain feedback on an appropriate teaching model 
for the delivery of the perinatal depression training, it was not deemed necessary to measure changes 
in knowledge or attitude towards perinatal depression nor was measuring the overall impact of the 
training on external stakeholders (i.e. pregnant women/new mothers) within the scope of the project. 
Thus the research team decided to look at only two metrics when evaluating the PMHP program - 
Reaction and Behaviour. The development of the evaluation tools will be discussed further in 4.4.3.4. 
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4.4.3.3 Developing training content (DEVELOP) 
In the DEVELOP phase of PMHP, the research team sought to elaborate upon the program blueprint 
developed in the DESIGN phase by generating the resources that would allow for the implementation 
of PMHP. 
The PMHP Guide 
The Perinatal Mental Health: A Guide for Australian Pharmacists was developed in accordance with 
the learning objectives and associated content outlined in Table 4.3. The Clinical Practice Guidelines 
(M. Austin, 2011) was used as a core reference to ensure that content would align with current 
evidence in relation to perinatal mental healthcare. A deeper emphasis was placed on 
pharmacotherapy in the Guide compared to the Clinical Guidelines given it was tailored to meet the 
requirements of a pharmacist audience. The research team sought to capitalise on the multimedia 
effect (Mayer, 2003/4) to enhance knowledge retention by attempting to present information in a 
visual format where appropriate. In addition, care was taken to make the twenty-three page Guide as 
visually appealing as possible (using Canva, a web-based design tool) to increase the likelihood that 
participants will read the entire guide. Once the Guide was completed, the draft was peer-reviewed by 
two senior members of the research team (and a perinatal mental health expert) with extensive 
experience in mental health and pharmacy education to ensure content validity. 
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Table 4.3 Contents of PMHP Guide content with associated learning objectives 
 
Section of the Guide Associated learning outcomes  
Part 1:  
Overview of Perinatal Mental Health 
● ―Postpartum Blues‖ 
● Postpartum Depression 
● Anxiety 
● Puerperal Psychosis 
● Impact of PPD on families 
Learning Objective 1 :To know the key features and prevalence rates of the most common perinatal mental health disorders; 
know how to differentiate between the various disorders and understand the impact on infant health and well-being 
 
Part 2: Detection of postpartum depression 
 
● Why screen for PPD? 
● Help-seeking beliefs of new mothers 
● A 4-step approach to screening 
● Using the EPDS 
● Limitations of the EPDS 
● Acceptability of the EPDS 
● Screening women from culturally 
Learning Objective 2: Understand the importance of conducting a broader psychosocial assessment, including risk 
assessment, for comprehensive clinical care in patients with possible PND 
Learning Objective 3: Understand the background, purpose and importance of screening, its application and limitations & 
implement screening (using the EPDS)    
Learning Objective 4: Interpret the EPDS scores and integrate with other assessment material as well as communicate these 
results to women using basic counselling skills and client-centred communication  
Learning Objective 5: Understand the importance of knowing where and how to refer to relevant referral pathways and existing 
treatments, interventions and support  
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Section of the Guide Associated learning outcomes  
diverse backgrounds 
● Acting on psychosocial assessments 
● Dealing with resistance to referral 
Additional Objective 1: Understand professional boundaries in relation to distress and disorders in the perinatal period 
Additional Objective 2: Understand how to encourage women to follow-up with any referrals made to other mental health 
professionals and engage other services 
Part 3: Treatment for postpartum depression 
● Treatment principles 
● Psychosocial treatment 
● Decision-making about 
pharmacotherapy 
● Benefits of pharmacological 
treatment in the perinatal period 
● Supporting informed decision-
making 
● Discussing the risks and benefits  
● Factors affecting drug entry into 
human milk 
● Psychotropic use during pregnancy 
● Psychotropic use while 
breastfeeding 
Learning Objective 5: Develop an awareness of evidence-based interventions for anxiety, depression and related disorders in 
the perinatal period 
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The PMHP Workshop 
The workshop was deliberately designed to be problem-centric rather than content-centric to enhance 
learning retention and align with evidence-based methods of adult education delivery (Knowles, 
1970).  Attendees were expected to read the Guide in advance to familiarise themselves with 
important concepts related to perinatal mental health and screening. The aim of the workshop was to 
contextualise these concepts by applying them in a simulated patient situation and encouraging 
discussion in a facilitated learning environment. Each activity during the workshop was designed to 
ensure that specified learning objectives were met. The rationale for all activities included in the 
workshop (and description of each activity, the associated learning objectives and evaluation criteria) 
can be found in Table 4.4.  
 
The activity types chosen to form the backbone of the workshop were:  
 
1 Patient Interaction- Participants were able to hear from and interact with a consumer who has 
experienced PND recently.  
Group discussion: Participants were assigned discussion questions in the context of a particular 
patient whose journey they would follow through a series of sequential scenarios.  
Role Plays: Role plays were carried out between sets of participants. 
Production: Participants were assigned tasks to produce certain deliverables by the end of the 
workshop. 
 
The workshop was centred around a hypothetical patient, Stephanie, who falls pregnant and presents 
to the pharmacist at various stages in her perinatal journey. This problem-based learning (PBL) 
approach is commonly used in pharmaceutical education (Galvao, Silva, Neiva, Ribeiro, & Pereira, 
2014).  All learning objectives and associated workshop activities were addressed in relation to 
Stephanie to increase contextual learning opportunities. The activity booklet (Appendix E) contained 
the three sequential case studies utilised during the workshop in addition to the activities described in 
Table 4.4. 
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Table 4.4 Workshop Activity Rationale 
 
Learning objectives 
(as defined by the Training Matrix) 
Learning Activity 
Associated with Learning Objective 
Rationale for activity Evaluation Criteria 
To know the key features and prevalence 
rates of the most common perinatal 
mental health disorders; know how to 
differentiate between the various 
disorders; and understand the impact of 
PND on infant health and well-being.  
Activity 1:  
Creating Infographic  
 (30 mins) 
 
Create an infographic about perinatal 
mental health as part of an in-pharmacy 
health promotion campaign.  
 
Relevant section in Training Guide 
Chapter 1: Overview of Perinatal Mental 
Health 
This activity will encourage participants to 
contextualise the information presented 
to them in Chapter 1 of the Guide to 
produce a tangible product that can 
reasonably be used in their professional 
practice. 
Level and quality of 
participation in anticipated activities 
 
Accuracy of information presented 
 
Successful completion of activity 
 
Engagement with the process 
 
 
 
Understand the importance of conducting 
a broader psychosocial assessment, 
including risk assessment, for 
Activity 2: 
 
Group discussion  
This activity will encourage critical 
thinking, peer-to-peer learning and the 
sharing of professional experiences 
Level and quality of 
participation in activity  
 
Community-based perinatal depression recognition and management  |  June 2016  | University of Sydney  
93 
Learning objectives 
(as defined by the Training Matrix) 
Learning Activity 
Associated with Learning Objective 
Rationale for activity Evaluation Criteria 
comprehensive clinical care in patients 
with possible PND 
(15 mins) 
 
Group discussion of Scenario 1: 
Stephanie Falls Pregnant preceded by a 
set period of time for discussion within 
teams. The discussion of scenario 1 will 
involve discussing the presentation of a 
patient, Stephanie, at the pharmacy and 
her request for a sleeping aide. Points of 
discussion will include assessing risk 
factors for PND and determining 
possibility of PND being present in 
Stephanie‘s case. 
 
Relevant section in Training Guide 
Chapter 1: Overview of Perinatal Mental 
Health 
between colleagues to facilitate a deeper 
understanding of the issues presented.  
 
 
Observation of participant attentiveness 
throughout discussion 
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Learning objectives 
(as defined by the Training Matrix) 
Learning Activity 
Associated with Learning Objective 
Rationale for activity Evaluation Criteria 
Understand the background, purpose and 
importance of screening, its application 
and limitations & implement screening 
(using the EPDS)    
 
Activity 3: 
Group discussion & critical thinking 
(15 mins) 
Group discussion of Scenario 2: 
Stephanie wants St. John‟s Wort 
preceded by a set period of time for 
discussion within teams. Scenario 2 will 
involve discussing Stephanie‘s return to 
the pharmacy at a future date and 
requesting St John‘s Wort. This 
discussion will encourage participants to 
think about ways to hold sensitive 
conversations with patients whom they 
suspect of experiencing PPD and 
approaching the topic of filling out the 
EPDS with them.  
Relevant section in Training Guide 
Chapter 2: PPD Detection & Referral 
This activity will encourage critical 
thinking, peer-to-peer learning and the 
sharing of professional experiences 
between colleagues to facilitate a deeper 
understanding of the issues presented. 
Level and quality of 
participation in activity  
 
Observation of participant attentiveness 
throughout discussion 
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Learning objectives 
(as defined by the Training Matrix) 
Learning Activity 
Associated with Learning Objective 
Rationale for activity Evaluation Criteria 
Interpret the EPDS scores and integrate 
with other assessment material as well as 
communicate these results to women 
using basic counselling skills and client 
centred communication  
Activity 4: 
Role play  
(40 mins) 
Role plays between the pharmacist and 
Stephanie (simulated patient) explaining 
her EPDS score. Participants will be split 
up into groups of three and will simulate 
the entire patient interaction  
according to a guide that will be provided 
to them. Groups will role play from initial 
conversation through to EPDS screening, 
discussion with Stephanie and referral to 
her GP)    
Relevant section in Training Guide 
Chapter 2: PPD Detection & Referral  
Role playing will provide participants with 
an opportunity to simulate a PPD 
screening in a safe environment free of 
judgement or consequence. Participants 
will be able to hone their counselling skills 
in the context of suspected postpartum 
depression and observe and provide 
feedback to each other. 
Level and quality of 
participation in activity  
 
Observation of participant attentiveness 
throughout role-play 
Understand the importance of knowing 
where and how to refer to relevant 
 
 
 Level and quality of 
participation in anticipated activities 
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Learning objectives 
(as defined by the Training Matrix) 
Learning Activity 
Associated with Learning Objective 
Rationale for activity Evaluation Criteria 
referral pathways and existing 
treatments, interventions and support  
 
Activity 5: 
Conceptualise PND screening 
professional service  
(40 mins) 
Groups will design (in principle) a PND-
screening service in the pharmacy which 
will encompass the entire detection and 
referral process and consideration of 
marketing, budgeting and resource 
allocation. Participants will be expected to 
incorporate their infographic from Activity 
1 and create a PND screening & referral 
checklist as part of this service. 
Relevant section in Training Guide 
Chapter 2: PPD Detection & Referral 
 
Ability to think laterally to overcome 
barriers to implementation 
 
Successful completion of activity 
 
Consideration of issues involved in 
setting up PND screening service 
Have awareness of evidence-based 
interventions for anxiety, depression and 
 
 
This activity will encourage critical 
thinking, peer-to-peer learning and the 
Level and quality of 
participation in activity  
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Learning objectives 
(as defined by the Training Matrix) 
Learning Activity 
Associated with Learning Objective 
Rationale for activity Evaluation Criteria 
related disorders in the perinatal period.  Activity 6: 
Group discussion & critical thinking 
(15 mins) 
Group discussion of Scenario 3:  
Stephanie Gets Treatment preceded by a 
set period of time for discussion within 
teams. Scenario 3 will encourage 
participants to draw upon their knowledge 
of psychotropic use in pregnancy and 
breastfeeding to answer Stephanie‘s 
queries about her medications. 
Relevant section in Training Guide 
Chapter 3: Treatment for PPD 
sharing of professional experiences 
between colleagues to facilitate a deeper 
understanding of the issues presented.  
 
Observation of participant attentiveness 
throughout discussion 
 
 
Have knowledge of Clinical Practice 
Guidelines for mental health disorders in 
the perinatal period.  
Copy of Guidelines included in the Health 
Professional Kit to be handed out at 
workshop 
(kindly provided by Beyond Blue) 
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4.4.3.4 Delivery & evaluation of the training program 
(IMPLEMENTATION & EVALUATION) 
In the IMPLEMENT and EVALUATE phases of PMHP, the research team delivered the resources 
created in the DEVELOP phase and sought to determine whether the research objectives of Phase 2 
were met. 
 Pre-workshop model 
Upon registration, participants were sent an online copy of the Guide via email and instructed to read 
and understand the content before attending the workshop. Each participant was given at least ten 
days to complete this task. Participants were also asked to complete a pre-workshop survey (Table 
4.5) to gain a baseline view of participant attitudes and confidence levels with respect to perinatal 
mental health screening. The pre-workshop survey was designed by the research team to collect 
participant characteristics as well as an understanding of participant‘s prior experience, training and 
preparedness for dealing with perinatal mental health using a 10-point Likert scale. Survey items 
pertaining to the level of confidence participants feel in relation to the assessment and referral of 
women suspected of having PND were also included. A study with nurse practitioners reported that 
nurses‘ confidence in their knowledge of how to use a screening tool was the single biggest predictor 
of screening behaviour (Goldsmith, 2007). Thus, understanding pharmacists‘ levels of confidence in 
relation to PND screening and referral was deemed appropriate. The research team drew upon their 
collective practice experience as well as items from a national PND awareness survey conducted with 
Australian midwives (Jones, Creedy, & Gamble, 2012) to inform the development of this pharmacist-
specific survey. The survey was then tested for face validity with a pharmacy mental health expert. 
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Table 4.5 Pre-workshop Survey Questions 
 
Survey Item Answer Format 
 Likert Scale 
1---------------10 
Not scaled 
Your date of birth?  DD/MM/YYYY 
(short answer) 
Age   18-25 
26-40 
41-65 
65+ 
(multiple choice) 
Gender?   M 
F 
Undisclosed 
(multiple choice) 
 
Are you an Australian or overseas registered pharmacist? 
 Australian-registered 
Overseas registered 
Neither  
(multiple choice) 
Are you currently practising?  Yes 
No 
(multiple choice) 
Have you practised in community pharmacy?  Yes 
No 
(multiple choice) 
If yes, which industry do you predominantly work in?  Hospital 
Industry 
Community 
Research 
Administration 
NGO 
Government 
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Survey Item Answer Format 
How adequately did your pharmacy degree program prepare you for 
working with postpartum and pregnant women? 
1= not at all adequate 
10=more than adequate 
 
During your pharmacy degree, how much emphasis was placed on 
perinatal mental health? 
1=no emphasis at all 
10=strong emphasis 
 
During your pharmacy degree, how much emphasis was placed on 
perinatal health in general? 
1=no emphasis at all 
10=strong emphasis 
 
During your pharmacy degree, how much emphasis was placed on the 
safe use of medications during pregnancy and breastfeeding? 
1=no emphasis at all 
10=strong emphasis 
 
How could your pharmacy degree program have better prepared you for 
your role in the screening and management of women with antenatal 
and/or postnatal depression? (Please select more than one if applicable) 
 More lecture time on antenatal 
and/or postnatal depression 
More practice in assessing 
antenatal and/or postnatal 
depression 
More knowledge in the 
treatment techniques for 
antenatal and/or postnatal 
depression 
More practice in managing 
antenatal and/or postnatal 
depression (e.g. counselling 
skills) 
(checkbox) 
Do you believe that the education or training you have received as a 
pharmacist has been adequate for effective care of antenatal and/or 
postnatal women with depression? 
 
1= not at all adequate 
10=more than adequate 
 
How confident do you feel ASSESSING a woman for the possibility of 
antenatal/postpartum depression and/or anxiety? 
1=not at all confident 
10=very confident 
 
How confident do you feel REFERRING a woman you believe may be 
suffering from antenatal/postpartum depression and/or anxiety? 
1=not at all confident 
10=very confident 
 
Do you think pharmacists are capable of screening for postpartum 
depression and/or anxiety and referring suspected cases? 
 Yes       No 
 Unsure 
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Workshop delivery and evaluation 
The workshop was held in the Faculty of Pharmacy building at the University of Sydney  
(Sydney, Australia) on the thirty-first of March 2016. A volunteer speaker from BeyondBlue, who had 
previously experienced perinatal depression and anxiety, was asked to talk about her personal 
experiences with the illness to set the scene for the rest of the workshop. The speaker attending the 
workshop also volunteered to stay for the entirety of the workshop and provide participants with a 
unique opportunity to complete learning activities in consultation with a member of the target patient 
group. 
 
The research team decided to engage the speaker in an attempt to provide the pharmacist audience 
with unique insights into the lived experiences of consumers who have experienced perinatal 
depression and anxiety - a patient and public involvement (PPI) exercise which has been 
demonstrated to improve the learning experience of health students and professionals (Farrell, 2004; 
Fudge, Wolfe, & McKevitt, 2008; Lonie, 2006; Stacy & Spencer, 1999). There is significant evidence 
(Bell, Johns, Rose, & Chen, 2006; O‘Reilly, Bell, & Chen, 2010, 2012) supporting the benefits of 
contact-based education as the most effective method of reducing pharmacist‘s stigma towards 
mental illness. The case for involving mental health consumers in the education of pharmacists is 
particularly pertinent given that mental health tutorials and lectures do not decrease pharmacist‘s 
stigmatising attitudes towards consumers with mental illness (Bell, Johns, & Chen, 2006). A strong 
determinant of mental health stigma amongst Australian pharmacy students (J. S. Bell et al., 2010) is 
the perception of unpredictability amongst patients; thus attempts to provide pharmacists (and indeed, 
pharmacy students) with opportunities to directly engage with mental health consumers may aid in 
mitigating these concerns. 
  
Upon completion of the opening presentation, the group was divided into five teams of three and each 
of the six activities assigned were completed chronologically as a team. Time was allocated to the 
completion of each activity and for class discussion of each activity. Due to time constraints, only five 
out of the six activities were completed before the end of the workshop (Activity 6 was not completed 
though participants were encouraged to attempt it in their own time). Assessment of learning 
objectives were made on a whole-class basis (rather than an individual basis) to provide the 
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researchteam with a very broad understanding of the class response to each individual activity. This 
evaluation activity was completed using the Evaluation Rubric developed for each activity in this 
workshop.  
Post-workshop model 
Participants were asked to complete the post-workshop survey to enable the research team to assess 
the impact of PMHP and obtain feedback from the participant group to inform future iterations of the 
training program. In order to fulfill continuing professional development requirements, participants 
were expected to complete a reflection exercise within three weeks of the workshop to receive a 
certificate of completion for the PMHP program.  
Post-workshop survey 
The focus of the post-workshop survey was to collect participant feedback about the quality of the 
PMHP program. The survey items were derived by the research team in consultation with an 
instructional design expert and in consideration of the parameters that would be useful to measure 
and inform future development of the PMHP program (Table 4.6). The post-workshop survey was 
designed to capture the reaction of participants, by ―measuring the level of (internal) customer 
satisfaction‖ (as per the Kirkpatrick Evaluation model chosen to underpin this pilot test (D. L. 
Kirkpatrick, 1975)). Furthermore, the updated Kirkpatrick model (D. Kirkpatrick & Kirkpatrick, 2005) 
considers that the degree to which participants found the training engaging and relevant to their jobs 
are similarly important metrics when applying Level 1 of the Kirkpatrick model to a training evaluation 
framework. The research team developed the post-workshop survey in consideration of the need to 
accurately and adequately characterise participant reactions to the PMHP program and the perceived 
relevance to their practice. To maintain confidentiality, participants were not asked to supply their 
names though their date of births was used to match pre- and post- workshop surveys to enable 
paired data comparisons.  
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Table 4.6 Post-workshop Survey Questions 
 
Item Answer Format 
 Likert Scale  
(multiple choice) 
1-------------------10 
Not scaled 
Your date of birth  DD/MM/YYYY 
(short answer) 
Did the workshop meet your expectations? 1=not at all 
10=very much 
 
How relevant were the workshop activities to your practice? 1=not at all  
10=very relevant 
 
How did you feel about the facilitation of sessions? 1=poor 
10=excellent 
 
What is the value of the workshop to you? 1=worthless 
10=worthwhile 
 
How relevant were the resources provided to you? 1=poor  
10=excellent 
 
What did you think about the:  
-structure of the workshop? 
 
1=poor 
10=well-structured 
 
 
-length of the workshop? 1=too brief 
10=too long 
 
-relevance of the workshop? 1=not at all relevant 
10=very relevant 
 
-style of the Guide? 1=poor  
10=excellent 
 
-amount of information provided in the Guide? 1=too little 
10=too much 
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Item Answer Format 
-readability of the Guide? 1=poor  
10=excellent 
 
How confident do you feel REFERRING a woman you believe 
may be suffering from antenatal/postpartum depression and/or 
anxiety AFTER attending this workshop? 
1=not at all confident 
10=very confident 
 
How confident do you feel ASSESSING a woman for the 
possibility of antenatal/postpartum depression and/or anxiety 
AFTER attending this workshop? 
 
1=not at all confident 
10=very confident 
 
Do you think pharmacists are capable of screening for 
antenatal/postpartum depression and/or anxiety and referring 
suspected cases? 
       Yes 
No 
Unsure 
(multiple choice) 
Please comment:  (Short Answer) 
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Reflection activity 
The reflection activity was an online written activity that expected participants to apply their learnings 
from the PMHP program to a real-life scenario and reflect upon how the PMHP experience helped 
them deal with the scenario (Table 4.7). The Behaviour component of the Kirkpatrick Model was used 
to inform the development of the reflection activity, whereby the extent of learning is measured as a 
function of the individual‘s application of that learning and change to usual practice (Alliger & Janak, 
1989). An open-ended question format was adopted to avoid the influence of numerical scales on 
participant responses (Schwarz & Oyserman, 2001) and to provide researchers with nuanced insights 
into the effect of the training on individual participant behaviour upon completion of the PMHP 
program. The questions were derived by the research team and informed by their collective pharmacy 
practice and training experience. The task was to engage with a woman in the perinatal period in the 
course of their professional practice and reflect upon the experience. This activity was intended to 
help participants meet continuing professional development requirements but also to provide the 
research team with valuable insights into the application of learnings from the PMHP program. The 
questions were generated by the research team to elicit responses that would provide the team with 
such insights.  
Table 4.7 Reflection activity questions 
 
1. Describe your encounter and the outcome 
2. What challenges did you face, if any? 
3. What did you learn from this experience? 
4. How did you apply your workshop learnings to this experience? 
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4.5 Results 
Twenty-nine pharmacists registered to attend the PMHP workshop and 52% of those registered 
(n=15) actually attended the workshop. Thirteen participants completed the pre-workshop survey and 
of those, nine also completed the post-workshop survey (matched by date of birth) and reflection 
exercise within three weeks of workshop completion. Characteristics of the participants (n=9) who 
fulfilled all requirements of the PMHP course (attended the workshop, completed both surveys and 
the reflection exercise) are highlighted in Table 4.8. The results described in 4.5.1 and 4.5.3 will only 
refer to evaluation exercises completed by these nine participants. 
Table 4.8 Sample Characteristics of PMHP participants 
Sample Characteristic n (%) 
Age 
18-25 
26-40 
41-65 
65+ 
 
1 (11%) 
8 (89%) 
0 
0 
Gender 
M 
F 
Undisclosed 
 
2 (22%) 
7 (78%) 
0 
Years in Practice 
1-3 
3-5 
5-10 
10+ 
 
2 (22%) 
1 (11%) 
4 (44%) 
2 (22%) 
Current Pharmacy Sector 
Community 
Industry 
Hospital 
 
6 (67%) 
1 (11%) 
2 (22%) 
Currently Practising 
Yes 
No 
 
9 (100%) 
0  
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4.5.1 Participant surveys 
The pre-workshop survey included several questions focusing on participant‘s previous exposure to 
PND training during tertiary studies in addition to baseline confidence with assessment of perinatal 
mental health and referral of suspected cases of perinatal depression. The majority of participants 
(n=7) believed that they should have received more lecture time on PND during their pre-registration 
pharmacy degree whilst others (n=2) wanted more practice assessing women for PND. Overall, 
participants did not feel that they were provided with adequate training in perinatal mental health and 
perinatal health generally during their pharmacy degree. Table 4.9 lists the scores provided by 
participants about perinatal mental health preparation during their degree. Seventy-eight percent of 
participants (n=7) believed that pharmacists were capable of screening for perinatal depression and 
one participant selected the ―Unsure‖ option. The only participant who reported that they did not 
believe pharmacists were capable of screening commented that the reason for this was that the 
pharmacy environment was a ―busy business environment which makes it very hard to screen‖. Those 
who responded that pharmacists were capable of screening commented that before screening could 
become a reality in community pharmacy, they would require further training (n=5) and a validated 
screening/referral protocol (n=2). 
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Table 4.9 Pre-workshop survey participant scores  
(NB: Though meaningful statistical analyses was not attempted due to sample size, the mean/standard deviation values for scores are merely presented to provide a sense of collated findings from 
all participants) 
 
Evaluation criteria Scale  
1-------10 
Individual Participant Scores Mean 
(n=9) 
Std 
Dev.+/- 
  1 2 3 4 5 6 7 8 9   
Adequate preparation for working with 
postpartum/pregnant women during 
pharmacy degree  
1= not at all adequate 
10=more than adequate 
5 6 3 4 1 2 2 1 4 3.11 1.76 
Emphasis on perinatal mental health 
during pharmacy degree 
1=no emphasis at all 
10=strong emphasis 
3 1 3 2 1 2 2 1 2 1.89 0.78 
Emphasis on perinatal health in general 
during pharmacy degree  
1=no emphasis at all 
10=strong emphasis 
3 3 8 2 1 2 2 1 2 2.67 2.12 
Emphasis placed on the safe use of 
medications during pregnancy/ 
breastfeeding during pharmacy degree 
1=no emphasis at all 
10=strong emphasis 
5 8 10 6 4 7 10 4 6 6.67 2.29 
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Do you believe that the education or 
training you have received as a 
pharmacist has been adequate for 
effective care of antenatal and/or 
postnatal women with depression? 
1= not at all adequate 
10=more than adequate 
5 5 1 2 1 8 3 1 3 3.22 2.38 
Confidence ASSESSING a woman for 
PND 
1=not at all confident 
10=very confident 
4 4 8 3 2 6 3 3 1 3.89 2.09 
Confidence REFERRING  a woman with 
suspected PND 
1=not at all confident 
10=very confident 
8 6 8 8 5 6 10 3 1 6.11 2.80 
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The post-workshop survey focused on collecting feedback about the workshop and the Training Guide 
provided. Table 4.10 lists mean and individual evaluation scores from participants for the workshop 
and the Guide. Participants also scored their post-workshop PND assessment (mean=8.1) and 
referral (mean=7.9) confidence. All but two participants reported higher scores for their level of 
confidence in PND assessment and referral after attending the workshop; two participants (participant 
4 and participant 7) reported marginally lower scores after the workshop. Eight participants responded 
that they did believe pharmacists could screen for PND and one was unsure. Through pairing of the 
surveys, we found that the participant who had originally responded ―No‖ to the question of whether 
pharmacists could screen for PND had changed their response to ―Unsure‖ and the original participant 
who had responded with an ―Unsure‖ had changed their answer to ―Yes‖. Those who answered ―Yes‖ 
in the post-workshop survey commented that there was a further need for training (n=3) before 
pharmacists could implement a screening program, a need for validated screening and referral 
processes (n=1) and also a need for a sustainable funding source (n=2). One participant provided 
feedback that the role play activity was sub-optimal since they were expected to role play with each 
other and not with the facilitators (who would be in a better position to guide the conversation 
appropriately.  
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Table 4.10 Post-workshop survey participant scores 
(NB: Though meaningful statistical analyses was not attempted due to sample size, the mean/standard deviation values for scores are merely presented to provide a sense of collated findings from 
all participants) 
Evaluation criteria Scale 
1----------10 
Individual Participant Scores Mean 
(n=9) 
Std Dev 
+/- 
  1 2 3 4 5 6 7 8 9   
Met Expectations 1=not at all 
 
10=very much 
8 9 9 8 9 9 8 8 8 8.44 0.53 
Quality of resources 1=poor 
10=excellent 
10 9 9 9 10 9 8 8 9 9.00 0.71 
Structure of the workshop 1=poor 
10=well-structured 
8 8 9 9 10 8 8 9 8 8.56 0.72 
Relevance of workshop 
activities to practice 
1=not at all relevant 
10=very relevant 
9 7 9 8 9 8 9 6 6 7.89 1.27 
Facilitation of sessions 1=poor  
10=excellent 
9 9 10 9 10 9 9 9 10 9.33 0.5 
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Value of the workshop 1=worthless 
10=worthwhile 
10 8 10 7 10 8 8 8 8 8.56 1.13 
Length of the workshop 1=too brief 
10=too long 
6 8 4 5 7 6 7 8 9 6.67 1.58 
Amount of information provided 
in the Guide 
1=too little 
10=too much 
4 9 6 9 10 8 7 5 9 7.44 2.07 
Style of the Guide 1=poor  
10=excellent 
8 9 10 9 10 9 7 10 7 8.78 1.20 
Relevance of the Guide 1=not at all relevant 
10=very relevant 
10 8 10 9 10 8 8 9 8 8.89 0.93 
Readability of the Guide 
 
1=poor  
10=excellent 
9 9 10 9 10 9 9 10 6 9.00 1.22 
Confidence ASSESSING a 
woman for PND 
1=not at all confident 
10=very confident 
10 9 9 5 9 8 7 8 8 8.11 1.45 
Confidence REFERRING a 
woman with suspected PND 
1=not at all confident 
10=very confident 
10 8 9 7 7 8 8 6 8 7.89 
 
1.16 
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4.5.2 Workshop activity evaluations 
The workshop activities were generally received well by participants, with deep engagement at a class 
and individual level. As reflected in the evaluation scores of each activity given by the facilitators of 
the workshop (Table 4.11), the two activities which scored the highest percentage score overall were 
the infographic (92.5%) (Appendix F) and the screening service development (97.5%) (both also 
scoring highest on measures of participant enthusiasm and team participation in class discussion). 
Levels of individual participation were highest for the role plays and levels of team participation in 
class discussions were lowest for the two activities involving case studies.  
 
The facilitators noted that participant responses to the volunteer speaker were very positive. Many 
participants made comments about the benefit of having a woman who previously experienced PND 
speak to them about her experiences and join them in their activities. There were repeated 
suggestions that a future training program should incorporate more of such speakers to allow for a 
holistic and comprehensive understanding of PND. Anecdotal feedback from participants also 
suggested that many would prefer the workshop be held over the course of a weekend rather than the 
evening workshop format. 
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Table 4.11 Workshop Marking Rubric scores 
 
Criteria 
(scored out of 5) 
 
Activity 1: 
Infographic 
 
Activity 2: 
Stephanie falls 
pregnant 
Activity 3: 
Stephanie 
wants St 
John’s Wort 
Activity 4: 
Role 
plays with 
Stephanie 
Activity 5: Build a 
screening service 
Originality 4  
n/a 
 
n/a 
 
n/a 
5 
Clarity 5 5 5 4 5 
Accuracy 4 5 4 4 5 
Organisation 5 n/a n/a n/a 5 
 
Reasoning 5 5 4 4 5 
Enthusiasm 5 3 3 4 5 
Team participation 
(in class 
discussions) 
5 3 3 4 5 
Individual 
participation 
4 4 4 5 4 
Total 37/40 25/30 23/30 25/30 39/40 
 92.5% 83.3% 76.7% 83.3% 97.5% 
 
4.5.3 Reflection activity 
All but one of the nine participants completing the reflection exercise consulted with a new mother 
within three weeks of the workshop and reflected upon the experience in the context of the learnings 
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they gained from the workshop they completed. One participant did not come across any pregnant or 
postpartum women and completed the exercise reflecting on what they would have done if they had 
encountered one. A thematic content analysis of the reflection activity submissions revealed three 
main themes: empathy, guiding the conversation and professional confidence. Where direct 
participant quotes are used, the code P refers to the pharmacist followed by a number indicating the 
participant who provided the quote. 
 
Empathy 
All participants expressed the need to develop empathy with the patient in some capacity. Empathy 
may manifest in various ways and lies in the ability of the clinician to develop a shared understanding 
with his/her patient through affective, cognitive or behavioural means (Norfolk, Birdi, & Walsh, 2007). 
Participants often suggested that the ability to empathise and be guided by cues from the patient was 
an important part of the counselling process. 
 
“I found it quite easy to talk to her as being a mother myself, I felt I could empathise with some of her 
experiences.” P2 
 
“Don‟t try to rush it or push it or the person becomes resistant. When you sense resistance, don‟t push 
through, but try to find a way of getting your point in a different way, e.g. talk about baby for a while, 
then mention about her again ...gain their trust first, don‟t assume that because she trusts you with her 
baby, she will trust you with her mental health.” P1 
 
The ability to recognise a new mother‘s motivations through the course of a conversation was 
reported as an important aspect of empathic counselling. 
 
““The biggest challenge was changing the conversation to be about mom (sic) and not the baby. Even 
when talking about mental health or maternal health she was open to it until it came to applying it to 
her. It was hard to get her to accept that she was important too…” P1 
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Guided conversation 
Participants suggested that engaging in meaningful conversation with the purpose of gauging the 
possibility of perinatal mental health problems underpinned their interactions with new mothers after 
attending the workshop.  
 
“I made a conscious effort to engage in conversation that would allow me to identify risk factors of 
postnatal depression, as opposed to just referring her to my colleague or just selling the patient a milk 
formula.“ P4 
 
Participants emphasised that there was an inherent need to guide the conversation in a way that 
would allow them to gain insights into the mother‘s mental health status without making her feel 
threatened. 
 
“I plan to initiate the conversation with less sensitive and personal topics such as changes to sleeping 
patterns due to the baby and when their reply indicates stress and/or anxiety, I can offer to ask them 
to enter our private counselling room and screen the patients for PND.” P7 
 
“I think there would be new mothers out there that may not feel as comfortable opening up with 
„strangers‟ or may even feel a sense of „failure‟ or „shame‟ when put in a position like this client‟s. Just 
start a conversation casually - talking about her baby „generally‟ rather than being specific and direct 
with the questions, which could come across as a little intimidating” P4  
 
Whilst most participants mentioned the need to guide a conversation, one participant added that 
disclosure about the direction of that conversation allowed for a more open and honest discussion. 
 
“Patient felt a bit apprehensive about why I was asking some of the questions - explained that I 
wanted to provide her with more information where required to support her through her first 
pregnancy. She was comfortable with talking openly afterwards...Asking open questions unrelated to 
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the patient request can sometimes be unexpected. Should try to ensure that patients are feeling 
relaxed and comfortable with these types of conversations before proceeding.” P9 
 
Professional confidence 
Participants frequently noted that the training provided them with increased confidence to engage in 
mental health discussions with new mothers. 
 
“The first thing was that I had gained confidence to start a conversation even though it may be a bit 
sensitive as now I have more knowledge on this topic.” P3 
 
“After attending the workshop I felt more confident to talk about PND with her and wasn‟t afraid to 
delve into deeper conversation with the patient...I let her know that we at the pharmacy, are always 
here for her if she needed anything.” P2 
 
“(Before the workshop) I would not have asked the customer about their mental health in the first 
place as I would not have known what to do other than refer to the doctor. I was able to broach the 
subject of the survey and make a number of useful recommendations for the customer.” P6 
 
However one participant did note that they still found it difficult to engage in sensitive conversations. 
 
“I found it is quite difficult to ask for personal lifestyle things as most people will feel uncomfortable.” 
P5 
4.6 Discussion 
The evaluation process of the PMHP program yielded interesting results about the ideal format, 
content and nature of a PND training program aimed at pharmacists. Findings from this pilot test 
suggest that the PMHP program was well-received and achieved its intended purpose - to fulfill the 
training needs of pharmacists regarding perinatal depression (and perinatal mental health generally) 
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and to generate feedback to inform future iterations of a PMHP program. The evaluation tools used 
(the surveys, marking rubric/facilitator observations and reflection activities) did not necessarily 
provide the research team with exhaustive data but they did provide enough scope to inform a 
discussion around the key benefits and limitations of the PMHP program and recommendations for 
future iterations of the program. 
 
Participant evaluation of the Guide and the workshop indicated an overall satisfaction with the quality, 
style and value of the program. The two metrics from the Kirkpatrick Model (D. L. Kirkpatrick, 1975) 
that were loosely evaluated in this study - Reaction and Behaviour - both showed positive results; 
participants reacted favourably to the experiential and blended learning approach utilised and 
successfully applied their learnings in the course of their practice, as seen in the reflection activities. 
Blended learning (a pedagogical approach which hybridises online and face-to-face teaching 
components) has been extensively studied in the clinical education of healthcare students (Rowe, 
Frantz, & Bozalek, 2012) and there is some evidence that it results in improved clinical competencies 
compared to pure face-to-face teaching methods. Blended learning offers the benefit of convenience 
and promotes learner-centred teaching (Gray & Tobin, 2010) which in the context of continuing 
professional development, aligns with the needs of practising pharmacists who often cite time 
constraints as a significant barrier to implementing pharmacy services (Garcia, Snyder, McGrath, 
Smith, & McGivney, 2009; Landau et al., 2009; O‘Loughlin, Masson, Déry, & Fagnan, 1999). The 
workshop facilitators observed (as reflected in the workshop evaluation notes and scores) that the two 
activities which generated the highest levels of interest amongst workshop attendees were the 
infographic activity (where participants were asked to create a poster about PND to hang in their 
pharmacies) and the development of a PND screening service development activity. Both of these 
activities were highly experiential, expected participant leadership and entailed a personal application 
of background knowledge to a potential real-world example. Participants responded positively to the 
learner-centred, participant-led environment created in the workshop; a study with pharmacy students 
developing and partaking in a medication reconciliation service (Meierhofer et al., 2013) highlighted 
that student-led initiatives bolstered learning opportunities and student development. Given the 
positive response to the experiential components of the program, it is recommended that future 
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iterations of the program retain these activities and incorporate further opportunities for experiential 
learning. 
 
Participant comments at the conclusion of the workshop suggested that they would have preferred a 
lengthier training program which provided a more in-depth view of perinatal mental health and how to 
screen and refer cases of PND. The item on the post-workshop survey asking participants to rate the 
length of the workshop attracted the lowest score which suggests a strong need to revise the length of 
future iterations of the PMHP program. The majority of participants noted that their tertiary training did 
not equip them to adequately screen women for the possibility of perinatal mental health illness nor 
did it prepare them to refer suspected cases of perinatal depression. These findings echo previous 
research suggesting that tertiary pharmacy (Cates, Monk-Tutor, & Drummond, 2007) and medical 
courses (Keitt, Wagner, Tong, & Marts, 2003) do not adequately focus on psychiatric pharmacy or 
women‘s health respectively, thus further justifying the need to develop postgraduate training 
programs to bridge that gap. Evidence suggests that a mental health first aid course conducted with 
pharmacy students (O‘Reilly et al., 2011) lowered their stigmatising attitudes to mental health illness 
and improved their confidence in providing services to patients with mental illness in a pharmacy 
setting. Given that lack of training in mental health issues has been noted as a significant barrier for 
pharmacists wanting to conduct mental health services (Scheerder et al., 2008), a comprehensive 
training program focusing on perinatal mental health in the context of pharmacy could justifiably 
remove a significant barrier for pharmacists looking to provide mental health support for new mothers. 
 
The positive feedback provided by participants with respect to the volunteer speaker emphasises the 
value of consumer-led mental health education as captured by previous research. Pharmacy students 
attending training led by mental health consumer educators (O‘Reilly et al., 2010) reported reduced 
mental health stigma, improved attitudes towards patients with a mental illness and an appreciation 
for the roles that pharmacists can play in providing non-judgemental care to patients with mental 
health illness. These findings have been corroborated by studies confirming the benefits of contact-
based education (Patten et al., 2012) and the positive impacts of such training on the pharmacist‘s 
professional practice and interactions with patients with mental illness (Bell, Johns, Rose et al., 2006; 
Nguyen, Chen, & O‘Reilly, 2012; O‘Reilly et al., 2012) though a recent systematic review concluded 
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that further research was required on the effects of consumer-led education on student‘s behaviour in 
healthcare environments (Happell et al., 2014). Regardless, a review of the literature on consumer-
based education (Repper & Breeze, 2007) found that involving patients in the education of healthcare 
professionals may lead to improved empathy in professional practice. The importance of empathy in 
patient-pharmacist interactions was frequently cited by PMHP in their reflection exercises (and 
incidentally, by the participants in Phase 1 of this study). Studies have looked at the effect of a training 
intervention on pharmacist‘s empathy scores (Lilja, Larsson, Hamilton, & Issakainen, 2000; Lonie, 
Alemam, Dhing, & Mihm, 2005) which showed modest improvements in the pharmacist‘s ability to 
empathise with patients. Two processes appear to underpin the development of pharmacist‘s 
empathic skills (Lonie, 2006), social learning (through critical observation) and the consistent use of 
self-reflective practices. As such, it can be argued that whilst empathy skills may be taught as part of 
a mental health training program, the development of empathy is essentially a function of experience 
and self-reflection (Lonie, 2010/1) and crucial to the development of patient-centred communication 
strategies. Recommendations for future iterations of the PMHP program would be to focus on 
delivering consumer-led perinatal mental health education with a component requiring participants to 
continually reflect upon and improve their patient communication strategies during the course of their 
professional practice.  
 
Overall, the results of this pilot test were promising and suggest that further investigations into the 
impact of a perinatal mental health education intervention on pharmacists‘ knowledge and attitudes is 
warranted. This pilot test represented an early foray into the possibility of developing an education 
program for pharmacists that could ultimately lead to the development of a pharmacist-led PND 
screening service and whilst the results appear positive, our findings are not prescriptive. A more 
robust and comprehensive study is needed to qualify our preliminary findings and to measure the 
impact of an educational intervention on pharmacist‘s knowledge, attitudes and confidence with PND 
screening and referral. A recommended next step would be to gain ethics approval to develop and 
validate a pharmacist PND knowledge and attitude questionnaire for use in an intervention study to 
assess the outcome of a reviewed PMHP program on pharmacist PND knowledge and attitude 
scores. However, an educational intervention represents just the first step of an overall need to 
determine the impact of a pharmacist-led PND screening program on depression outcomes. Long-
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term, the development of a randomised controlled trial to assess the impact of pharmacist intervention 
on the perinatal depression outcomes of affected women is recommended. 
4.7 Limitations 
Several key limitations were noted during this study. The study focused only on measuring Reaction 
and Behaviour metrics in the evaluation process without considering Learning or Results outcomes 
(the second and fourth steps of the Kirkpatrick model). This study was therefore not able to measure 
changes in knowledge of perinatal mental health. Furthermore, the pre-workshop survey was 
distributed after the delivery of the Training Guide which may have affected confidence and attitude 
scores. The reliability of scores measured were limited by the very small sample size which limited the 
research team‘s ability to conduct comprehensive statistical analyses of change in confidence and 
attitude after the training program. However, this study was intended primarily as a pilot program to 
gain insights into the training program developed thus the team did not consider a large sample 
necessary for the purposes of Phase 2 of this study. The insights gained from Phase 2 will be utilised 
to develop a comprehensive training program and associated ethics application for a larger study to 
measure the impact of the training program on pharmacists‘ knowledge and attitudes towards PND. 
Furthermore, two participants reported lower confidence scores after the workshop. Due to survey 
and sample size limitations, we were unable to determine the significance of these score changes nor 
capture individual participant feedback about why their confidence scores may have lowered or 
whether these score changes reflect confusion about the numerical scales provided (Alliger & Janak, 
1989). This may be an indication of internal weaknesses within the survey developed and justifies the 
need to develop and validate a pharmacist-specific knowledge and attitude questionnaire.  
4.8 Conclusion 
Despite these limitations, the PMHP program provided a solid, foundational base for future attempts 
to develop a perinatal mental health training program with a pharmacy focus. This pilot test was 
successful as a number of participants reported a need for comprehensive training in perinatal mental 
health. Preliminary evaluation attempts have highlighted several key areas for improvement of the 
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PMHP program and informed recommendations for a larger study investigating the outcomes of a 
PND educational intervention. 
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Chapter 5:  
Discussion & Recommendations 
The perinatal period is a challenging time for pregnant and new mothers. Given the adverse impacts 
of PND on mothers and their families, there is a strong need to identify ways of detecting and treating 
this disorder as early as possible and the findings from Phase 1 and 2 of this study suggest that 
pharmacists may have an important role to play in early PND detection. 
 
The literature review conducted at the initial part of this research project demonstrated that there was 
insufficient evidence to support the long-term benefits of universal PPD screening programs, however, 
there was recognition that despite the need for further RCTs (or diagnostic accuracy studies) to 
quantify the long-term outcomes of such programs, that there was nonetheless a need to implement a 
model that would enhance the detection and subsequent referral of mothers with depression 
(Chaudron & Wisner, 2014). A few decades ago, the World Health Organisation (WHO) published ten 
criteria (Wilson et al., 1968) as discussed in Chapter 1.  
 
In the context of depression screening, much debate has transpired about whether perinatal 
depression as a disease-state meets this criteria (M. Austin, Hadzi-Pavlovic, Saint, & Parker, 2005; 
Thombs, Arthurs et al., 2014; Wickberg, 2007). Whilst there are conflicting opinions and studies about 
the value and cost-effectiveness of universal PPD screening programs (Chaudron & Wisner, 2014; 
Thombs, Arthurs et al., 2014), primary care contexts which provide unfettered access to health 
professionals improve the likelihood that a patient-provider interaction will result in a PPD case being 
detected and referred [Note: PPD being the term we selected for our literature review for reasons 
cited earlier]. In 2005, Kessler et al. (2005) advocated that depression screening should be conducted 
within primary care settings since there were key reasons why depression may not fulfill some of the 
Wilson and Jungner criteria – chiefly, that depression has no clearly defined pre-clinical phase. The 
authors suggest that perhaps the better course of action would be to screen those with a severe form 
of the condition, or those more likely to come to harm. Furthermore, modifications to the Wilson and 
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Jungner model have been suggested (R. Harris, Sawaya, Moyer, & Calonge, 2011) by researchers 
who have advocated that these principles not be used as a formal checklist but rather, as a paradigm 
which considers the net benefits of screening against the possibility of harm. Harris et al. (2011) 
propose that the purpose of screening is to improve quality of life and should be measured by the 
degree to which early recognition of a disease justifies the resources required by the program in 
question.  
 
There are risks involved in universal PND screening, namely the possibility of women without 
depression being falsely identified as having PND, making a follow-up diagnostic appointment 
essential (Eberhard-Gran, Eskild, Tambs, Opjordsmoen, & Samuelsen, 2001). Conversely, it may 
lead to false negatives and the subsequent perceived invalidation of a woman‘s mental health needs 
(Rosenfield, 2006). It may also create anxiety and fear in patients unnecessarily. However, it has 
been argued that attempting to identify and acknowledge the possibility of depression outweighs the 
risk of negative long-term consequences (Buist et al., 2002). Given the tangible and potentially severe 
consequences of PND on the family unit, there is a genuine need to consider the merits of 
implementing PND screening policies, whether such policies encourage mass screening or selective 
case-finding strategies (Rosenfield, 2006).  
 
The literature review set the stage for an exploration of the role of the pharmacist in PND screening 
generally since community pharmacy provides pregnant women and postpartum mothers with ample 
opportunities to interact with pharmacists. The findings presented in this dissertation support the 
notion that utilising pharmacists and potentially other non-medical allied health professionals who are 
skilled in recognising cases and referring them to general practitioners (GPs) may be a way forward. 
The average Australian adult consults or visits their pharmacist fourteen times compared to a single 
annual visit to their GP (KordaMentha, 2011) therefore accessibility is a key advantage that the 
pharmacy sector offers in the context of PND detection. Pharmacists already engage in screening 
activities for physical conditions such as COPD (L. Fuller et al., 2012), sleep apnea (Tran et al., 2009) 
and hypertension (Mangum et al., 2003). There is also evidence supporting the feasibility of involving 
pharmacists in depression screening (O‘Reilly et al., 2015a; Ragland et al., 2010). Given pharmacists‘ 
foray into screening services and their inherent accessibility as professionals, there is a case to be 
Community-based perinatal depression recognition and management  |  June 2016  | University of Sydney  
128 
made for the possibility of implementing PND screening programs in the context of the community 
pharmacy.  
 
The willingness and ability of pharmacists to implement services for traditionally stigmatised 
populations is also relevant in the context of a discussion about mental health screening. Studies 
have indicated that pharmacists in the US generally hold a positive view towards in-pharmacy HIV 
testing (Amesty, Blaney, Crawford, Rivera, & Fuller, 2012) and pharmacists in the UK would be willing 
to offer chlamydia testing and treatment services (Cameron et al., 2007). Positive attitudes towards 
service provision for drug misusers by pharmacists (Eades et al., 2011) also indicates that 
pharmacists are generally open to engaging with screening and treatment services for people with 
sensitive health issues. As such, the importance of understanding pharmacist attitudes to proposed 
screening and disease state management (DSM) services cannot be overstated.  
 
The long-term implementation of services in the pharmacy context cannot occur without taking a 
systematic approach to first understanding the barriers, needs and attitudes of pharmacists and 
patients (Kaae & Christensen, 2012). Feasibility studies conducted on pharmacist-led screening and 
DSM services are usually informed by qualitative studies aimed at collecting stakeholder feedback 
about the service being proposed. A similar pattern of investigation leading to the establishment or 
improvement of existing screening services has been observed in relation to physical disease states 
such as diabetes (Blenkinsopp & Hassey, 2005; Krass, Delaney, Glaubitz, & Kanjanarach, 2009), 
asthma (Saini et al., 2011) and cardiovascular disease (Tod, Read, Lacey, & Abbott, 2001) but also in 
mental health (O‘Reilly et al., 2015a) and insomnia (J. M. Fuller, Wong, Hoyos, Krass, & Saini, 2015).  
 
The findings from the qualitative study are often used to inform the development of an educational 
intervention designed to equip the pharmacist with the skills to subsequently partake in a feasibility 
study designed to determine the overall impact of a proposed in-pharmacy and pharmacist-led 
screening program (Armour et al., 2007; J. M. Fuller et al., 2015; L. Fuller et al., 2012; Tran et al., 
2009) (Figure 5.1). In our case too, the research team sought to follow a similar research path by 
initially exploring pharmacists‘ understanding, experiences and attitudes in relation to PND and to 
identify their views on and perceived barriers to implementing PND screening in pharmacy. The 
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results of this effort resulted in the development of a pilot two-stage educational intervention in Phase 
2 which aimed to pilot a pharmacist-focused PND training program and gather feedback which could 
inform future research and iterations of the program.  
 
The training of health professionals is crucial for PND-screening programs to be successful since 
simply providing a screening tool will not improve detection of depression (Donoghue et al., 2004). 
The training should encompass more than a deliberation on the use of the screening tool; it must also 
improve the quality of the interaction between the health provider and woman in question by 
improving their listening skills and ability to manage distress (Rosenfield, 2006). Feedback gathered 
from participants of the PMHP program in Phase 2 of this study highlighted the importance of 
pharmacists undertaking further training in perinatal mental health to supplement gaps in their 
knowledge and experience. Pharmacists have been trained to provide specialised asthma care (Saini, 
Smith, Armour, & Krass, 2006) and sleep behaviour interventions (J. M. Fuller et al., 2015) which 
emphasises the importance of providing specialised training as a prerequisite for delivering 
comprehensive screening and DSM programs.  
 
Though these educational interventions and subsequent feasibility studies have often been conducted 
with practising pharmacists, there is a compelling need for pharmacy schools to consider a 
reconfiguration of their curricula to ensure that emerging screening services (such as mental health 
screening) are adequately represented in the course syllabus. Pharmacy schools often do not place 
enough emphasis on mental health education (Cates et al., 2007). There are many opportunities 
within the pharmacy syllabus to introduce and consolidate student understanding in relation to PND; 
the topic lends itself well to integration into existing modules focusing on pregnancy, women‘s health, 
paediatrics or mental health. Attempting to saturate all possible opportunities within the course 
syllabus with references to PND may increase the likelihood that graduates would commence their 
professional practice with an appreciation of the complexities associated with the disorder. In fact as 
highlighted in Chapter 3, our interview participants had indicated that the opportunities to learn about 
antenatal and postpartum depression at pharmacy school had been minimal, and a reference to PND 
in their final year of study had been brief and did not fulfill practice needs. 
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Figure 5.1 Observed process to screening service implementation 
 
Participants in Phase 1 cited lack of time in the community pharmacy environment; this meant that 
pharmacists had competing priorities which may hinder the implementation of a pharmacist-led PND 
screening program. Many studies have suggested that time constraints in the pharmacy (Landau et 
al., 2009; O‘Reilly et al., 2015a; Scheerder & Iris De Coster, 2015; Semple et al., 2006) are a 
significant barrier to pharmacists delivering professional services and spending quality time with 
patients. This barrier may be resolved through a government-funded remuneration scheme which 
funds extra pharmacist staff (or pharmacist hours) to conduct screening services. Twenty-eight 
pharmacy service remuneration models were identified in a systematic review (Chan et al., 2008) that 
reported government agencies as the most common financiers of remuneration systems designed to 
provide payment for each individual intervention delivered. In practice, such interventions often occur 
in the context of an established pharmacy workflow such as dispensing. Similarly, a successful (and 
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potentially remunerated) implementation of PND screening may need to be attached to an existing 
pharmacy workflow not only to enhance efficiency but also to complement existing services.  
 
One possible avenue would be to integrate PND screening into existing in-pharmacy baby clinics 
(often run by nurses) (Flowers, 2008; Zadoroznyj et al., 2013). Baby clinics are often seen by mothers 
as a useful avenue for them to seek parenting advice and psychosocial support and referrals 
(Kearney & Fulbrook, 2012) and the drop-in style of engagement offered by pharmacy-run baby 
clinics confers benefits of convenience and accessibility to such parents. Such clinics may be a good 
forum for discussing mood and mental well-being in mothers with new babies; women have reported 
wanting an avenue to discuss their childbearing experiences with supportive health professionals 
(Cooke & Stacey, 2003) and the provision of supportive care by health professionals in the perinatal 
period contributes positively to a reduction in maternal depression symptoms (Gamble et al., 2005). 
Baby clinics already operate in many pharmacies and potentially serve as useful conduits for PND 
screening protocols or as templates for the future development of pharmacy-based PND screening 
programs.  
 
In addition to in-pharmacy baby clinics, pharmacists also have a plethora of informal opportunities to 
initiate PND screening such as during breastfeeding consultations, discussions about treatment for a 
sick infant or antenatal vitamin consultations. In all of these cases, a pharmacist will need to exercise 
professional discretion when deciding to initiate formal PND screening procedures and as reported by 
participants in Phase 2, this often depends on the level of rapport between the patient and the 
pharmacist.  
 
An important argument against the concept of universal screening in a pharmacy context (and 
potentially other venues) lies in the role that patient-provider trust and familiarity plays in the detection 
of mental health disorders (MaGPIe Research Group, 2005). GPs are more likely to detect mental 
health disorders in patients that they know since such a diagnosis often occurs as a result of multiple 
consultations rather than an isolated event (MaGPIe Research Group, 2005). It has been reported 
that public trust in the community pharmacist‘s ability to deliver perceived ―high-risk‖ services 
(Gidman, Ward, & McGregor, 2012) is linked to the perception that GP interactions are underpinned 
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by a sense of care continuity whereas interactions with pharmacists are perceived to be temporary. 
However, this stands in contrast to studies which report a high level of public trust and satisfaction 
with pharmacists (Bawazir, 2004; Hargie, Morrow, & Woodman, 1992; Perepelkin, 2011). Regardless, 
the development of a pharmacy model which nurtures long-term trusting relationships between 
mothers and their pharmacists is likely to result in better PND detection in the pharmacy setting. 
Given the accessibility of pharmacists to perinatal women, there is a case for investigating models 
which remunerate pharmacists for spending the time to develop such relationships. Practice 
incentives are often issued by government agencies for time spent delivering an intervention and may 
apply to pharmacist-led screening initiatives. The task of identifying an appropriate remuneration 
model for pharmacy-based PND screening may not require immediate attention but it is nonetheless a 
consideration that is worthwhile keeping in mind for future investigation. 
 
The development of a pharmacist-led PND screening model would require strong interprofessional 
collaboration between pharmacists and other healthcare providers, general practitioners (GPs) in 
particular. A frequent assertion made by participants in Phase 1 was the belief that GPs would view 
pharmacist-led PND screening as a transgression of professional boundaries and an encroachment 
on GP territory. Some studies (Blenkinsopp et al., 2008; Edmunds & Calnan, 2001) do substantiate 
these views though the point is made that such professional tensions are facilitated by pharmacist 
acquiescence to GP authority and a defensive reluctance to respond to GP apprehensions about 
pharmacists‘ clinical abilities. However, studies show, for example, that a high proportion of women 
with screening results that indicated possible depression often are not provided with further evaluation 
or treatment since clinicians who do screen for depression don‘t always use the results to enable 
further assessment (Georgiopoulos et al., 2001; Olson et al., 2002). Many paediatricians do not 
consider it their responsibility to recognise maternal depression (Olson et al., 2002) whereas most 
primary care physicians do consider it their responsibility (Leiferman, Dauber, Heisler, & Paulson, 
2008) but often do not; time pressures being a real deterrent and clinical hesitancy a close second.  
The gap this creates in the continuum of care for perinatal women presents an opportunity for non-
medical allied health professionals operating in the community setting to step in and provide an 
additional opportunity for mothers to be screened. Thus the redesign of maternity care to include 
pharmacists (and potentially other non-medical allied health professionals) in an interprofessional 
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collaboration designed to improve overall PND detection rates may be warranted. Furthermore, there 
is a need to provide health professionals working with mothers with depression with ongoing 
supervision and support (Elliott, Ashton, Gerrard, & Cox, 2003) which creates a further opportunity for 
pharmacists to collaborate with medical professionals traditionally involved in the delivery of maternity 
mental health services.  
 
Though this debate is larger than the study in question, some recommendations may be made to 
enhance professional trust and facilitate this collaboration. Firstly, professional networking 
opportunities focusing on pharmacist-GP interaction may help boost professional trust and encourage 
conversations about collaborative care models within primary care. Furthermore, in the context of 
PND specifically, collaborative education opportunities between pharmacists and GPs (Bryson & 
Ryan, 2016) may provide a platform for discussion about the most appropriate way to divide 
responsibilities in the context of perinatal care. There is strong evidence that interprofessional learning 
projects in the context of health promotion activities fosters positive collaboration between health 
students (Saini et al., 2011). The establishment of local networks of health providers and mental 
health organisations to enable a collaborative, closed-loop approach to PND referral and 
management would also depend on the ability of pharmacists to build rapport with relevant 
stakeholders within their local area. This is particularly important since there is a strong body of 
evidence supporting the need for structured procedures following a screening result that suggests 
possible depression (Leung et al., 2011; Segre et al., 2012; Weingarten et al., 2002). Screening 
models with effective follow-up and treatment should also include the provision of educational 
materials, treatment maintenance and medication advice (Wells et al., 2000); all of which pharmacists 
are capable of completing. In fact, the vast majority of participants in Phase 2 believed that 
pharmacists were capable of screening for PND but that pharmacists required established and 
coordinated referral procedures to do so effectively. This supports the finding that health staff need to 
be confident that resources will be available after screening to justify the effort they put into doing so 
(Ericksen et al., 2005).  
 
In the pharmacy context, such coordinated approaches are particularly necessary given that mental 
health screening is still a relatively new concept for many pharmacists who are likely to expect an 
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established framework to guide them through the entire process. Whilst participants in Phase 2 
suggested that the PMHP training program helped build confidence in their ability to screen for PND, 
their call for a standardised screening and referral framework may reflect an underlying lack of self-
efficacy (Bandura, 2010) and confidence in their ability to implement a screening program without the 
guidance of clear-cut protocols. Thus further research may be required to understand pharmacist‘s 
apprehensions about PND screening and measures taken to boost pharmacist‘s self-efficacy by 
responding to these apprehensions in future iterations of the PMHP program and any pharmacist-led 
PND screening programs that may result. Whilst the qualitative interviews conducted in Phase 1 of 
this study attempted to gauge such apprehensions, a phenomenological approach utilising 
unstructured interviews may capture unexpected pharmacist concerns and reduce the impact of 
researcher assumptions on the responses collected (Englander, 2012).  
 
This study represents one of the first investigative forays into the topic of pharmacist-led PND 
screening. Whilst the findings of this study appear to support the notion of pharmacist-led PND 
screening, the research team recognises that these findings simply offer an introductory glimpse into 
the feasibility of pharmacist-led screening and that further research is required to validate the concept. 
Although attempts have been made to consider the role of hospital pharmacists in detecting comorbid 
depression in cases of gestational diabetes (Ragland et al., 2010), there appears to be very little 
published research exploring the role of pharmacists in perinatal depression screening, referral and 
management. Future research areas could include the development and validation of a PND 
knowledge, attitude and self-efficacy scale for pharmacists and subsequent distribution to a larger 
sample of pharmacists to determine training needs. An educational intervention developed as a result 
of such research, which may indeed be similar to the one we have piloted, may be the subject of a 
randomised controlled trial to test pharmacists‘ knowledge, attitudes and self-efficacy outcomes and 
potentially form the backbone of a larger diagnostic accuracy type investigation into the impact of 
training on the PND outcomes of mothers screened and referred by pharmacists. The small sample 
size and skewed sample characteristics (limited practice locations and age range) severely restricted 
the generalisability of our findings. Furthermore, the lack of time to complete all planned activities 
limited us from pilot testing the entirety of the developed PMHP program. Whilst the PMHP program 
could have been extended to develop and validate a pharmacist-specific knowledge and attitude 
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questionnaire, lack of time and funding prevented us from doing so. As such, the limitations 
surrounding this study were a consequence of circumstances that should be addressed in future 
investigations. In addition, the conclusions drawn from the qualitative interviews may have been 
affected by a social desirability bias which suggests that future studies looking to validate the findings 
in this study may need to consider alternative ways of collecting pharmacist views about a PND 
training program for pharmacists through postal or online surveys. As discussed in Chapter 4, the next 
stage of this research may be to develop and validate a pharmacist-specific knowledge and attitude 
questionnaire about PND before developing an intervention study which tests the impact of PND 
education on pharmacist‘s knowledge, attitudes and ability to screen through the use of the validated 
questionnaire and patient simulation exercises.  
 
In conclusion, the community pharmacy sector represents a potentially underutilised resource in the 
push to detect and treat perinatal depression as early as possible. Whilst the value of primary-care 
based screening programs have been the subject of rigorous debate, it has also been acknowledged 
that the benefits likely outweigh the harms, and where screening is implemented, it should be followed 
up with established assessment and treatment protocols. This study represents a positive view of the 
potential for pharmacists to be at the frontier of public health attempts to implement primary-care 
based PND screening programs. Further research into the feasibility and implications of pharmacist-
led PND screening is recommended.  
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Appendix A 
Modified STARD checklist for reporting of studies of diagnostic accuracy 
 
(modified by Sabrine Elkhodr; Bandana Saini) 
 
Section and Topic Item 
# 
 On page # 
TITLE/ABSTRACT/ 
KEYWORDS 
1   
INTRODUCTION 2   
METHODS    
Participants 3 The study population: The inclusion and 
exclusion criteria, setting and locations 
where data were collected. 
 
 4   
 5 Participant sampling: Was the study 
population a consecutive series of 
participants defined by the selection criteria 
in item 3 and 4? If not, specify how 
participants were further selected. 
 
 6 Data collection: Was data collection 
planned before the screening test  test 
wasperformed (prospective study) or after 
(retrospective study)? 
 
Test methods 7   
 8 Technical specifications of material and 
methods involved including how and when 
measurements were taken, and/or cite 
references for index tests screening tool. 
 
 9 Definition of and rationale for the units, cut-
offs and/or categories of the results of the 
screening  tests and the reference 
standard. 
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 10 The number, training and expertise of the 
persons executing and reading the 
screening test results tests and the 
reference standard. 
 
 11   
Statistical methods 12   
 13   
RESULTS    
Participants 14 When study was performed, including 
beginning and end dates of recruitment. 
 
 15 Clinical and demographic characteristics of 
the study population (at least information 
on age, gender, spectrum of presenting 
symptoms). 
 
 16 The number of participants satisfying the 
criteria for inclusion who did or did not 
undergo the index tests and/or the 
reference standard; describe why 
participants failed to undergo either test (a 
flow diagram is strongly recommended). 
 
Test results 17   
 18 Distribution of severity of disease (define 
criteria) in those with the target condition; 
other diagnoses in participants without the 
target condition. 
 
 19   
 20   
Estimates 21   
 22 Explanation of how indeterminate results, 
missing data and outliers of the index tests 
were handled. 
 
 23 The screened population is followed up to 
see outcome at appropriate intervals.  
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 24   
DISCUSSION 25 Discuss the clinical applicability of the 
study findings. 
 
TOTAL   /13 
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Appendix B 
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Appendix C 
PHARMACIST SEMI-STRUCTURED INTERVIEW GUIDE 
 
Community pharmacist perspectives on their role in supporting women with perinatal 
depression in professional practice.  
 
Interviewer Script 
 
First, I‘d like to thank you for participating in this project. As I mentioned before, I would like to record 
the interview for data accuracy. May I start recording? 
 
Thank you. Just a few basic questions to start:  
 
 Interview/ID number 
 Date 
 Venue 
 Job Type ( pharmacist employee, pharmacy manager, pharmacy owner) 
 Size of the community pharmacy (no of scripts dispensed/week, no of staff) 
 Location ( shopping centre, medical centre, shopping strip etc.) 
 No. years in practice 
 How many days per week do you work in community pharmacy? 
 
 
 
 
 
 
 
 
Thanks. Now we‘ll begin with the main set of questions. Just for reference purposes. When I ask 
about ―postpartum mothers‖, I am referring to a mother who has given birth within the previous 12 
months, whether she is already a mother to an older child or a first time mother.  
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PREGNANCY & POSTPARTUM MOTHERS IN THE PHARMACY 
 
First, I‟d like to gain an understanding of your experiences as a community pharmacist when 
encountering pregnant women or women who have just given birth. What has been your experience 
with postpartum and pregnant mothers in the pharmacy? 
 
<PROMPTS> 
 Types of product queries (eg. Vitamins, baby formula etc.)  
 Special Issues/Questions (eg. maternal/infant sleep, baby colic, drugs in pregnancy) 
 Common counseling points (eg. vitamin supplementation, sleep hygiene, etc.) 
 General services offered (eg. baby checkup clinics, lactation consultant etc.) 
 
Thinking specifically about postpartum or pregnant mothers, What observations have you made 
in your professional capacity as a pharmacist when counselling them? 
M 
 mood, coping style, stress levels, communication style etc.? 
 ―change‖ after having a babydealing with new responsibilities that come with motherhood?  
 
 
 
 
PERINATAL DEPRESSION IN THE PHARMACY: CURRENT PRACTICE 
 
Thank you for answering those questions. As you know, my area of research is exploring perinatal 
depression and current practice within community pharmacy. First, I will be asking you some 
questions in relation to postpartum or pregnant mothers and how they present to you in the pharmacy. 
 
How frequently do you come across postpartum and pregnant mothers in your professional practice? 
 
When new mother or pregnant woman comes in to the pharmacy, how do you or how would you 
gauge the possibility that she may be experiencing emotional or health problems ? 
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<PROMPTS> 
 Signs of exhaustion, they don‟t seem as “happy” as usual etc  
 Effects on the mother/infant etc. 
 
If these have occurred how have you approached cases (or potential cases) of perinatal depression 
(or PND) in your professional practice? 
 
<PROMPTS>  
 Referral to GP‟s/mental health clinics, lifestyle advice eg. sleep hygiene, infant health/sleep 
etc. 
 
Case Study 1:  A young woman in her twenties who recently gave birth to her first child comes 
into the pharmacy. You’ve known her for a couple of years when she comes in to get her 
scripts filled and know her to be a friendly, talkative person. On this occasion however, she 
looks really tired, seems down and withdrawn. Her 3 month old baby is asleep in the stroller 
and she asks you for something to help her sleep at night because she’s too “restless” to 
sleep even when her baby does. 
 
How would you approach this situation? 
<PROMPTS> 
 Your concerns, thoughts and actions  
 
Case Study 2:  A woman in her thirties comes in to your pharmacy and you do not recognise 
her as a regular patient. She is holding a baby that looks to be almost a year old and an older 
toddler is following her around. She seems really flustered, moody and anxious to get her 
scripts filled as soon as possible (She is getting her Xanax & Diabex scripts filled). She 
mentions that she’s been taking Xanax for a couple of months now.  
How would you approach this situation? 
<PROMPTS> 
 Your concerns, thoughts and actions taken 
How eould your approach differ in this case compared to the previous one?  
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If you decided to ask a patient to consult with another health provider such as their GP in a suspected 
case of PND, what methods would you use to ensure this occurs? 
 
<PROMPTS>  
 phone call/written letter to GP/mental health clinic 
 
How confident and comfortable do you feel referring a woman who you suspect is experiencing 
perinatal depression?  
 
What would help you feel more confident in referring suspected PND cases to an appropriate health 
provider?  
 
PERINATAL DEPRESSION IN THE PHARMACY: FUTURE PRACTICE 
Now we‟ll talk about the possibility of perinatal depression screening in community pharmacy and your 
thoughts on this.  
 
Do you believe community pharmacy has the capacity of screening for perinatal depression? If yes,  
 
a. What steps do you feel need to be taken before it can become a professional service within 
community pharmacy? 
 
b. What tools do you feel would help you screen for perinatal depression in the pharmacy? 
<PROMPTS>  
 leaflets with information about PND, screening questionnaires etc.  
 
c. How do you feel you would incorporate such tools into the counseling session if you 
suspected that a woman was experiencing PND?  
 
What potential barriers do you believe need to be addressed before PND screening can   become a 
reality in community pharmacy and how do you feel that they can be resolved? 
 
What are your thoughts on: 
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a. the perceived stigma around PND and its implications on implementation of a screening 
program in community pharmacy?  
b. the interaction between patient privacy and PND screening?  
c. perceived acceptability of PND screening being conducted by pharmacists ( according to 
patients and other health providers)-by patients and by other health professionals 
d. cost issues in setting and sustaining a screening program? 
e. (other) pharmacy owners willingness to implement such a service and the factors that may 
influence their decision 
 
If a CPD-accredited training program that equips pharmacists with the skills to detect and refer 
women with perinatal depression were to made available, what would you prefer for this program to 
be like?  
 
If positive reaction,  
a. Content, format, assessment of competence 
b. Accessibility  
 
If negative reaction, 
a. May I ask why you feel that way? 
b. What would change your mind? 
c.  
Please share any thoughts you believe the research team should know. Thanks for your 
participation! 
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By the end of this chapter, pharmacists will understand:
P A R T  1
the spectrum of perinatal mental health disorders, prevalence, common signs and
symptoms & risk factors
the impact of untreated PPD that can facilitate positive wellbeing during the perinatal
period and/or improve recovery
In this manual, all references to perinatal mental health apply to mothers unless
otherwise stated. Although paternal mental health is also a significant issue that
requires consideration, it will not be the focus of this guide.
Highet NJ and Purtell CA (2012) The National Perinatal Depression Initiative: A synopsis of progress to dateand recommendations for beyond 2013. Melbourne: beyondblue, the
national depression and anxiety initiative.August 2012.
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Postpartum (or puerperal) Psychosis
is a serious illness that can be severe
and life threatening. The psychotic
symptoms include delusions,
hallucinations or disorganised
thinking. Although this usually
manifests within 48 hours of birth, it
may begin up to 12 weeks
postpartum. Up to 0.5% of new
mothers (5) will have a psychotic
episode within the first three months
after birth and it is essential for such
women to be evaluated and treated
immediately due to the threat to
maternal and infant safety. Although
pharmacists are unlikely to encounter
this in their practice, be aware that
women with a history of bipolar
disorder are at greater risk of
experiencing psychosis after birth (5).
1. Manjunath NG, Venkatesh G, Rajanna (2011) Postpartum Blue is Common in Socially and Economically Insecure Mothers. Indian J Community Med 36:231–233.
2. Matthey, S., Barnett, B., Howie, P. & Kavanagh, D. J. Diagnosing postpartum depression in mothers and fathers: whatever happened to anxiety? J. Affect. Disord. 74, 139–147 (2003).
3. Leigh, B. & Milgrom, J. Risk factors for antenatal depression, postnatal depression and parenting stress. BMC Psychiatry 8, 24 (2008).
4. Horowitz, J. A., Murphy, C. A., Gregory, K. E. & Wojcik, J. A community­based screening initiative to identify mothers at risk for postpartum depression. J. Obstet. Gynecol. Neonatal Nurs. 40, 52–61 (2011).
5. Valdimarsdóttir U, Hultman CM, Harlow B, et al (2009) Psychotic illness in first­time mothers with no previous psychiatric hospitalizations: a population­based study. PLoS Med 6:e13.
6. Pearlstein T, Howard M, Salisbury A, Zlotnick C (2009) Postpartum depression. Am J Obstet Gynecol 200:357–364.
7. Woolhouse, H., Gartland, D., Mensah, F. & Brown, S. J. Maternal depression from early pregnancy to 4 years postpartum in a prospective pregnancy cohort study: implications for primary health care. BJOG 122, 312–321 (2015).
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Mothers often describe anxiety as
feeling like “they can’t relax”, are “losing
control” or are constantly “on edge” (2).
Anxiety can be just as debilitating as
depression and although they may
overlap, they are considered to be two
separate conditions though they have
similar prevalence rates.  Like PPD, it is
estimated to affect up to 20% of
pregnant women (3).  Antenatal and
postpartum anxiety may be
characterised by (4):
constant feelings of fear and worry 
feeling irritable & always ‘on edge’
palpitations
panicky thoughts
insomnia
avoidance behaviour
repeated thoughts or images of
frightening things happening to the
baby
Postpartum depression (PPD) is a more serious type of depression than the ‘baby blues’ as it can be more severe, more
persistent and may be suspected if the depressive symptoms do not resolve within 2-4 weeks of birth (6) . Studies across
the world show that postpartum depression affects up to 20% of postpartum mothers and can begin at any time within
the first year postpartum (3) though some have suggested it may manifest as late as 4 years postpartum (7). Depression
in pregnancy is the strongest predictor of postpartum depression (3) and is particularly concerning as it may affect the
mother’s capacity for self-care, possibly leading to poor nutrition, drug or alcohol abuse and poor antenatal clinic
attendance. These can all disturb a woman's health & by default, the health of her infant. 
Postpartum blues (or “baby
blues”) is the most common
postpartum mood disturbance
affecting up to 80% of new
mothers (1). It is associated with
symptoms such as teariness,
moodiness, irritability, appetite
changes & concentration
problems which show up within
3-4 days of giving birth and last
from several hours to a couple
of weeks.
Since the “baby blues” are
limited to the first couple of
weeks postpartum, they do not
usually require
treatment. However up to 20%
of women with the baby blues
will go on to develop major
depression in the first year
postpartum (1).
Other PPD risk factors
birth complications
single marital status
poor partner relationship
lower SES
Strong PPD risk factors (3)
history of depression
antenatal depression
antenatal anxiety
stressful life events
low social support
Moderate PPD risk factors
childcare stress
low self-esteem
difficult infant temperament
SIGNS & SYMPTOMS OF PPD
L O S S  O F  P L E A S U R E  &
M O T I V A T I O N
S L E E P I N G  M O R E  O R
L E S S  T H A N  U S U A L
R E C U R R E N T  T H O U G H T S
O F  D E A T H  O R  S U I C I D E
F E E L I N G S  O F
W O R T H L E S S N E S S  &  G U I L T  
I M P A C T  O F  P P D  O N  F A M I L I E S
PPD has been strongly implicated in affecting the mother’s relationship with
her infant and the subsequent detrimental impact on the infant’s long-term
emotional development (8), cognitive delays (9) and increased risk of
developing psychiatric disorders in adolescence (10). Affected mothers are
less likely to breastfeed (11), to adhere to the recommended vaccination
schedule (12) and are at a significantly greater risk of expressing thoughts of
harming their infant compared to non-depressed mothers. PPD is strongly
implicated in cases of maternal suicide –it has been reported as a leading
cause of maternal death (13) and infanticide, creating an understandable
sense of urgency around developing methods to identify and treat PPD
before it escalates to such situations.
C H A N G E S  I N  W E I G H T  O R
A P P E T I T E
N E G A T I V E  F E E L I N G S
T O W A R D S  O R  T H O U G H T S
O F  H A R M I N G  T H E  I N F A N T
8.Field, T., Diego, M. & Hernandez­Reif, M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav. Dev. 29, 445–455 (2006).
9. Beardselee, W. R., Versage, E. M. & Giadstone, T. R. G. Children of Affectively Ill Parents: A Review of the Past 10 Years. J. Am. Acad. Child Adolesc. Psychiatry 37, 1134–1141 (1998).
10. Pawlby, S., Sharp, D., Hay, D. & O’Keane, V. Postnatal depression and child outcome at 11 years: the importance of accurate diagnosis. J. Affect. Disord. 107, 241–245 (2008).
11. Dennis, C.­L. & McQueen, K. Does maternal postpartum depressive symptomatology influence infant feeding outcomes? Acta Paediatr. 96, 590–594 (2007).
12. Minkovitz, C. S. et al. Maternal depressive symptoms and children’s receipt of health care in the first 3 years of life. Pediatrics 115, 306–314 (2005).
13. Hall, M. Why mothers die 1997­1999: the confidential enquiries into maternal deaths in the United Kingdon. 5th Report of the National Confidential Enquiries (2001).
PPD Detection
& Referral 
By the end of this chapter, pharmacists will understand:
P A R T  2
the importance of perinatal depression screening and using basic counselling skills and
client-centred communication to introduce screening to mothers
the background of the Edinburgh Postpartum Depression Scale (EPDS), its application,
acceptability and limitations. 
professional boundaries in relation to distress and disorders in the perinatal period
 the importance of knowing where and how to refer to relevant pathways
how to encourage women to follow-up with any referrals made to other mental health
professionals and engage other services 
Suggested Reading
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bipolar disorder and puerperal psychosis in the perinatal period. A guideline for primary care
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Low levels of social support are a major predictor of postpartum
depression with increased social support has been shown to be
associated with a lower risk of developing postpartum depression 6 to 8
weeks postpartum (14). These support structures include those acting within
the mother’s primary healthcare team who are likely to be aware of her
previous mental health state and be on the lookout for symptoms that indicate
the onset of PPD. Depressed women are unlikely to recognise and seek help
for their depression (15). This may be due to a multitude of factors­ fearing the
stigma that they perceive to be associated with PPD or feelings of shame and
a fear that admitting to thoughts of self­harm or harming the baby may result in
having the baby taken away from them (16). Such obstacles make it more
difficult to detect PPD, necessitating the development of screening initiatives
that women can easily access within their immediate environments and feel
comfortable to engage with. Given the challenge PPD presents as a mental
disorder that often escapes the attention of treating health providers and even
the mothers themselves, the case for universal screening in primary care has
been well­supported and advocated by all levels of health governance ­ from
global health care authorities to the World Health Organisation (17).
Why should we screen for
PPD?
14.Kritsotakis, G. et al. Social capital in pregnancy and postpartum depressive symptoms: A prospective mother–child cohort study (the Rhea study). Int. J. Nurs. Stud. 50, 63–72 (2013).
15. MacLennan, A., Wilson, D. & Taylor, A. The self­reported prevalence of postnatal depression. Aust. N. Z. J. Obstet. Gynaecol. 36, 313 (1996).
16. Mauthner, N. S. The darkest days of my life: Stories of postpartum depression. (Harvard University Press, 2002).
17. Wisner, K. L., Chambers, C. & Sit, D. K. Y. Postpartum depression: a major public health problem. JAMA 296, 2616–2618 (2006).
PPD is one of the most common and pervasive postpartum illnesses
affecting women worldwide with many possible repercussions if left
untreated. It has become a major public health concern and for good
reason­ it not only affects the mother but also the long­term health of
her children.
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Validated Screening Tools For
PPD
Edinburgh Postnatal
Depression Scale (EPDS)
PHQ­9 Patient Health
Questionnaire
PHQ­2 Patient Health
Questionnaire
PPDS Postpartum Depression
Scale
Beck Depression Inventory­II
Center for Epidemiological
Studies­Depression Scale
(CES­D)
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           ne of the most challenging
aspects of screening is overcoming
barriers to help­seeking behaviours by
women and their families. Up to 60% of
women suffering from PPD do not seek
help (18) and it is important to
understand why in order to improve rates
of detection.
Many studies have indicated that one of
the primary reasons for lack of help­
seeking behaviours is fear of stigma and
associated concerns (19). A common
help­seeking barrier expressed is the
mother’s inability to disclose her
feelings, often reinforced by health
professionals’ reluctance to respond to
her emotional and practical needs. The
lack of awareness about postpartum
depression renders mothers unable to
recognize the symptoms of depression
and allows them to accept myths that
deem symptoms of PPD “a normal part
of motherhood”. Interestingly, one
particular barrier which has emerged in
several studies is the fear that disclosing
their feelings will necessarily result in
pharmacotherapy treatment which they
may prefer to avoid. Mothers from
culturally and linguistically diverse
(CALD) communities may have added
pressures contributing to this including
lack of knowledge of available
resources, linguistic and cultural
barriers, perceived ‘‘coldness’’ of health
care providers and lack of understanding
of mental health services (20,21)
ome women may naturally be less inclined to open up about
their feelings and be willing to undergo screening. The most
important thing to do is attempt to build rapport with the
patient before initiating any sort of screening process. As the
pharmacist, you may have already built up a rapport through
your previous interactions with her but the following
techniques may also help facilitate that process.
UD
HELP-SEEKING
BELIEFS OF NEW
MOTHERS
HOW TO TALK TO WOMEN ABOUT
SCREENING: A 4-STEP APPROACH
 Opening up with a conversation about the weather or your shared interest in the cricket may seem
cliche but can bring down the patient's guard just enough to let you have a deeper conversation.
ì;NSJS;a#S";N711;S1/
Listen to what the patient is saying very carefully and find ways to connect through shared
experiences to maintain the conversation.
í;#8;=77=8;J=W8
Conversations can be steered in a particular direction by simply knowing how to listen and asking the
right questions. Find a way to connect your current topic of conversation to how the patient is going
with motherhood/how she’s feeling and use this as an entry point to the topic of screening.
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Once you’ve broached this potentially sensitive issue, it’s important that you remain empathetic and
be mindful of the patient's response to your questioning. One way to enter the discussion is to offer
the screening as a service you provide to all new mothers. 
Find your own way of opening this conversation and integrate it into your daily practise so that it
becomes habit. Remember, the more women we have this conversation with in the pharmacy, the
more cases of postpartum depression we can potentially detect and refer for treatment. 
“We actually provide a service in this pharmacy as part of our work trying to help new mums work
with the challenges that can come with a new baby. We like to see how you’re going with the new
demands placed on you and find ways to help you through this time. Would you be open to
completing a short, 10 question form to help us start that process?”
ï;7/#8;S";=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18.McGarry, J., Kim, H., Sheng, X., Egger, M. & Baksh, L. Postpartum depression and help­seeking behavior. J. Midwifery Womens. Health 54, 50–56 (2009).
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             here are many different ways
of detecting postpartum depression:
from using screening questionnaires
to exercising clinical judgement,
there is no simple way to determine
whether a mother is suffering from
PPD. It is important to remember
that screening does not equal a
diagnosis. Screening is simply the
first step in a process that seeks to
evaluate the likelihood of existing
PPD, referral for diagnosis and
subsequent treatment. As a
pharmacist in the community, you
are not responsible for making a
diagnosis of PPD (nor are
pharmacists trained to do so) but
can be instrumental in 
S detecting women who may benefit
from having their symptoms
looked at further.  To assist in this
process, screening tools have
been developed to standardise the
screening process and help
practitioners better detect cases
than they would on clinical
judgement alone (30,31). One such
tool is the Edinburgh Postnatal
Depression Scale (EPDS).
The EPDS is a 10-item questionnaire that has been
validated for use in the postpartum period, is widely
accepted and has been translated into many different
languages, making it the most commonly used tool to
screen for PPD worldwide. EPDS scores can range
from 0- 30 points, with higher points reflecting an
increased likelihood of PPD. The widely accepted
optimal cutoff point for major depression is >=13
which indicates a high chance of existent depression
(22) although a wide variety of cut-off points for the
EPDS have been used.
Although the EPDS may be administered anytime after
birth, an optimal cut-off at 6-8 weeks postnatally (23-
26) with a repeat screen at 3-6 months (27) is the most
widely recommended screening routine within clinical
guidelines globally. Some researchers suggest that the
optimal time to initially conduct the EPDS is at 12
weeks when the initial sleep deprivation stage has
been overcome (28). Very high scores in the early
postpartum period can indicate a high risk of
subsequent PPD (29) however conducting the EPDS at 
too early a stage will also conflate the results given
the likely presence of the “baby blues”. 
Limitations of the EPDS 
 It will simply assess the risk of
PPD being present but cannot
diagnose PPD. Conversely, it may
also miss cases of mothers that do
have PPD. When using the EPDS, it
is important to recognise that the
score it yields is just a starting
point and certainly not definitive.
Leading on from this point, the
EPDS asks questions where a
positive response may also be an
indication of anxiety (specifically
questions 3,4 and 5). High scores
on the EPDS in such cases may
therefore be indicative of anxiety
rather than PPD (though both
often do occur together). Both of
these conditions should be
investigated further anyway so a
high score should be referred
regardless. 
As with any screening tool, the
EPDS does have its limitations
which pharmacists need to be
aware of. First of all, it is not a
diagnostic measure so may
indicate that a woman is
depressed when she isn’t.
DEPRESSION SCREENING
USING THE EPDS
What is the EPDS?
22.Cox, J. L., Holden, J. M. & Sagovsky, R. Detection of postnatal depression. Development of the 10­item Edinburgh Postnatal Depression Scale. Br. J. Psychiatry 150, 782–786 (1987).
23. Murray, L. & Carothers, A. D. The validation of the Edinburgh Post­natal Depression Scale on a community sample. Br. J. Psychiatry 157, 288–290 (1990).
24. Harris, B., Huckle, P., Thomas, R., Johns, S. & Fung, H. The use of rating scales to identify post­natal depression. Br. J. Psychiatry 154, 813–817 (1989).
25. Zelkowitz, P. & Milet, T. H. Screening for post­partum depression in a community sample. Can. J. Psychiatry 40, 80–86 (1995).
26. Boyce, P., Stubbs, J. & Todd, A. The Edinburgh Postnatal Depression Scale: validation for an Australian sample. Aust. N. Z. J. Psychiatry 27, 472–476 (1993).
27. Elliott, S. A. et al. Promoting mental health after childbirth: a controlled trial of primary prevention of postnatal depression. Br. J. Clin. Psychol. 39 ( Pt 3), 223–241 (2000).
28. Downie, J. et al. Using the Edinburgh Postnatal Depression Scale to achieve best practice standards. Nurs. Health Sci. 5, 283–287 (2003).
29. Stewart, D. E., Robertson, E., Dennis, C.­L., Grace, S. L. & Wallington, T. Postpartum depression: Literature review of risk factors and interventions. Toronto: University Health Network Women’s Health Program for Toronto Public Health (2003). 
30.Holden, J. Using the Edinburgh postnatal depression scale in clinical practice. Perinatal Psychiatry­­Use and Misuse of the Edinburgh Postnatal Depression Scale (1994).
31. Cox, J. L., Holden, J. M. & Sagovsky, R. Detection of postnatal depression. Development of the 10­item Edinburgh Postnatal Depression Scale. Br. J. Psychiatry 150, 782–786 (1987).
The EPDS is generally very well-received by
mothers who are offered screening. It has a
high acceptability rate by patients and health
professionals alike (32) and most women will
agree to filling out the EPDS when asked (33).
It is important to note that some of the more
common objections to screening  with the
EPDS from the mother’s perspective is the
feeling that it is too simplistic (34) and
conducted in an area with little privacy. To
overcome these barriers in a community
pharmacy context, you may need to be
creative with your time and space available
to you. Take the mother in question to a
quiet corner (or consultation room if you
happen to have one) and offer the EPDS as
part of a larger discussion about how she’s
coping rather than as the basis of your
interaction with her.
One concern that is often brought up by
health professionals is the discomfort
associated with discussing answers to
Question 10 (suicide and self-harm).
Understandably, this may be a difficult issue
to discuss for both the pharmacist and the
mother if a positive response is indicated.
You will be provided with some strategies to
deal with such a situation during
the workshop.
Other scales that are sometimes used to
screen for PPD include the PHQ-2, PHQ-9,
PPDS and BDI. However, the EPDS is used
most frequently as it has been widely
validated for use in postpartum depression
screening.
Acceptability of the EPDS
32.El­Den S, O’Reilly CL, Chen TF (2015) A systematic review on the acceptability of perinatal depression screening. J Affect Disord 188:284–303.
33.Gemmill, A. W., Leigh, B., Ericksen, J. & Milgrom, J. A survey of the clinical acceptability of screening for postnatal depression in depressed and non­depressed women. BMC Public Health 6, 211 (2006).
34.. Ciliska, D. Unacceptability of routine screening for postnatal depression was related to the screening process, the intrusiveness of questions, and the stigma of disease. Evid. Based. Nurs. 7, 61 (2004).
35.Austin M P, H. N. Clinical practice guidelines for depression and related disorders: anxiety, bipolar disorder and puerperal psychosis in the perinatal period. A guideline for primary care health professionals. (BeyondBlue, 2011).
The EPDS Questionnaire 
 Please refer to the Perinatal mental
health of women from culturally and
linguistically diverse (CALD)
backgrounds: A guide for primary care
health professionals 
Screening women from
culturally diverse
backgrounds
 factsheet in the Appendix for
detailed information about how to
address PPD concerns in mothers
from culturally diverse
backgrounds. 
Pharmacists do not have the appropriate knowledge or skills to undertake
comprehensive mental health assessment to diagnose PPD thus where PPD
is suspected, a referral for further evaluation should be made. The most
appropriate referral pathway that pharmacists should follow is to the
patient's GP. This can either be done through a direct call to the GP to discuss
concerns or by providing the patient with a copy of her EPDS and requesting
she visit her GP to discuss further (and then following up with her). Consent
from the patient should be sought if referring directly to the GP except where
the safety of the woman or infant is considered to be at risk, in which case
the imperative to refer for help is stronger than respect for patient
autonomy. Consideration needs to be given to the urgency of the referral,
particularly when women have severe symptoms or suicidal thinking. In
cases of severe mental health disorders, women may need to be referred
directly to the local mental health team (through your Local Health District)
for urgent assessment.
Acting on psychosocial
assessments
Psychosocial assessments such as the EPDS provide information about
a woman’s mental health and wellbeing but not a diagnosis.
Pharmacists may suspect depression but must refer onwards for
further assessment and diagnosis. Not all mothers require further
assessment. In the following situations, referral for comprehensive
mental health assessment is advisable (35):
-the woman has a past history of major depression, anxiety disorder,
bipolar disorder or puerperal psychosis;
-the woman is experiencing abuse or has experienced abuse in the past;
-the woman or her partner has a problem with alcohol or drugs;
-there are observed difficulties with the mother–infant interaction;
-the woman’s EPDS score suggests possible major depression and/or
anxiety;
-the woman has a score of 1, 2 or 3 on Question 10 of the EPDS
Whether or not referral is required,
pharmacists have an ongoing role
in the psychosocial
care of women in the perinatal
period, including maintaining the
therapeutic relationship, supporting
the woman’s emotional health and
monitoring mother and infant well-
being.
EPDS Screening & Referral Flowchart (35)
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Dealing with resistance to referral
In some cases, women may prefer not to undertake comprehensive mental health
assessment with their GP or may want further care but not actively seek
it. Some reasons for this include fear of authorities or having their child taken away, lack of
money or shame. Discussing the benefits of assessment and reassuring the woman of any
concerns may alleviate this hesitation to seek further treatment. Pharmacists have a strong
role to play in addressing these concerns and encouraging further treatment. 
For women with PPD, treatment options include psychological therapy or pharmacological
treatment. Among physical therapies, there is evidence to suggest that exercise may
contribute to the treatment of mild to moderate depression (35-37). Some women may
express concerns about receiving pharmacological treatment. It is important to convey to
them that pharmacotherapy may form part of an overall treatment plan and that their GP will
be able to develop an effective and appropriate management plan for them which may or
may not include pharmacotherapy.
36. Daley AJ, Winter H, Grimmett C et al (2008) Feasibility of an exercise intervention for women with postnatal depression: a pilot randomised controlled trial. Brit J Gen Pract 58(548): 178–83.
37. Heh SS, Huang LH, Ho SM (2008) Effectiveness of an exercise support program in reducing the severity of postnatal depression in Taiwanese women. Birth 35: 60–65.
Courses of action depending on depression severity
( extracted from the Perinatal Mental Health Clinical Guidelines; see for chapter references (35))
Treatment for
PPD
By the end of this section, pharmacists will:
Develop an awareness of evidence-based psychosocial and
pharmacotherapeutic interventions for anxiety, depression and
related disorders in the perinatal period
Suggested Reading
Marks JM, Spatz DL (2003) Medications and lactation: what PNPs need to know. J Pediatr Health
Care 17:311–7; quiz 318–9.
Austin M P HN (2011) Clinical practice guidelines for depression and related disorders: anxiety,
bipolar disorder and puerperal psychosis in the perinatal period. A guideline for primary care
health professionals. BeyondBlue: Chapter 8
P A R T  3
TREATMENT
PRINCIPLES
ìíU
ONLY
OF MUMS WITH
PPD
GET THE TREATMENT
THEY NEED (38)
Like all mental illness, PPD is a complicated disorder which
requires a multi-faceted approach to treatment. There are many
factors that contribute to the development of PPD and what may
work for one patient, may not work for another. PPD is
particularly complicated due to the nature of the disorder. It
occurs at a time of great change in a mother’s life, when
unavoidable sleep deprivation is expected, hormonal imbalances
are likely to occur and mothers may be breastfeeding which will
greatly affect treatment choice. It is a time when parents need to
completely reassess their lives and fit their own personal choices
around the highly demanding needs of a very young and
completely helpless child. The combination of all of these factors
together with predisposing risk factors means that the treatment
for PPD must be handled with a great degree of care and
foresight. As a pharmacist, your role in a PPD-afflicted mother’s
care will be reasonably limited but it is crucial that you have an
understanding of what her care will involve.
38.Horowitz JA, Cousins A (2006) Postpartum depression treatment rates for at­risk women. Nurs Res 55:S23–7.
Table 3: Overview of mental healthcare in the perinatal period (39)
39. Austin M P, H. N. Clinical practice guidelines for depression and related disorders: anxiety, bipolar disorder and puerperal psychosis in the perinatal period. A guideline for primary care health professionals. (BeyondBlue, 2011).
Although many of the
challenges associated with
early parenthood are
unavoidable, there are self-
care strategies that may help
to make this stage of life a
little bit easier. Sleep
deprivation & stress are often
described as some of the most
difficult aspects of this time
and there are strategies that
you can help mothers
incorporate into their daily
lives to improve their sleep
quality and mood generally.
Provide women with advice on
diet, physical activity, sleep,
smoking and alcohol &
encourage them to discuss
any nutritional or other
supplements they are
taking. Inadequate nutrition
can be quite common at times
of high stress and may
contribute to poor mood so
discussing this with the
mothers you come across in
your pharmacy is worthwhile. 
Lifestyle Advice
Psychotherapy
Psychosocial Treatment
Psychotherapy is indicated in cases of mild-moderate depression and usually falls into two main categories: Cognitive
Behavioural Therapy (CBT) or Interpersonal Psychotherapy (IPT). CBT is centred around trying to equip patients with
necessary self-help skills to become aware of and control their own thought processes. Programs are usually
individualised and are premised on the belief that patients are capable of becoming self-aware, recognising the
thought patterns that create depressive feelings and be able to counter them through positive self-reinforcement,
assertive communication & developing their problem-solving skills.
IPT is an approach that categorises depression as a phenomenon which occurs in response to current difficulties in
our everyday interactions with others. It may occur as a result of grief, role transitions, interpersonal deficits and/or
interpersonal conflict. This approach aims to help the patient identify which of the four categories their own
depression is most likely linked to and working through strategies to help resolve the issues contributing to that
depression.
The decision about which type of therapy to engage in is made based on several factors including severity of
depression, the woman’s willingness to engage in the therapy and other psychological co-morbidities. 
Lifestyle suggestions for new mothers (35)
Pharmacological Treatment
Decision-making about pharmacological treatment
A pharmacist's role in the pharmacological
treatment of mothers with PPD is
important. Pharmacological treatment of
perinatal depression is similar in approach
to depression at any other time with one
caveat: the benefit associated with
treatment must outweigh the potential
harms to the fetus and breastfed infant. A
decision to treat with medication must be
made after careful discussion with the
mother around potential adverse effects to
her fetus or infant (if she is breastfeeding).
This is where a pharmacist’s contribution is
crucial. Having an in-depth understanding
of potential harms associated with common
psychotropics used to treat perinatal
mental health disorders will assist a mother
considering pharmacological treatment
make the appropriate choice. This section
will cover the most common medications
used (antidepressants, benzodiazepines,
anticonvulsants, mood stabilisers,
antipsychotics) and advise on strategies to
use when discussing them with your
patients. 
Table 4: Factors affecting prescribing decisions (40)
Psychotropic medication may be indicated during the perinatal period for:
• prophylaxis of a pre-existing disorder, such as bipolar disorder; or
• treatment of a new episode of mental health disorder.
While there are risks associated with the use of psychotropic medications in this period, it should not be assumed
that it is always better to avoid medication. Untreated mental health disorders in this period can significantly affect
the physical and/or mental wellbeing of the woman, the infant, significant other(s) and family. For
example, depression is associated with an increased rate of obstetric complications, stillbirth, suicide attempts,
postnatal specialist care for the infant and low birth weight infants (41). Among women with bipolar
disorder, there is also an increased rate of suicide (42), potentially significant exacerbation of the
disorder if not treated, and poorer obstetric outcomes including increased preterm birth, low birth weight infants
and infants who are small for their gestational age (43).
Where a pregnancy is planned, preconception planning for medication use in pregnancy and breastfeeding should
be undertaken. As many pregnancies are unplanned, some women are exposed inadvertently to psychotropic
medications. In such cases, women should be advised to seek advice from the prescribing doctor. In some
situations, specialist advice may need to be sought through drug information services. When a woman with a past
history of a severe mental health disorder has been unmedicated during pregnancy, serious consideration needs
to be given to recommencing medication immediately after the birth.
40. eTG Complete [Internet]. (Melbourne: Therapeutic Guidelines Limited, 2015).
41. Bonari L, Pinto N, Ahn E et al (2004) Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 49: 726–35.
42.Appleby L, Mortensen PB, Faragher EB (1998) Suicide and other causes of mortality after post­partum psychiatric admission. Brit J Psychiatry 172: 209–11.
43. Howard LM (2005) Fertility and pregnancy in women with psychotic disorders. Eur J Obstet Gynecol Repro Biol 119: 3–10.
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For pregnant women with bipolar
disorder and stabilised on
medication, there is some evidence
that continuing lithium in pregnancy
helps to reduce relapse (45,46). For
women who discontinue lithium
during pregnancy, there is some
evidence for recommencing lithium
immediately after the birth to
reduce recurrence (47,48).
Benefits of pharmacological interventions in the perinatal
period
There is insufficient evidence
from studies speci cally in
antenatal or postnatal
populations regarding the
pharmacological treatment of
anxiety disorders (35).
There is insufficient evidence
from studies speci cally in
antenatal or postnatal
populations regarding the ef cacy
of antidepressant medication.
However, there is limited
evidence to suggest that
maintaining rather than
discontinuing antidepressant
medication during pregnancy
reduces relapse at this time (44).
The preceding information was extracted from the Australian Clinical Practise Guidelines for Perinatal Mental Health (43)
When considering treatment choices for mental health
disorders during pregnancy and breastfeeding, or when a
pregnancy is planned, it is important to place risks from
pharmacological treatment in the context of the individual
woman’s condition. It should also be noted that the
background risk of birth defects in the general population is
between 2% and 4%.
In discussing the risks of pharmacological treatments, it is
important to (NICE 2007):
• acknowledge the uncertainty surrounding the risks;
• explain the background risk of birth defects for pregnant
women without a mental health disorder;
• describe risks using natural frequencies (such as 1 in 10)
rather than percentages;
• in comparing risks, use the same denominator (for
example, 1 in 100 and 25 in 100, rather than 1 in 100 and 1 in
4);
• if possible use decision aids in a variety of verbal and visual
formats that focus on an individualised view of the
risks; and
• provide written material to explain the risks (preferably
individualised). 
Supporting informed decision-making
Discussions about treatment options with a woman and her
significant other should cover (49):
• the risk of relapse or deterioration in symptoms and the
woman’s ability to cope with untreated symptoms;
• the severity of previous episodes, response to treatment and
the woman’s preferences;
• early side-effects of antidepressants, their likely duration and
the need for extra support during this time;
• the possibility that birth defects may still occur even if a
medication is ceased after pregnancy is confirmed;
• the risks from stopping medication abruptly;
• the need for prompt treatment because of the potential
impact of an untreated mental health disorder on the fetus
or infant;
• the increased risk of harm associated with pharmacological
treatments during pregnancy and the postnatal period,
including the risk of overdose;
• treatment options that would enable the woman to
breastfeed if she wishes, rather than recommending that she
does not breastfeed; and
• possible interactions between pharmacological agents and
complementary or traditional remedies.
Discussing the risks and benefits of
treatment for mother and infant
44.Cohen LS, Altshuler LL, Harlow BL et al (2006) Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295(5): 499–507. 
45.Viguera AC, Newport DJ, Ritchie J et al (2007b) Lithium in breast milk and nursing infants: clinical implications. Am J Psychiatry 164: 342–45.
46. Viguera AC, Nonacs R, Cohen LS et al (2000) Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 157: 179–84.
47.Cohen LS & Nonacs RM (eds) (2005) Mood and anxiety disorders during pregnancy and postpartum. Rev Psychiatry 24(4).
48.Wisner KL, Hanusa BH, Peindl KS et al (2004) Prevention of postpartum episodes in women with bipolar disorder. Biological Psychiatry 56: 592–96
49. NICE (2007) Antenatal and Postnatal Mental Health: The NICE Guideline on Clinical Management and Service Guidance. Leicester: The British Psychological Society & The Royal College of Psychiatrists.
Clinical guidelines favour use of SSRI’s (ADEC Category C)  (except paroxetine which is ADEC
Category D) during pregnancy over other anti-depressants due to current evidence which
suggests that they do not confer additional risk of birth defects (50) over the rates found in
the general population and its suggested association with spontaneous abortion and low
birth weight has not been confirmed by the literature. They can however be responsible for
up to 30% of infants suffering from withdrawal symptoms post-delivery, resulting in
irritability, difficulty settling, feeding difficulties  and breathing problems. Women using
paroxetine who fall pregnant unexpectedly should be advised to speak with their GP
regarding their medication use ( remind them not to stop abruptly or without their GP’s
advice). Preliminary data suggest venlafaxine is not associated with congenital abnormality,
but neonatal withdrawal has been reported. The safety during pregnancy of agomelatine
(Cat B1), desvenlafaxine (Cat B2), duloxetine (Cat B3), moclobemide (Cat B3) and reboxetine
(Cat B1) has not been adequately studied (40).
TCA's (all ADEC Category C) are also used in pregnancy as there is no evidence that they
carry any increased risk of malformation ( with the exception of doxepin where isolated
reports have indicated a relationship ). TCA’s are potentially more lethal and less tolerated
due to adverse effects than SSRI’s which may limit their use (51). Maternal use has been
associated with anticholinergic effects and rebound reaction
(irritability, insomnia, fever and colic) in the infant after birth. Reducing the dose in the week
before delivery may reduce the chance of withdrawal symptoms in the neonate (52). Among
TCAs, clomipramine seems to be associated with more severe and prolonged neonatal
symptoms- they have been associated with cardiac defects & abrupt discontinuation during
pregnancy has been associated with premature delivery & seizures in the newborn.
Nortriptyline is generally considered the TCA of choice due to its lower anticholinergic side
effect profile. (50) There is insufficient evidence on other antidepressant classes to warrant
their routine use in pregnancy.  
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Effects of exposure to psychotropics during pregnancy
Anti-depressants
All antipsychotics (both 1st and 2nd generation) are Category C in pregnancy and should
only be given when absolutely required, recognising that poorly controlled psychotic
disorders may pose greater harm to the mother and infant than medication use. There is
insufficient evidence to suggest that either first or second generation antipsychotics are
associated with birth defects (apart from olanazapine though this has also been contested)
(53) however, they have been associated with adverse obstetric & neonatal outcomes.
Significantly lower birth weight, gestational age and a significantly higher rate of preterm
birth have been associated with the use of haloperidol (54) whilst higher birth weight have
been associated with use of second generation agents, particularly clozapine and
olanzapine. Little is known about the long term neurodevelopmental effects on the infant.
Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk
of extrapyramidal and withdrawal symptoms following delivery and may experience
agitation, tremor, sedation, respiratory distress and feeding problems.
Anti-psychotics
Benzodiazepines
Anticonvulsants
Lithium (Cat D) is often used for maintenance therapy in bipolar disorder and clinicians may
choose to continue with it to manage risk of relapse. However, it is associated with an
slightly increased risk of congenital heart defects (55). Lithium clearance increases
dramatically towards the end of pregnancy so must be titrated down quickly after delivery
to avoid toxicity. 
Benzodiazepine (all Cat C except clonazepam (Cat B3)) use during pregnancy has historically
been associated with increased risk of cleft palate formation though more recent studies
have suggested otherwise (56). If long half-life benzodiazepines are taken in late pregnancy,
they can cause neonatal drowsiness, respiratory depression, poor temperature regulation,
poor feeding and hypotonicity including neonatal withdrawal symptoms (57). Not enough is
known about neurodevelopment outcomes of benzodiazepine use to make a conclusion on
this front. Some studies have suggested an association between zopiclone (Cat C), zolpidem
(Cat B3) and adverse pregnancy outcomes such as low birth weight and preterm deliveries
but no increased risk of malformations (58). However, zolpidem is known to cause
abnormal sleep phenomena which should be factored into any decision to prescribe this
medication during pregnancy. The AMH (59) states with respect to benzodiazepine use in
pregnancy: “Avoid if possible, particularly large doses and regular use (risk of neonatal
withdrawal syndrome). Administration of high doses near term or during labour may
cause respiratory depression, hypothermia and floppy infant syndrome (hypotonia,
lethargy and poor suckling). If used during pregnancy short-acting drugs are preferable to
long-acting; plan to stop gradually before delivery; Australian category C.”
Anti-convulsants (carbamazepine, lamotrigine and sodium valproate (all Cat D)) are
often used in the treatment of bipolar disorder; however, they are associated with a
high risk of birth defects due to their role as folate antagonists. This effect is
particularly pronounced in cases of polytherapy (60). Sodium valproate in particular
has the highest risk of neural tube defects, impaired neurodevelopment (61) and
other serious malformations (up to 10-fold increase)(62) ; carbamazepine has a 3-fold
increase in birth defects (63) and preterm delivery (63) whilst lamotrigine does not
appear to increase the risk of birth defects in utero (64) though, this finding should be
taken with caution. The use of anti-epileptic drugs have been associated with delay in
the development of fine motor skills in infants exposed to them in utero (65). 
Comparative information about benzodiazepines
50. Einarson, T. R. & Einarson, A. Newer antidepressants in pregnancy and rates of major malformations: a meta­analysis of prospective comparative studies. Pharmacoepidemiol. Drug Saf. 14, 823–827 (2005).
51. Bellantuono, C., Migliarese, G. & Gentile, S. Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Hum. Psychopharmacol. 22, 121–128 (2007).
52.. Australian Medicines Handbook 2015,. (Australian Medicines Handbook Pty Ltd; Adelaide.).
53.Jeffrey Newport, M. D. et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am. J. Psychiatry 164, 1214–1220 (2007).
54. McKenna, K. et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J. Clin. Psychiatry 66, 444–449 (2005).
55. Newport, D. J. et al. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am. J. Psychiatry 162, 2162–2170 (2005).
56. Ban, L. et al. First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population­based cohort study. (2014). 
57. Wikner, B. N., Stiller, C. O. & Bergman, U. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. and drug safety (2007). 
58.Bellantuono, C., Tofani, S., Di Sciascio, G. & Santone, G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen. Hosp. Psychiatry 35, 3–8 (2013).
59.Australian Medicines Handbook 2015,. (Australian Medicines Handbook Pty Ltd; Adelaide.).
60. Meador, K. J. et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 360, 1597–1605 (2009).
61. Galbally, M., Roberts, M. & Buist, A. Mood stabilizers in pregnancy: a systematic review. Australian and New Zealand (2010). at <http://www.tandfonline.com/doi/full/10.3109/00048674.2010.506637>
62. Matalon, S., Schechtman, S., Goldzweig, G. & Ornoy, A. The teratogenic effect of carbamazepine: a meta­analysis of 1255 exposures. Reprod. Toxicol. 16, 9–17 (2002).
63. Meador, K., Reynolds, M. W., Crean, S., Fahrbach, K. & Probst, C. Pregnancy outcomes in women with epilepsy: A systematic review and meta­analysis of published pregnancy registries and cohorts. Epilepsy Res. 81, 1–13 (2008).
64. Veiby, G., Engelsen, B. A. & Gilhus, N. E. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol. 70, 1367–1374 (2013).
65. Cohen, L. S., Friedman, J. M., Jefferson, J. W., Johnson, E. M. & Weiner, M. L. A reevaluation of risk of in utero exposure to lithium. JAMA 271, 146–150 (1994).
9 ? 8   &    ;   ê ì
Effects of exposure to psychotropics during breastfeeding
Anti-depressants Fetal exposure to antidepressants in utero is much greater than breastmilk exposure
thus where a woman has been taking an antidepressant during pregnancy for
treatment of depression or anxiety, this should be continued into the postpartum
period rather than switching to a different agent. Evidence suggests that SSRIs (67)
are transferred in only low concentrations to breast milk though some infant plasma
levels have been reported to up to 10% of the maternal serum levels . Fluoxetine
however has the potential to accumulate in the breastfed infant, and cause
insuffcient weight gain, irritability, difficulty settling and GI disturbances.
Factors affecting drug entry into human milk
Multiple pharmacokinetic factors affect the diffusion of medication into a mother's milk and some of 
these are discussed below (66). 
Milk/plasma ratio
As the level of the medication in the
mother's plasma increases, so too
does the milk concentration. Thus the
higher the milk/plasma (M/P) ratio,
the greater the amount of the drug
found in breast milk. A M/P ratio
greater than 1.0 suggests that the
drug may be transferred in high
concentrations whereas a M/P ratio
less than 1.0 indicates that only low
drug concentrations will be
transferred into breast milk.
However, even if the medication has a
high M/P ratio, if the maternal plasma
concentration of the drug is minute,
then the  dose of a drug entering
breast milk will also be small.
Drug half-life 
The longer the half-life of a drug, the greater the likelihood of accumulation in breast milk.  When prescribing
medications to breastfeeding mothers, short half-life drugs are preferred since they generally peak and are eliminated
from the maternal plasma quickly. Half-life can be used to determine whether the mother can successfully breastfeed
by taking the medication immediately after nursing. If the half-life is short enough ( <3 hours ), then the drug level will
usually have declined at the next feed time. This may minimize drug transfer through breast milk by avoiding peak
plasma and milk drug concentrations. Sustained release medications should be avoided as their long half-life
potentially exposes the infant to a medication at higher concentrations and for longer periods of time
Ionised vs non-ionised drug
The pKa of a drug is the pH at which a
drug exists equally in ionic and
nonionic states. Drugs that have a pKa
higher than 7.2  (average plasma pKa
is 7.4) transfer into breast milk to a
slightly higher degree than those with
a lower pKa since the nonionized
molecule of a high pKa (weakly basic)
drug is quickly ionized when it enters
the weakly acidic breast milk and then
is ion-trapped and prevented from
diffusing out of breast milk back into
the maternal circulation. Drugs with a
higher pKa tend to have higher M/P
ratios, so medications with a lower
pKa are preferred in breastfeeding
women.  Conversely, drugs that are
weak acids are ionized in maternal
plasma, which minimizes their
diffusion into breast milk.
Size of drug
The semi-permeable lipid
membrane of the mammary
epithelium contains small pores
that allow medications with a low
molecular weight to move easily
into breast milk. The smaller the
drug, the higher the concentration
in breast milk. Drugs with MW>
200, (e.g. heparin, insulin) pass
through at such low concentrations
that they don't really enter human
breast milk at all. Therefore, if
possible, it is recommended that
medications with higher molecular
weights be given to lactating
mothers
Benzodiazepines
Anticonvulsants
Benzodiazepines are best avoided (or used for a very limited time) due to adverse
effects on the infant. Diazepam in particular has a long-half life and should be
avoided. Benzodiazepines with short half-lives may be used temporarily as they are
transferred to breastmilk in low concentrations and pose a smaller risk than those
with longer half-lives. Zolpidem /zopiclone have very low excretion into breastmilk
and no short-term adverse outcomes have been reported however, the risk of
abnormal sleep-related events with zolpidem must be considered before
prescribing.
There is insufficient evidence for the safety of anticonvulsants during breastfeeding
though valproate is generally considered safe to use (69). Carbamazepine has been
associated with jaundice and impaired liver function though this is also general
considered safe. Monitoring of infant biochemistry is recommended if either of
these agents are used by the mother. Lamotrigine has relatively high transmission to
and slow elimination from the infant and has been associated with serious skin
conditions in breastfed infants.
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Evidence concerning first & second generation antipsychotics and breastfeeding is
limited.There is evidence from observational studies to support avoiding the use of
clozapine (51) where relatively high breast milk concentrations can cause possible
agranulocytosis in the infant; in this case, formula feeding is usually recommended.
Some data suggests that olanzapine and risperidone have low infant doses relative
to the maternal weight-adjusted dose however there is an association between
olanzapine and jaundice, impaired weight gain, sedation, irritability and tremor in
breastfed infants. Concurrent use of more than one antipsychotic while
breastfeeding appears to substantially increase the likelihood of adverse infant
reactions.High doses of first-generation antipsychotics have been associated with
adverse reactions in breastfed infants though lower doses are usually regarded as
safe. Where an antipsychotic causes adverse effects in the infant ( either depot
injection or oral), breastfeeding should be ceased and replaced with formula.
Lithium transmission into breastmilk is highly variable & interpretation of infant
serum lithium level is difficult to assess in terms of safety. Some guidelines globally
have listed breastfeeding as a contraindication to lithium use ( although it has been
used where the infant is greater than 2 months old and the mother is only using
lithium). Unless the mother insists on breastfeeding whilst using lithium, it may be
preferable to formula-feed the infant. If she does continue to breastfeed, infants
should be monitored closely. Serum lithium, serum creatinine, blood urea nitrogen,
and TSH every 4–12 weeks during breastfeeding and maternal lithium therapy
should be checked regularly and specialist monitoring is advised (68). Breastfeeding
should be avoided or stopped if there are signs of infant illness, sedation,
dehydration, hypothyroidism and/or respiratory depression.
Anti-psychotics
Sertraline and paroxetine appear to have the lowest transmission into breastmilk
and fluoxetine, escitalopram and citalopram the highest.  Isolated cases of
irritability, sleep disturbance and colic have been associated with SSRI use so this
possibility should not be ignored if a breastfed infant presents with these symptoms.
Venlafaxine may be present in infant plasma at up to 9% (51) of maternal serum
levels and is best avoided. Similarly, TCA’s have been found in low levels in
breastmilk though long-term adverse effects on infant cognition do not appear to
occur (67). Avoid doxepin if possible (neonatal respiratory depression has been
reported). Moclobemide has very low transfer into breastmilk and is probably safe.
Agomelatine, desvenlafaxine, duloxetine, mianserin, mirtazapine, reboxetine and the
irreversible nonselective monoamine oxidase inhibitors (MAOIs) have not been
adequately studied.
The perinatal period is a challenging time for
many mothers and the potential for mental
health disorders to arise during this time is
relatively high. As the most highly accessible
professional within a mother’s healthcare team,
pharmacist's are in a prime position to help
mothers navigate this sometimes difficult period
and be able and willing to refer her to
appropriate help when necessary. For more
information about perinatal mental health
disorders and how to detect and manage them,
visit The BeyondBlue website and undertake their
free online, CPD-accredited course on Perinatal
Mental Health.
A  F I N A L  N O T E
F U R T H E R  R E S O U R C E S
NRAMP ­ The National Register of
Antipsychotic Medication in Pregnancy
http://www.maprc.org.au/nramp
Perinatal Psychotropic Medicine Info Service
http://www.ppmis.org.au/
Perinatal Anxiety & Depression Australia
(PANDA)
http://www.panda.org.au/
Motherisk
http://www.motherisk.org/women/index.jsp
Beyond Blue
http://beyondblue.org.au
Mothersafe
http://www.mothersafe.org.au/
headspace Knowledge Centre
www.headspace.org.au/knowledge­centre
TGA Prescribing in Pregnanacy Database
https://www.tga.gov.au/prescribing­medicines­
pregnancy­database
The Black Dog Institute
www.blackdoginstitute.org.au/healthprofessional
s/index.cfm
square — Suicide, QUestions, Answers and
REsources
square.org.au
Living is for Everyone
www.livingisforeveryone.com.au
Lactmed
http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm
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Perinatal Mental Health in the Pharmacy: A Guide for 
Australian pharmacists 
 
Workshop Outline  
 
Welcome to the Perinatal Mental Health in the Pharmacy: A Guide for Australian Pharmacists held at 
the University of Sydney. This 3-hour workshop is an interactive, group-based learning activity which 
will be centred around six smaller activities intended to enhance your understanding of perinatal 
mental health, perinatal depression and how to detect patients with this disorder. The following 
learning objectives were developed in line with the Perinatal Training Matrix, a set of learning 
guidelines constructed under the National Perinatal Depression Initiative (NPDI). The NPDI is an 
initiative by the Australian Government in conjunction with Beyond Blue which aims to improve 
prevention and early detection of antenatal and postnatal depression and provide better support and 
treatment for expectant and new mothers experiencing depression.  
 
For those who wish to access wifi during this workshop, please note wifi details below: 
USERNAME = pharm_itpevent 
PASSWORD = ITP2016a 
Background  
 
This workshop is a culmination of the research efforts within the Faculty of Pharmacy, University of 
Sydney, which aims to look at the feasibility of screening for postpartum depression in the context of 
community pharmacy. A series of qualitative interviews conducted with Australian pharmacists in late 
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2015 as part of a larger research study highlighted the need for further training in perinatal mental 
health for pharmacists before PPD screening in community pharmacy can become a reality. Adult 
learning principles were matched with feedback from study participants to develop and deliver a 
workshop which was highly interactive and gave attendees the opportunity to explore their own 
understanding and align them with that of their peers. The following activity types will be form the 
backbone of this workshop. 
 
Activity Types during Workshop 
 Group discussion: Participants will be assigned discussion questions in the context of a 
particular patient whose journey they will follow through a series of sequential scenarios.  
 Role Plays: Role plays will be carried out between sets of participants and facilitators around 
ley problems in PND 
 Written reflection: A written reflection activity will be assigned as post-work to encourage 
consolidation of learning through reflecting on personal professional experience with PND. 
 Production: Participants will be assigned tasks to produce certain deliverables by the end of 
the workshop. 
 
The workshop will be centred around a hypothetical patient, Stephanie, who becomes pregnant and 
presents to the pharmacist at various stages in her perinatal journey. All learning objectives and 
associated activities will be addressed in relation to Stephanie to increase active learning 
opportunities. Assessment of learning objectives will be made on a team-by-team basis. If all pre-work 
and post-work is completed as assigned ( including pre-readings), participants should be eligible for 
up to 10 Group 1 CPD points. All participants will be provided with a certificate of participation at the 
end of this workshop.  
 
Learning Objectives 
 
Learning objectives 
(as defined by the Training 
Matrix) 
Learning Activity 
Objective 
Rationale for activity Evaluation 
Associated with Learning Criteria 
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 To know the key 
features and 
prevalence rates of the 
most common perinatal 
mental health 
disorders; know how to 
differentiate between 
the various disorders; 
and understand the 
impact of PND on 
infant health and well-
being.  
Activity 1:  
Creating Infographic  
(30 mins) 
 
Create an infographic about 
perinatal mental health as 
part of an in-pharmacy 
health promotion campaign.  
Facilitated by: Sabrine Elkhodr 
 
Relevant section in Training 
Guide 
Chapter 1: Overview of Perinatal 
Mental Health 
 
This activity will 
encourage participants 
to contextualise the 
information presented to 
them in Chapter 1 of the 
 Guide to produce a 
tangible product that can 
reasonably be used in 
their professional 
practice. 
Level and quality 
of 
participation in 
anticipated 
activities 
 
Accuracy of 
information 
presented 
 
Successful 
completion of 
activity 
 
Engagement 
with the process 
 
 
Understand the 
importance of 
conducting a broader 
psychosocial 
assessment, including 
risk assessment, for 
comprehensive clinical 
care in patients with 
possible PND 
Activity 2: 
 
Group discussion  
(15 mins) 
 
Group discussion of 
Scenario 1: Stephanie Falls 
Pregnant preceded by a set 
period of time for discussion 
within teams. The 
discussion of scenario 1 will 
involve discussing the 
This activity will 
encourage critical 
thinking, peer-to-peer 
learning and the sharing 
of professional 
experiences between 
colleagues to facilitate a 
deeper understanding of 
the issues presented.  
 
Level and quality 
of 
participation in 
activity  
 
Observation of 
participant 
attentiveness 
throughout 
discussion 
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presentation of a patient, 
Stephanie, at the pharmacy 
and her request for a 
sleeping aide. Points of 
discussion will include 
assessing risk factors for 
PND and determining 
possibility of PND being 
present in Stephanie’s case. 
Facilitated by: Sabrine Elkhodr 
 
Relevant section in Training 
Guide 
Chapter 1: Overview of Perinatal 
Mental Health 
 
Understand the 
background, purpose 
and importance of 
screening, its 
application and 
limitations & implement 
screening (using the 
EPDS)    
 
Activity 3: 
 
Group discussion & 
critical thinking (15 mins) 
 
Group discussion of 
Scenario 2: Stephanie 
wants St. John’s Wort 
preceded by a set period of 
time for discussion within 
teams. Scenario 2 will 
involve discussing 
Stephanie’s return to the 
pharmacy at a future date 
and requesting St John’s 
This activity will 
encourage critical 
thinking, peer-to-peer 
learning and the sharing 
of professional 
experiences between 
colleagues to facilitate a 
deeper understanding of 
the issues presented. 
Level and quality 
of 
participation in 
activity  
 
Observation of 
participant 
attentiveness 
throughout 
discussion 
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Wort. This discussion will 
encourage participants to 
think about ways to hold 
sensitive conversations with 
patients whom they suspect 
of experiencing PPD and 
approaching the topic of 
filling out the EPDS with 
them.  
Facilitated by: Sabrine Elkhodr 
 
Relevant section in Training 
Guide 
Chapter 2: PPD Detection & 
Referral 
 
Interpret the EPDS 
scores and integrate 
with other assessment 
material as well as 
communicate these 
results to women using 
basic counselling skills 
and client centred 
communication  
 
Activity 4: 
 
Role play  
(40 mins) 
 
Role plays between the 
pharmacist and Stephanie 
(simulated patient) 
explaining her EPDS score. 
Participants will be split up 
into groups of three and will 
simulate the entire patient 
interaction  
according to a guide that will 
be provided to them. 
Groups will role play from 
 
Role playing will provide 
participants with an 
opportunity to simulate a 
PPD screening in a safe 
environment free of 
judgement or 
consequence. 
Participants will be able 
to hone their counselling 
skills in the context of 
suspected postpartum 
depression and observe 
and provide feedback to 
each other. 
 
Level and quality 
of 
participation in 
activity  
 
Observation of 
participant 
attentiveness 
throughout role 
play 
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initial conversation through 
to EPDS screening, 
discussion with Stephanie 
and referral to her GP)    
Facilitated by: A/Prof Delwynn 
Bartlett 
 
Relevant section in Training 
Guide 
Chapter 2: PPD Detection & 
Referral  
Understand the 
importance of knowing 
where and how to refer 
to relevant referral 
pathways and existing 
treatments, 
interventions and 
support  
 
Activity 5: 
 
Conceptualise PND 
screening professional 
service  
(40 mins) 
Groups will design (in 
principle) a PND-screening 
service in the pharmacy 
which will encompass the 
entire detection and referral 
process and consideration 
of marketing, budgeting and 
resource allocation. 
Participants will be expected 
to incorporate their 
infographic from Activity 1 
and create a PND screening 
& referral checklist as part 
of this service. 
 Level and quality 
of 
participation in 
anticipated 
activities 
 
Ability to think 
laterally to 
overcome 
barriers to 
implementation 
 
Successful 
completion of 
activity 
 
Consideration of 
issues involved 
in setting up 
PND screening 
service 
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Facilitated by: Sabrine Elkhodr & 
A/Prof Bandana Saini? 
 
Relevant section in Training 
Guide 
Chapter 2: PPD Detection & 
Referral 
Have awareness of 
evidence-based 
interventions for 
anxiety, depression 
and related disorders 
in the perinatal period.  
Activity 6: 
 
Group discussion & 
critical thinking (15 mins) 
 
Group discussion of 
Scenario 3:  
Stephanie Gets Treatment 
preceded by a set period of 
time for discussion within 
teams. Scenario 3 will 
encourage participants to 
draw upon their knowledge 
of psychotropic use in 
pregnancy and 
breastfeeding to answer 
Stephanie’s queries about 
her medications. 
Facilitated by:  
Dr Claire L. O’Reilly? 
 
Relevant section in Training 
Guide 
Chapter 3: Treatment for PPD 
 
This activity will 
encourage critical 
thinking, peer-to-peer 
learning and the sharing 
of professional 
experiences between 
colleagues to facilitate a 
deeper understanding of 
the issues presented.  
Level and quality 
of 
participation in 
activity  
 
Observation of 
participant 
attentiveness 
throughout 
discussion 
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Have knowledge of 
Clinical Practice 
Guidelines for mental 
health disorders in the 
perinatal period.  
Copy of Guidelines included 
in the Health Professional 
Kit to be handed out at 
workshop 
(kindly provided by Beyond 
Blue) 
  
 
Workshop Timetable  
 
5.30pm 
Dinner and refreshments + networking 
6pm 
Welcome and introductions.  
6.15pm 
Talk with Kirsten from Beyond Blue discussing her experiences with PPD + Q&A.  
6.30pm 
Activity 1: Infographic 
6.50pm 
Discussion of Activity 1 
7pm 
Team discussion of Activity 2 (Scenario 1: Stephanie falls pregnant) (Appendix C) 
7.10pm 
Workshop discussion of Activity 2 
7.15pm 
Team discussion of Activity 3 (Scenario 2: Stephanie wants St Johns wort) (Appendix D) 
7.25pm 
Workshop discussion of Activity 3 
7.30pm 
Working Break (10mins) + Activity 4: Role Play with Stephanie and the GP 
7.50pm 
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Group role plays with Stephanie and the GP 
8.10pm 
Activity 5: PND Screening service 
8.45pm 
Discussion of Activity 5 
9 pm 
Team discussion of Activity 6 (Scenario 3: Stephanie Gets Treatment) (Appendix E) 
9.15pm 
Workshop discussion of Activity 6 
9.25pm  
Wrap Up and Next Steps 
 
Post-workshop activities 
 
Participants will be requested to complete a survey at the completion of the workshop and an online 
written reflection activity within 3 weeks of attending the workshop, reflecting upon the impact that the 
training has had on their understanding of PPD and their confidence in dealing with it. This activity is 
eligible for inclusion in your CPD plan.  
 
 
 
Activity 1 
 
Create an infographic for perinatal depression 
 
Description of this activity: 
Create an infographic about perinatal mental health as part of an in-pharmacy health 
promotion campaign you’re running. The purpose of this poster is to provide mothers 
in your pharmacy with quick and easy information about postpartum depression and 
encouraging them to seek help. 
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 Time:  
20 mins  
(+ 10 mins class discussion) 
 
Some prompts to help you along: 
 
What’s the prevalence of PND? 
What are the main symptoms? 
What are treatment options? 
Challenging stigma 
Challenging a mother’s fears (we wont take your child away etc.) 
Where can a mother get help if she feels she has PPD? 
 
Some great websites to help you create a good-looking poster: 
 
www.canva.com 
 
www.piktochart.com 
 
www.venngage.com 
 
Or use coloured pens to do it the old-fashioned way! 
 
Sample Infographics (next page) 
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Activity 2 
 
Case Study: Stephanie Falls Pregnant  
Time: 10 mins ( + 5 mins class discussion) 
 
Stephanie is a regular patient at your pharmacy and was a working as a full-time 
teacher when she became pregnant with Emma. Stephanie was taking sertraline to 
treat her GAD but she stopped taking it when she discovered she was pregnant. 
Through previous conversations with her, you know that her mother is currently 
taking Lexapro® for depression and has had a “breakdown” in the past. After a long 
and difficult labour, Emma was born by caesarean birth in December 2015. She 
does not have to return to work until May though Stephanie feels torn between her 
new role as a mother and her desire to continue working and is concerned that she 
will be replaced if she goes on leave for six months. Emma is an aggressive 
breastfeeder and poor sleeper. She is colicky and catnaps most of the day, never 
sleeping for more than 20 minutes and no more than 2 hours at night. Stephanie’s 
nipples have become cracked because of the frequent and aggressive 
breastfeeding. Stephanie’s husband works in a busy law firm, comes home late each 
night, and often needs to work during weekends. Stephanie spends most of her time 
alone with the baby and rarely even has dinner with her husband. She’s the only one 
of her friends who has a baby, and her colleagues at work are busy with the end of 
the school year. She does however have a lot of family support and often has her 
mother or mother-in-law visit to help with the baby and give her some time to sleep. 
Today, Stephanie comes in to your pharmacy to buy some Restavit® because she 
says she “feels too wired to fall asleep even when the baby sleeps”. 
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 What risk factors does Stephanie present with for perinatal anxiety and/or 
depression? 
 
What protective factors (if any) are present which may help buffer against PND 
in her case? 
 
Suggest ways to modify Stephanie’s risk for developing PND. 
 
How would you approach this situation?  
 
 
This case study was extracted from the following article and modified for a pharmacist audience: Zauderer CR (2008) A Case 
Study of Postpartum Depression & Altered Maternal‐Newborn Attachment. MCN: The American Journal of Maternal/Child 
Nursing 33:173. 
Activity 3 
Case Study: Stephanie Wants St Johns Wort 
Time: 10 mins ( + 10 mins class discussion) 
Stephanie returns to your pharmacy a few weeks later with Emma, who is now 3 
months old. She seems quite tired and you feel there might be something wrong. 
Stephanie is browsing through the vitamin aisle when you ask her if she needs any 
help to which she replies that she’d like some St John’s Wort and wants to know 
which brand to buy. 
 
How would you respond to this request? 
 
You will be assigned one of scenarios outlined below. Please discuss the 
following questions in the context of the scenario you are assigned. 
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How would you approach this situation? 
 
How comfortable would you be asking Stephanie to fill out an EPDS (Edinburgh 
Postnatal Depression Scale) form? If so, how would you go about it? 
 
If you had a strong suspicion that Stephanie was experiencing PPD/anxiety (and/or 
she had a high score on the EPDS) regardless of her response to you, what would 
your course of action be? 
 
SCENARIO A 
Stephanie has said “ I’m just browsing, thank you”, and does not appear to 
want to discuss anything further.  
 
SCENARIO B 
Stephanie has said “ I’m just having a look, thanks” but seems to be open to 
further conversation.  
 
SCENARIO C 
Stephanie seems quite receptive to having a deeper conversation about her 
situation. She admits to you that she’s been really tired and is home with the 
baby all day. She no longer gets as much help from family as they are all busy 
with work now and she’s feeling very isolated. Stephanie says she feels lost in 
her new role, with no one to talk to. She is not sure she is doing a good job 
with baby Emma. She’s stopped getting dressed in the mornings and even 
stopped showering because she feels she doesn’t have the time or energy to 
do so. Even when the baby sleeps, Stephanie would sometimes doze off, only 
to be awakened by a full-blown panic attack. She’s not sleeping at all and asks 
you if you think St John’s Wort would help calm her down. 
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 Activity 4 
 
Role Play Scenarios 
 
You’ve been chatting with Stephanie for a few minutes and have identified that 
Stephanie may be experiencing PPD. You would like her to fill out an EPDS form to 
explore this possibility further and determine next steps. Please go through all of the 
scenarios below before class discussion. In groups of three, please practise the role 
plays below and take turns b. 
 
Time: 
20 mins 
(+15 mins class discussion) 
 
Role Play 1 
You would like to ask Stephanie to sit aside with you for a few minutes to discuss her 
situation further and to fill out the EPDS form.  
 
Possible scenarios:  
Stephanie happily agrees 
Stephanie is reluctant 
Stephanie completely refuses 
 
Role Play 2 
 
Scenario 1: Stephanie has completed the EPDS and the high score (>12) indicates 
that she may be experiencing PPD. You will now be explaining her score to her and 
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her options. If you choose to refer to a GP, please role play the discussion you will 
have with the GP.  
 
Scenario 2: Stephanie has completed the EPDS but her score is lower than the 
cutoff. However, you still believe there is a problem and would like to take this 
further. You will now be explaining her score to her and her options. If you choose to 
refer to a GP, please role play the discussion you will have with the GP. 
 
Scenario 3: Stephanie has completed the EPDS and she has a very low score.You 
don’t feel further investigation is necessary but you would like Stephanie to be aware 
of PPD symptoms and provide her with information about what to do if she suspects 
she may be developing PPD. You will now be explaining her score to her and her 
options. 
 
Activity 5 
 
Develop an in-pharmacy screening program for perinatal 
depression 
 
Description of activity: 
Groups will design (in principle) a PND-screening service in the pharmacy which will 
encompass the entire detection and referral process and consideration of marketing, 
budgeting and resource allocation. Participants will be expected to incorporate their 
infographic from Activity 1 and create a PND screening & referral checklist as 
part of this service. You will be expected to draft a brief “business plan” for this 
service which should take the following into consideration: 
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 Service description: What is the service and what will it actually do? What are the 
aims and outcomes? Be very specific.  
 
Operations: How will this service operate? What processes will be involved in 
running this service on a day-to-day basis? What resources will you need? 
 
Marketing plan: How will you let the community know you offer this service? Where 
and how will you advertise this service?   
 
Financial plan: What costs will be involved in the running of this service? How will 
you offset these costs?  
Referral system: How will you refer patients who screen positive for PPD? Where 
will you refer them? How will you setup these networks?  
 
You are welcome to present this plan anyway you see fit (interpretive song and 
dance is an acceptable option). If you’d prefer to follow a template, please see 
the Sample Plan overleaf. 
 
Time: 
30 mins + 15 min class discussion 
 
Sample Service Plan  
 
(source: Chisholm-Burns MA, Vaillancourt AM, Shepherd M (2012) Pharmacy Management, Leadership, Marketing, and 
Finance. Jones & Bartlett Learning, LLC) 
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Activity 6 
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Stephanie Gets Treated 
 
Stephanie saw her GP on your request who prescribed sertraline and short-
term lorazepam while the sertraline takes effect. She has also been referred to 
a local psychologist but the earliest she can be seen is 3 weeks from now. She 
mentions that she is still breastfeeding and is concerned that taking “ all these 
drugs” will harm her baby. 
 
What factors must be considered before psychotropics can be safely used 
whilst breastfeeding?  
 
In Scenario 1, we found out that Stephanie was on Zoloft when she fell 
pregnant but stopped. Was this an appropriate choice given Stephanie’s 
situation and background? 
 
How do you respond to Stephanie’s concerns about breastfeeding while on 
sertraline & lorazepam? 
 
What organisations and resources can you point Stephanie to for support and 
trusted information? 
 
How do you respond to Stephanie’s request for herbal remedies? 
 
What lifestyle advice can you offer Stephanie to help her manage her PPD? 
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Appendix A: Sample GP Referral Letter 
 
Template referral letter to the GP 
 
   Pharmacy Stamp 
 
 
Dr…….. 
……….. 
……….. 
…..NSW…. 
 
Dear Dr {name}, 
 
I recently saw Ms. {patient name} at the pharmacy and based on our conversation and her EPDS 
score, I believe there is a possibility she may be experiencing perinatal depression. She exhibited 
symptoms suggestive of this disorder and subsequent administration of the EPDS (see attached) 
delivered a score of ……. 
 
I have discussed these EPDS results with Ms. {patient name} and with her permission, have sent the 
attached form to you for further appraisal. I have advised Ms. {patient name} that her score is not a 
diagnosis of perinatal depression and that it is recommended she see you as soon as possible for a 
deeper discussion. 
 
Dispensing History 
 
Medication Directions Date Dispensed 
 
Please do not hesitate to contact me on …….. if you would like to discuss this further. 
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 Kind Regards 
 
{your name} 
Pharmacist 
……...Pharmacy 
 
 
Appendix B: Self-reflection Activity 
 
Dear Pharmacist 
 
Thank you for attending the Perinatal Mental Health in the Pharmacy Workshop on the 31st March 
2016. As a valuable member of the primary healthcare team, you have an important role to play in the 
detection and management of women with perinatal depression. The workshop was the first step to 
equipping you with the confidence and skills to fulfill this role. In order to complete this course and 
gain your certificate of completion, we ask that you complete the following activity by the 21st April 
2016. 
 
------------------------------------------- 
Self-reflection activity 
 
Your task is to take the opportunity to speak to at least one pregnant or postpartum mother in the 
pharmacy within the next three weeks and have a conversation about her mental health using the 
skills you developed during the workshop. You are then to write at least 200-300 words reflecting 
on this experience; what you learned, what you could have done better and how you applied the 
skills you learnt in the workshop. 
 
As you are aware, this is potentially a very sensitive issue for some so we ask that you exercise great 
care and professional judgement when completing this task. We are not expecting you to detect or 
even refer a case of suspected PND ( though if you do, that’s great). We simply want you to take the 
opportunity to consolidate what you learnt at the workshop and share that experience with us. 
 
Due date: Friday 21st April 
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 Once this activity is complete, you will receive your certificate of completion to keep for CPD 
recording purposes. 
 
Appendix F 
 
Photographic Images from the PMHP Workshop 
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